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Abstract 
 
Natural Killer (NK) cells are immune effector cells capable of responding to infected 
cells through cytotoxic activity and production of pro-inflammatory cytokines. In recent 
years there has been increasing interest in studying how vaccine- or pathogen-induced 
antibodies promote NK cell responses to pathogens through the immunoglobulin G 
receptor CD16.  
The initial work described in this thesis uses imaging flow cytometry to examine the 
ability of human NK cells to interact with erythrocytes parasitised with the human 
malaria parasite Plasmodium falciparum (PRBCs). Although several limitations of this 
technology became apparent, I was able to establish that conjugates between NK cells 
and PRBCs form within 30 minutes of co-incubation and persist for up to 3 hours. 
PRBCs were observed forming conjugates with both CD56bright and CD56dimCD57+ NK 
cells. 
The role of antibody in promoting NK cell responses via CD16 was then assessed in 
two models. Firstly, an in vitro model using NK cells and plasma from individuals 
vaccinated with trivalent influenza vaccine was used to establish assay conditions and 
to investigate the mechanisms by which CD16 is downregulated after antibody-
dependent activation. In this model, I have shown that influenza antigen-antibody 
complexes are able to induce downregulation of CD16 on NK cells, resulting in 
degranulation. These antibody dependent functions are more potent in highly 
differentiated CD56dimCD57+ NK cells. Using imaging flow cytometry, I have also shown 
that downregulation of CD16 after ligation is due to shedding of the molecule from the 
surface of the NK cell, rather than through a process of internalisation. 
Secondly, I established an in vitro system to investigate the impact of antibody on NK 
cell responses to PRBCs in Gambian and UK resident individuals. This study also 
assessed the contributions of different NK cell differentiation subsets to these 
responses. I have shown that NK cells are able to mount a robust antibody-dependent 
response to PRBCs, involving production of IFN-γ and degranulation. I have also shown 
that NK cells vary in their responsiveness to antibody stimulation, with ‘adaptive’ FcεRIγ- 
and ‘differentiated’ CD57+ NK cells demonstrating enhanced responses to anti-malarial 
antibodies. Finally, I have shown that the cytokines interleukin 12 and interleukin 18 
contribute to the anti-malarial antibody-dependent response in certain NK cell subsets, 
as does ligation of CD2 on the NK cell. 
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CHAPTER 1 
Introduction 
1.1 Basic biology of the natural killer cell  
Natural killer (or NK) cells are large granular lymphocytes traditionally considered to be 
a bridge between the innate and adaptive immune systems. Although a product of the 
lymphocytic progenitor pathway 1, unlike other lymphocytic cells such as T-cells, NK 
cells possess an innate capacity to respond to cancerous or infected host-cells. This 
activity is mediated through a large number of germline-encoded receptors capable of 
recognising pro-inflammatory molecules and changes in the expression of ligands 
associated with infection or cellular dysfunction (reviewed in 2).  
In humans, NK cells typically constitute 5-15% of peripheral blood mononuclear cells 
(PBMCs).3. They are typically characterised as cells expressing the surface marker 
CD56 (albeit to varying degrees depending on the NK cell subset) whilst lacking the T-
cell co-receptor CD3. Generic human NK cells are thus phenotypically classified as 
CD56+ CD3- cells. Within this basic subset there is considerable diversity in both the 
receptors NK cells express and their consequent immunoreactivity and function, as will 
be discussed in more detail over the following sections (reviewed in 4). 
 
1.2 Natural killer cell functions 
NK cells are responsible for responding to a wide range of dysfunctional and infectious 
cellular targets, including cancer cells 5, cells infected with intracellular bacteria such as 
Salmonella 6, and cells infected with viruses such as Human Cytomegalovirus (HCMV) 
7. There is also increasing evidence that NK cells can respond through a range of 
mechanisms to host cells infected with intracellular parasites such as malaria, as will 
be discussed later in greater detail (reviewed in 4).  
The function of NK cells in instances of infection or cancer can be broadly broken down 
into two categories; production of pro-inflammatory cytokines to upregulate immune 
responses indirectly, and direct killing of target cells through cytotoxic activity. These 
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functions can be triggered by a range of direct and indirect mechanisms, explored in 
detail in the following sections. 
1.2.1 Cytotoxic activity and killing of cellular targets 
The titular function of NK cells is to kill infected or cancerous cellular targets through 
cytotoxic activity. This requires physical contact between the NK cell and its target, 
leading to a multi-stage killing process. 
Initial contacts between NK cells and potential targets are mediated by NK-expressed 
integrins such as lymphocyte function-associated antigen 1 (LFA1) and macrophage-1 
antigen (MAC1), which cluster at sites of contact 8. These receptors have a large 
number of known ligands, though the most relevant for adhesive purposes appear to 
be the intercellular adhesion molecule family, or ICAMs (reviewed in 9). After making 
initial adhesive contacts, a balance of activating and inhibitory signals will determine 
whether the NK cell choose to attack the bound target cell. The receptors that mediate 
this will be discussed in detail in sections 1.2.1.1 and 1.2.1.4. 
If the NK cell recognises a target cell as something it should attack, preliminary cellular 
contacts are reinforced as NK cells begin to form a tight ‘immunological synapse’ with 
the target. The immunological synapse consists of two distinct zones of receptors that 
polarise towards the site of contact; an outer ring of adhesion molecules (including LFA-
1 and MAC1) known as the peripheral supramolecular activation cluster (pSMAC), and 
a central zone of activating receptors known as the central supramolecular activation 
cluster (cSMAC) 10. This process is mediated by formation of F-actin filaments within 
the cell from a pool of monomeric G-actin which reorganise the NK membrane, 
increasing the surface area of the cellular contact 11. Once this synapse is fully formed, 
the intracellular microtubule-organising center (MTOC) gravitates towards the site of 
contact, forming a microtubule network throughout the cell which serves to guides 
cytotoxic granules towards the contact site 12. These granules contain cytotoxic 
mediators such as perforin and granzymes A and B. Once released, perforin proteins 
insert themselves into the membrane of the target cell, forming a larger pore structure 
consisting of multiple perforin subunits 13. Granzyme A and B then enter the target cell 
through this pore, inducing cell death through lysis of cytoskeletal and intracellular 
proteins leading to rapid cell death 14.  
NK cells are also capable of expressing so called ‘death’ ligands, such as Fas ligand 
(FasL) and TNF-related apoptotic inducing ligand (TRAIL) 15. These ligands bind Fas 
and TRAIL receptors commonly expressed on target cell surfaces, inducing cell death 
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through activation of the caspase cascade. Expression of these ligands is upregulated 
in response to signals sent by NK activating receptors such as CD16 and LFA-1, leading 
to enhanced cytotoxicity 16. 
NK cytotoxic functions can be mediated through three primary mechanisms; antibody-
independent cellular cytotoxicity mediated through a wide range of germline-encoded 
activating and inhibitory receptors, antibody-dependent-cellular cytotoxicity (ADCC) 
utilising B-cell produced immunoglobulin G which binds to the NK immunoglobulin 
receptor CD16, and exposure to various pro-inflammatory cytokines which upregulate 
NK cell cytotoxic functions by binding to cytokine receptors (Fig. 1.3). These 
mechanisms of activation will be explored in more detail in the following sections. 
 
1.2.1.1 ‘Missing self’ and cytotoxic activity in response to innate receptors 
During antibody-independent cytoxicity, NK cells initially recognise suitable tumour cells 
or infected host cells through innate germline-encoded receptors that ‘read’ the surface 
of the intended target (reviewed in 2). These receptors can be either activating or 
inhibitory, and bind a vast range of both host and pathogen-derived ligands (Fig. 1.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Examples of major NK cell receptors and their ligands 
NK cells are capable of degranulating in response to infected or cancerous cells, releasing cytotoxic mediators such as 
perforin and granzymes. The transition of the NK cell to an activated state is mediated by a wide range of activating and 
inhibitory receptors. The balance of activating versus inhibitory signals determines if the NK cell becomes cytotoxic. 
Figure republished in accordance with the Creative Commons attribution licence from Chester et al (2015) Frontiers in 
Immunology 245 
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Many NK receptors interact with ‘classical’ Major Histocompatibility Class 1 molecules 
(MHC-I) that are constitutively expressed on almost all human cell types 17. Classical 
MHC-I molecules are composed of three alpha chain subunits in association with β2-
microglobulin. Under homeostatic conditions their function is to bind host-derived or 
‘self’ peptides produced through proteolytic processes in the cell and present them to 
CD8+ cytotoxic T-cells via the T-cell receptor (TCR) 18. If the proteins are recognised 
as being ‘self’, T-cells are not activated. In the event a cell is infected or cancerous, 
pathogen-derived or cancerous mutant proteins will be presented by classical MHC-I 
molecules instead, leading to activation of CD8+ T-cells with complementary TCRs and 
subsequent killing of the afflicted cell (reviewed in 19).  
The expression of classical MHC-I molecules is often downregulated by host cells 
during infection or cancer leading to evasion from killing by cytotoxic T cells  20,21. NK 
cells express a range of receptors that bind classical MHC-I, many of which provide 
inhibitory signals to the NK cell. In the event classical MHC-I expression is lost during 
infection or cancer, NK cells become activated, acting as a secondary safeguard. This 
concept is generally known as the ‘Missing Self’ hypothesis. Host cells which are not 
recognised as being immunologically healthy or ‘self’ due to the downregulation of 
MHC-I are considered dangerous and a valid target for NK cell cytotoxic attack 22.  
Killer Immunoglobulin-Like Receptor family (or KIRs) represent the principal family of 
NK receptors which detect classical MHC-I on target cells. The KIR receptors have 
either two or three extracellular immunoglobulin domains, called 2D or 3D, and either a 
long (L) or a short (S) intracellular domain 23. The KIR family is large and polymorphic, 
currently consisting of 15 expressed receptors with both inhibitory and activating 
members. These receptors utilise intracellular immunoreceptor tyrosine-based 
inhibitory or activation motifs (ITIM or ITAM) to send either inhibitory or activating 
signals on recognition of their respective MHC-I ligands, though most are inhibitory 
(reviewed in 24). KIR family members with established HLA ligands bind classical MHC-
I molecules such as HLA-A, HLA-B or HLA-C, although several recognise non-classical 
MHC-I molecules, including KIR 2DL4 and KIR3DS1, which bind HLA-G and HLA-F 
respectively. Additionally, the ligands for several other KIR are currently unknown 
(reviewed in 25). In the case of most KIRs which bind classical HLA, the loss of this 
molecule on targets due to cellular stress leads to downregulation of inhibitory signals, 
skewing the NK cell towards activation (reviewed in 26).  
In recent years KIRs have also been found to play a role in so-called NK cell ‘education’, 
or ‘licensing’. Developing NK cells expressing inhibitory KIRs for self HLA demonstrate 
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enhanced responsiveness (both degranulation and cytokine production) to other 
activating signals, whereas NK cells lacking inhibitory KIR signals or expressing 
activating KIR signals for self-HLA become hyporesponsive. This process is believed 
to allow NK cells to develop a rudimentary form of self-tolerance, preventing excessive 
cytotoxic activities from being directed towards other self-cells 27. 
KIR proteins exhibit considerable diversity between individuals due to a predilection for 
individual variation in the content and copy number of genes carried, as well as frequent 
allelic polymorphisms. They consequently assemble into a diverse range of haplotypes 
that are broadly designated into classes A and B. Both haplotypes consists of a basic 
genetic framework containing the genes KIR2DL4, KIR3DL2, KIR3DL3 and the 
pseudogene KIR3DP1, but vary in the other genes carried 28. Group B haplotypes are 
characterised by the presence of one or more of the KIR genes KIR2DL5, KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS5 and KIR3DS1 23. Group A haplotypes lack these genes. 
Many group B haplotype genes are activating, and as a result B haplotypes generally 
have more genes encoding activating KIR than A haplotypes (reviewed in 29).  
In addition to expressing receptors that recognise classical HLA molecules, NK cells 
also express receptors targeting several ‘non-classical’ HLA molecules. Non-classical 
MHC-I molecules share a certain level of structural homology with the classical 
molecules but differ both in their mechanism of action and in the receptors they interact 
with. Examples include the molecule HLA-E, which binds signal peptides derived from 
classical HLA molecules and acts as a ligand for members of the NKG2 family of C-
type lectins 30. These include NKG2C; an activating NK receptor that dimerises with the 
transmembrane glycoprotein CD94, and NKG2A; an inhibitory receptor that also 
dimerises with CD94 and provides overriding signals to prevent activation through 
NKG2C 31. A related receptor,NKG2D, forms an activating homodimer that binds a 
diverse range of HLA homologues such as MICA and MICB that are overexpressed on 
stressed cells (reviewed in 32). 
However, loss of inhibition associated with the downregulation of HLA is itself not 
sufficient to drive NK cell activation, NK cells also express a range of receptors which 
provide the necessary activating signals through direct targeting of pathogenic ligands 
or host stress-induced molecules. These include the Natural Cytotoxicity Receptor 
family (NCRs); consisting of NKp30, NKp44 and NKp46, which bind a broad spectrum 
of ligands, including viral and bacterial molecules, in addition to host cellular ligands 
expressed in response to cellular stress (reviewed in 4). Specific examples include 
binding of viral haemagglutinins expressed by viruses such as influenza and vaccinia 
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to NKp30 and NKp46 33,34; binding of mycobacterium cell wall components to NKp44 35; 
and binding of host molecules such as heparin sulphate and HLA-B-associated 
transcript 3 (BAT3) by NKp30 and NKp46 36,37. Additional research has also suggested 
that the NCRs may be involved in killing of intracellular parasites such as Plasmodium 
falciparum, with at least one study suggesting that NKp30 and NKp46 may also bind 
Duffy binding-like (DBL) domain of P. falciparum erythrocyte membrane protein-1 
(PfEMP–1), expressed on parasitized erythrocytes 38.  
Additionally, activating adhesion molecules such as LFA-1 and the  costimulatory-
receptor DNAM-1 (CD226) have been shown to play a role in mediating NK cell 
interactions with both cellular models and pathogenic targets such as Plasmodium 
falciparum-infected erythrocytes, as discussed later in more detail 39, 40.  
While most activating germline activating receptors such as the NCRs and NKG2D are 
expressed on the majority of NK cells to some degree (though expression may vary 
between NK differentiation subsets within a single individual), others including NKG2C 
and the activating KIR exhibit considerable heterogeneity in their expression due to 
genetic differences between individuals. NKG2C expression is known to be reduced or 
even absent in some individuals due to a relatively common ~16kb deletion mutation 
present in approximately 20% of the global population. Consequently around 4% of 
individuals are homozygous negative for the NKG2C gene with a corresponding 
absence of surface expression. 41.  
 
1.2.1.2 Cytotoxic activity in response to cytokine stimulation  
Cytotoxic activity by NK cells can also be upregulated by exposure to pro-inflammatory 
cytokines produced or presented by a range of accessory peripheral blood 
mononuclear cells (PBMCs).  
In viral infections plasmacytoid and myeloid dendritic cells can be activated by binding 
of their Pattern-Recognition Receptors (PRRs) to viral molecules such as nucleic acids, 
causing them to produce Type I interferons including interferons  and  (IFN- and 
IFN-) (reviewed in 42). These interferons act to further activate plasmacytoid dendritic 
cells in a positive feedback loop, but have also been demonstrated to regulate NK cell 
expansion and differentiation in response to virally-infected cells by binding to the 
interferon-α/β receptor 43. Type I interferons have also been demonstrated to play a vital 
role in inducing NK cell cytotoxic responses against tumour cells 44, as well as 
intracellular parasites such as malaria in our own groups’ published work45. 
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Studies investigating the cytotoxic response of NK cells in both cancer and infection 
models have shown that pro-inflammatory interleukins such as IL-12 and IL-18 
produced by accessory monocytes or myeloid DC can also significantly upregulate the 
degranulation of NK cells in response to tumours and intracellular pathogens. In models 
of metastatic melanoma IL-12 and IL-18 have been shown to significantly upregulate 
NK cell cytotoxic activity as well as expression of the IL-2 receptor CD25, suggesting a 
synergistic effect of these cytokines 46. In studies investigating the interaction between 
NK cells and haematological tumour lines IL-12 has been demonstrated to upregulate 
expression of cytotoxic effector molecules such as TRAIL and perforin, as well as 
inducing phosphorylation of signalling molecules such as STAT1, STAT4, and ERK1/2, 
which regulate cytotoxic activity by NK cells 47. In mice models of cytomegalovirus 
infection, binding of viral DNA to the dendritic PRR Toll-like Receptor 9 has been 
demonstrated to lead to production of IL-12 by dendritic cells, leading to enhanced NK 
cell responses 48. Similarly, in in mouse models of herpes infection a deficiency in IL-18 
has been associated with reduced NK cell cytolytic capacity and increased viral load 49. 
In influenza models a deficiency in either IL-12 or IL-18 has also been associated with 
significantly reduced production of granzyme B, an essential cytotoxic mediator 50. 
Production of interleukin IL-15 by both plasmacytoid and myeloid dendritic cells can 
also enhance NK cell cytotoxic responses. In parasitic models of infection, IL-15 has 
also been shown to upregulate NK cell meditated lysis of Cryptosporidium-infected 
epithelial cells due to upregulation of the activating NK receptor NKG2D, leading to 
enhanced parasite clearance 51. NK cell cytotoxic activity has been shown to be 
upregulated against K562 tumour cell lines when cultured in contact with IL-15 
producing dendritic cells, leading to significantly higher expression of co-stimulatory 
receptors such as CD25, NKG2D and NKp30 52.  
T-cell derived IL-2 has also been shown to upregulate NK cell cytotoxic activity in both 
cancer and infection models. In in vivo models of lymphoma, supplementation with IL-
2 has been shown to restore NK cell cytotoxic activity in NK cells suffering from loss-of-
function mutations 53. In models of cytomegalovirus infection T-cell derived IL-2 has 
also been shown to significantly upregulate NK cell responses to virally-infected 
macrophages 54. In in vitro models of Plasmodium falciparum infection exogenous IL-2 
has also been shown to upregulate cytotoxic responses against parasitized 
erythrocytes 55. As with IL-12 and IL-18 the effects of IL-2 on NK cells appear to 
synergise with other cytokines, as studies have shown that IL-2 enhances the response 
to IL-12 through upregulation of the IL-12 receptor and associated intracellular 
signalling molecules such as STAT4 56. 
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1.2.1.3 Cytotoxic activity in response to physical contact with accessory cells 
Physical contact between NK cells and accessory cells such as macrophages and 
dendritic cells is required to present monocyte-derived cytokines to NK cells and induce 
optimal IFN-γ production. Optimal IL-12 release by peripheral blood myeloid dendritic 
cells appears to require the formation of an immunological synapse between activated 
dendritic cells and NK cells, while optimal ‘priming’ of NK cells by IL-15 requires trans-
presentation of the cytokine to the NK cell via the IL-15 receptor alpha chain expressed 
on the surface of dendritic cells 57,58, 59. These cytokines have also been demonstrated 
to play a vital role in upregulating NK cell cytotoxic responses, indicating that physical 
contact between NK cells and myeloid accessory cells also leads to enhanced 
cytotoxicity.  
Studies have shown NK cell cytotoxic activity against tumour cell lines is enhanced 
when cultured in contact with IL-15 producing dendritic cells, suggesting upregulation 
of NK cytotoxic responses by IL-15 may be dependent on physical trans-presentation 
of the cytokine via the IL-15 alpha chain 52. Additional tumour studies have shown that 
presentation of IL-12 by accessory monocytes significantly upregulates expression of 
cytotoxic mediators such as perforin, and that this process appears to be partially 
dependent on physical interactions between NK cells and monocytes 47. In mouse 
models Il-15, IL-18 and IFN-β produced by macrophages has also been shown to 
upregulate NK cell cytotoxicity directed against target cells in a process that is partially 
contact-dependent, though soluble versions of these cytokines also appear to have 
some effect 60. 
In addition to optimising the presentation of pro-inflammatory cytokines, physical 
contact between NK cells and accessory monocytes can lead to direct interactions 
between NK receptors and activating ligands, leading to enhanced cytotoxicity. In 
mouse models, macrophages can upregulate cytotoxic killing of tumour cell lines by NK 
cells by upregulating their own expression of HLA-like ligands for the NK activating 
receptor NKG2D 60. Similar results have been found in human in vitro models, where 
increased expression of the NKG2D ligand MICA enhances the cytotoxicity of both NK 
and CD8+ T-cells 61. Coincubation of NK cells with macrophages activated by low-dose 
LPS increased has also been shown to induce expression of NK cell activating 
receptors such as NKp46 as well as increase expression of cytotoxic molecules such 
as perforin via physical interactions between macrophage ligands and the NK cell 
receptor 2B4. This leads to enhanced killing of both tumour cell lines and virally-
transformed target cells by NK cells 62. 
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Studies have also demonstrated the ability of dendritic cells to activate NK cell cytotoxic 
functions through physical contacts. In cancer models, binding between dendritic-
expressed ligands and the NK receptor NKp30 has been shown to upregulate NK cell 
proliferation and killing of lymphoid tumour cell lines through cytotoxic activity 63. 
Increased expression of MICA and MICB on dendritic cells in response to IFN-α also 
appears to upregulate NK cell killing of tumour cells lines by binding the NK activating 
receptor NKG2D 64. Additional studies have shown that the adhesion molecule and 
activating receptor LFA-1 expressed on NK cells can also mediate interactions with 
dendritic cells, triggering the release of cytotoxic perforin and granzymes 65. 
 
1.2.1.4 Cytotoxic activity in response to antibody-antigen complexes 
In instances of antibody-dependent cellular cytotoxicity (ADCC), B-cell produced 
immunoglobulin G binds to pathogen- and cancer-specific epitopes, forming antibody-
antigen complexes. The Fc region of bound IgG1 and IgG3 antibodies bind to the 
principal NK cell immunoglobulin receptor CD16 (also known as FcyRIIIa). When 
multiple antibodies bind CD16 receptors in close proximity on the NK cell surface, the 
CD16 receptors become ‘cross-linked’, sending activating signals through 
immunoreceptor tyrosine-based activation motifs (ITAMs) to either the CD3ζ and/or 
FcεRIγ adaptor proteins 66. These adaptor proteins then transduce activating signals to 
the downstream cytosolic signalling pathway consisting of the classical SYK-family of 
tyrosine kinases 67, which ultimately trigger the release of lytic granules from the NK cell 
towards the opsonised cell target 68. As will be discussed in more detail in section 
1.2.2.3, this process can also induce the production of IFN-γ by the NK cell 69.  
Antibody-dependent cellular cytotoxicity by NK cells has been shown to play a vital role 
in the immune response to both virally-infected cells and cancers 70,71. Studies have 
demonstrated that these antibody-dependent cytotoxic responses can be upregulated 
by co-stimulation with pro-inflammatory cytokines such as IL-12 and also by CD4+ T 
cell-derived interleukin-2 (IL-2) 72. Further information regarding antibody-dependent 
responses will be discussed in the section dealing with adaptive NK cell subsets. 
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KEY 
DC = dendritic cell 
IgG = immunoglobulin G 
PAMPs = pathogen-associated molecular patterns 
PRRs = pattern recognition receptors 
MHC-I = major histocompatibility complex class 1 molecules 
 
 
Figure 1.3 Natural killer cells degranulate in response to several forms of stimulation 
NK cells are capable of degranulating in response to infection or cancer, subsequently releasing cytotoxic mediators such as 
perforin and granzymes which destroy dysfunctional or infected host cells. This process is regulated by a range of signals; 
including exposure to pro-inflammatory cytokines such as IL-2, IL-12, IL-15 and IL-18; direct contact with accessory PBMCs 
such as macrophages and monocytes through stress ligands such as MICA and MICB; binding of antibody-antigen complexes 
to the NK cell, leading to crosslinking of the IgG receptor CD16; and direct activation of the NK cell by infected or cancerous 
cells due to expression of stress ligands or downregulated expression of ‘self’ MHC-I (HLA) molecules. 
 
 
 
 
 
CD48 = cluster of differentiation 48 
2B4 = cluster of differentiation 244 
CD16 = immunoglobulin G Fc domain receptor 
MICA = MHC class I polypeptide-related sequence A 
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1.2.2 Pro-inflammatory cytokine production and the importance of IFN-γ 
A central role of NK cells in mounting an innate immune response to tumours and 
pathogens is the production of cytokines designed to upregulate the activity of other 
immune cells. Depending on the activating stimulus, these can include TNF-α, TNF-β, 
GM-CSF, IL-10 and IL-13 [97].  
Also amongst the primary pro-inflammatory cytokines produced by activated NK cells 
is Interferon gamma (IFN-γ), currently the only known member of the type II class of 
interferons (reviewed in 73). IFN-γ has been demonstrated to upregulate the activity of 
a range of immune cells in response to a variety of pathogens and cancers, and thus 
plays an important role in both the innate and adaptive immune responses.  
The receptor for IFN- (IFN-R) is widely expressed on a range of both immune and 
non-immune cells, though it is most prominently expressed on cells of myeloid lineage 
such as monocytes 74. Once bound to its receptor, IFN-γ upregulates cellular activities 
such as phagocytosis, proliferation and pro-inflammatory functions through activation 
of the JAK-STAT pathway (reviewed in 75). Specific examples include upregulating the 
production of bactericidal reactive oxygen species inside human mast cells in response 
to bacteria such as Staphylococcus aureus 76, activation of cytotoxic CD8+ T-cell 
responses to cancers such as intraocular tumours 77, and upregulation of cytokine 
production and antigen presentation by accessory cells such as macrophages 78. 
NK cells are thought to be an important early source of IFN-γ in many infection models 
prior to the activation of an adaptive T-cell response 79, 80, 81. In in vitro models of malaria 
infection for example, our own research group has demonstrated NK cells to be the 
primary source of IFN-γ during short-term incubation with malaria-infected cells when 
the T-cell response is minimal 82.  
Production of IFN-γ by NK cells in instances of infection or cancer is regulated by a 
range of signals, including exposure to pro-inflammatory cytokines, direct receptor-
mediated contact with activated accessory PBMCs such as macrophages and 
monocytes, and binding of antibody-antigen complexes to the NK cell (Fig. 1.1). These 
sources of stimulation will be explored in more detail in the following sections. 
1.2.2.1 IFN-γ production in response to pro-inflammatory cytokines 
Production of IFN-γ by NK cells in instances of infection or cancer is regulated by a 
range of signals, including exposure to a range of pro-inflammatory and regulatory 
cytokines (Table 1.1).  
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CYTOKINE NK CYTOKINE RECEPTOR (SUBUNITS) PRODUCED BY 
Interleukin 1 (IL-1) 83 IL-1R (IL-R1 and IL-1RAcP) Multiple cell types 
Interleukin 2 (IL-2) 84 IL-2R (IL-2Rα, IL-2/IL-15Rβ and common c chain) T-cells, dendritic cells 
Interleukin 12 (IL-12) 85 IL-12R (IL-12Rβ1 and IL-12Rβ2) Dendritic cells, macrophages 
Interleukin 15 (IL-15) 86 IL-15R (IL-15Rα, IL-2/IL-15Rβ and common c chain) Dendritic cells, macrophages 
Interleukin 18 (IL-18) 87 IL-18R (IL-18Rα and IL-18Rβ) Dendritic cells, macrophages 
Interleukin 21 (IL-21) 88 IL-21R (IL-21Rα and common c chain) Regulatory T-cells 
Type I Interferons 
e.g. IFNα, IFNβ 89 
IFNAR (IFNAR1 and IFNAR2) Multiple cell types 
  
 
The interleukins IL-12, IL-15 and IL-18 in particular have been shown to be an important 
activator of NK IFN-γ production in several in vitro models of innate immune activity 90, 
91, 92. These cytokines are produced primarily by monocytes, macrophages and 
dendritic cells (DC) that have been activated through direct recognition of pathogenic 
targets. Monocytes express innate pattern recognition receptors (PRRs) designed to 
detect extracellular and intracellular pathogen-associated molecular patterns (PAMPs). 
These PRRs include protein families such as the Toll-like receptors (TLRs) and C-type 
lectins (CLRs), which when bound to their cognate ligands induce activation of the 
monocyte and production of pro-inflammatory cytokines (reviewed in 93). Specific 
examples include induction of IL-18 production in circulatory and liver resident 
macrophages when exposed to hepatitis C 94, and induced production of IL-12 in 
macrophages exposed in vitro to Acanthamoeba castellanii, an opportunistic amoeba 
95. Production of the interleukin IL-15 by dendritic cells can also be important in the 
‘priming’ of NK cells in instances of infection, upregulating the expression of other 
cytokine receptors and increasing their responsiveness to these other pro-inflammatory 
cytokines 57,58.  
Later, during the adaptive immune response, T-cell derived IL-2 has also been 
demonstrated to be an important for activation and clonal expansion of NK cells. The 
CD56bright subset of NK cells constitutively express the high affinity CD25/CD122  
heterodimer and respond to picomolar concentrations of IL-2 96. CD25 is also 
upregulated on the larger CD56dim NK cell subset after NK cell activation by accessory 
Table 1.1 List of cytokines capable of activating NK cell activity and their primary cellular sources  
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cytokines 97. Therefore, by combining with accessory cell-derived IL-12, IL-15 and IL-
18, IL-2 provides a synergistic signal leading to both enhanced IFN-γ production and 
increased NK cell proliferation. For example, our own research group has demonstrated 
that in models of both tetanus and rabies vaccination IL-2 production by CD4+ memory 
T-cells significantly upregulates production of IFN-γ by NK cells 98, 99. Additionally, ex 
vivo studies have demonstrated that a numerical and functional decline in T-cells due 
to active HIV infection leads to reduced IFN-γ production by NK cells in response to 
secondary bacterial infections 100.  
 
1.2.2.2 IFN-γ production in response to physical contact with accessory cells 
In addition to exposure to soluble cytokines, direct contact with peripheral blood 
mononuclear cells (PBMCs) such as dendritic cells and macrophages can induce 
production of IFN-γ by NK cells. Physical contact between NK cells and PBMCs can 
both optimise trans presentation of cytokines to NK cells by monocytes and allow for 
other direct activating interactions between NK activating receptors and PBMC 
expressed ligands. 
As previously discussed in section 1.2.2.1, several studies have also suggested that 
physical contact between dendritic cells and NK cells is required for optimal activation 
of NK cells by dendritic-derived cytokines. Optimal IL-12 release by dendritic cells 
appears to require contact between dendritic cells and NK cells, while optimal ‘priming’ 
of NK cells by IL-15 requires trans-presentation of the cytokine to the NK cell via the IL-
15 receptor alpha chain 59, 101.  
In addition to presenting cytokine through physical contact however, dendritic cells can 
also express stress-induced ligands that are capable of directly activating NK cells by 
binding to activating receptors. These include Major Histocompatability Class I Chain-
related proteins A and B (MICA and MICB) which form activating contacts with the NK 
cell surface receptor NKG2D. Expression of MICA and MICA on virally-infected 
dendritic cells has been shown to inducing production of IFN-γ by NK cells in several 
viral infection models 64 102.  
Contacts between macrophages and monocytes and NK cells are also stabilised 
directly through interactions between adhesion molecules such as LFA-1 expressed on 
NK cells and ICAM-1 expressed on these accessory cells 103, 104. Blocking of these 
interactions has been demonstrated to result in significantly decreased IFN-γ 
production by NK cells in models of malarial parasitic infection 103, 105. The pro-
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inflammatory cytokine IL-18 has been demonstrated to increase expression of ICAM-1 
on monocytes, suggesting a positive feedback loop whereby activated monocytes 
produce this cytokine and enhance their own ability to activate NK cells through 
adhesive contacts 106.  
Several studies have indicated that such physical interactions between NK cells and 
accessory PBMCs may be vital for inducing an optimal response to pathogens. In 
models of Salmonella infection for example, NK cells have been shown to produce 
significant quantities of IFN-γ in response to Salmonella-infected macrophages through 
a contact-dependent mechanism 6.  In studies investigating chronic hepatitis C infection, 
virally induced downregulation of MICA and MICB expression on dendritic cells leads 
to reciprocal downregulation in IFN-γ production by NK cells 64. Similar observations 
have been made in studies investigating autoimmune disorders such as rheumatoid 
arthritis. Physical contact between NK cells and monocytes in these disorders induces 
reciprocal activation, leading to production of IFN-γ by NK cells and TNF-α by 
monocytes, suggesting these kinds of cell-cell contacts can also play a maladaptive 
role by mediating autoinflammation 107 
 
1.2.2.3 IFN-γ production in response to antibody-antigen complexes and co-
stimulation 
Binding of antibody-antigen complexes to the NK cell has been shown to induce IFN-γ 
production in models of cancer and viral infections such as HIV 108, 109, 110. This occurs 
via binding of antibody to the high-affinity Fc receptor for immunoglobulin G (FcRIIIA/ 
CD16), which is expressed on the surface of the majority of NK cells. When multiple 
antibodies bind CD16 receptors in close proximity on the NK cell surface, the CD16 
receptors become ‘cross-linked’, sending activating signals through the CD3ζ and 
FcεRIγ adaptor proteins 66,  which transduce activating signals to downstream signalling 
pathways and trigger transcription of the IFN-γ gene 111,112. Several studies have 
suggested that this response can be upregulated by co-stimulation with pro-
inflammatory cytokines such as IL-12 and IL-2, particularly in models of breast cancer 
113,114. More recent studies have also suggested that IL-18 is involved in the 
upregulation of IFN-γ production during the antibody-dependent CD16 response 109. In 
leukaemia models, physical contact with accessory cells such as monocytes has also 
been shown to upregulate IFN-γ production by NK cells in response to antibody, 
suggesting there may be additional regulatory pathways requiring physical contact with 
monocyte ligands or physical presentation of cytokines 115.  
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KEY 
DC = dendritic cell 
IgG = immunoglobulin G 
PAMPs = pathogen-associated molecular patterns 
PRRs = pattern recognition receptors 
ICAM1 = intercellular adhesion molecule 1 
LFA1 = lymphocyte function-associated antigen 1 
CD16 = immunoglobulin G Fc domain receptor 
 
 
 
 
Figure 1.1 Natural killer cells produce IFN- in response to several forms of stimulation 
Production of IFN-γ by NK cells in infection or cancer is regulated by a range of signals; including exposure to 
pro-inflammatory cytokines such as IL-2, IL-12, IL-15 and IL-18; direct contact with accessory PBMCs such 
as macrophages and monocytes through receptors such as ICAM1, and binding of antibody-antigen 
complexes to the NK cell, leading to crosslinking of the IgG receptor CD16. 
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1.3 NK cell subsets: ‘differentiation’ and ‘adaptation’ 
Though all NK cell are capable of producing pro-inflammatory IFN-γ and killing cells 
through cytotoxic activity, the extent to which any one individual NK cell will perform 
these activities is dependent on its state of functional differentiation. This will determine 
the expressed receptor repertoire, and which epigenetic modifications regulate its 
activity. Research conducted over the last few years has increasingly suggested that 
prior exposure to infected or cancerous cells can induce different forms of cellular 
differentiation in NK cells, leading to altered phenotype and subsequent altered 
function. 
 
1.3.1 Differentiation: CD56 downregulation and CD57 expression 
In human peripheral blood, there are two major subsets of NK cells as defined by the 
degree of CD56 expression. ‘CD56bright’ cells (hereafter referred to as ‘Brights’), which 
typically represent around 10% of peripheral NK cells, are the least differentiated subset 
of NK cell, as evidenced by expression of the stem cell factor receptor c-kit, their long 
telomeres, high prevalence in blood relative to other subsets after haemopoietic stem 
cell transfer, and ability to differentiate into CD56dim NK cells (hereafter referred to as 
‘Dims’) 116–118. These cells are highly responsive to pro-inflammatory cytokines such as 
IL-12, IL-18, IL-15 and IL-2, and constitutively express high levels of cytokine receptors, 
including IL-12R and the high affinity IL2-R heterodimer CD25/CD122 (IL-2R and IL-
2R). Although a minor subset of blood NK cells, individual Brights consequently 
produce exceptionally high levels of IFN-γ in response to cytokine stimulation 90. 
Conversely, these cells express low levels of activating NK cell receptors such as 
NKG2C and activating KIR, little or none of the immunoglobulin G receptor CD16, and 
high levels of the inhibitory C-type lectin-like receptor NKG2A (reviewed in 119), thereby  
demonstrating limited responsiveness to direct contact with target cells or antibody-
antigen complexes 120.  
Brights also produce minimal amounts of cytotoxic mediators such as perforin and 
granzymes, and express low levels of death ligands such as TRAIL 121. However, 
studies have demonstrated that ‘priming’ of Brights with cytokines such as IL-15 can 
increase their production of perforin and granzyme B in addition to increasing 
expression of TRAIL, leading to enhanced cytotoxic capacity 122. As such, although they 
are still capable of killing cells through cytotoxic activity, they do not appear to be 
particularly predisposed to this function.  
P a g e  | 29 
 
As NK cells encounter sources of activation they begin to differentiate, with reduced 
levels of CD56 123 (Fig. 1.4). These ‘Dims’ express higher levels of receptors such as 
CD16 and KIRs and lower levels of NKG2A, becoming more efficient at both antibody-
dependent and antibody-independent cytotoxicity (reviewed in 119). Conversely they 
express lower levels of cytokine receptor subunits such as CD25, becoming less 
responsive to pro-inflammatory cytokines such as IL-2 and subsequently demonstrate 
reduced IFN-γ production in response to pro-inflammatory cytokines during long-term 
immune responses 124. However, as these cells make up the bulk of the NK cell 
population, they are generally still responsible for the majority of IFN-γ produced in 
models of infection or cancer, and recent studies have indicated that they are capable 
of potent short-term IFN-γ production when activated through receptors such as NKp30 
and NKp46 125. 
Between 30-60% of Dims in healthy adults also express a secondary surface maker, 
CD57, which is associated with late differentiation, telomere shortening and reduced 
proliferative capacity. CD57+ Dims (hereafter referred to as ‘Mature Dims’) display even 
further reduction in their capacity to respond to pro-inflammatory cytokines, including 
IL-12 and IL-18, and to produce IFN-γ in this context 126. Conversely, Mature Dims 
contain higher frequencies of cells expressing KIR, CD16, and NKG2C, often 
associated with increased surface expression of these molecules (Fig. 1.4). As such, 
Mature Dims are highly efficient at both antibody-independent and antibody-dependent 
cytotoxic killing of cell targets (reviewed in 127).  
Brights, Dims and Mature Dims are therefore thought to exist on a functional spectrum, 
differentiating in response to exposure to pro-inflammatory cytokines 126 and cellular 
targets such as virally-infected cells 128. Several studies have identified HCMV as a 
potent effector of NK cell maturation to Mature Dims 128, 129. Greater frequencies of Dim 
and Mature NK cells versus Bright NK cells have also been associated with increased 
age 130, though currently it is unclear whether age itself is a causal factor or simply an 
indirect measure of the extent of prior exposure to infection. 
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Figure 1.4 Models for the CD56/CD57 differentiation pathway of natural killer cells in response to 
activation and age  
CD56bright, CD56dim and CD56dim CD57+ NK cells are thought to exist on a functional spectrum of differentiation. 
Undifferentiated CD56bright cells exhibit greater proliferative capacity and responsiveness to cytokines, whilst 
differentiated CD56dim and CD57+ cells exhibit greater cytotoxic potential. Differences in effector functions 
between subsets are tied to differential expression of surface receptors and internal cytotoxic mediators. NK 
cells progress down the differentiation pathway in response to exposure to pro-inflammatory cytokines and 
cellular targets such as virally-infected cells.  
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1.3.2 ‘Adaptation’: downregulation of FcεRIγ and functional changes in 
response to HCMV 
Recent research has revealed that, in addition to classical functional differentiation, 
human NK cells from HCMV infected individuals also modulate their intracellular 
signalling pathways to achieve functional adaptation. Early studies suggested that a NK 
cells expressing the activating NK receptor NKG2C in combination with its lectin co-
receptor CD94 were expanded in response to HCMV-infected host cells 131,132. Although 
these cells had a late differentiation phenotype, they demonstrated increased IFN-γ 
production, particular in the presence of HCMV antigens, leading to the suggestion that 
they had ‘adapted’ to HCMV infection 133.  HCMV responsive NK cells were 
characterised by increased expression of receptors including NKG2C, CD2, CD57 and 
KIR, but reduced expression of the activating receptors NKp46 and NKp30. (reviewed 
in 134). Though originally considered to have adapted to HCMV specifically, subsequent 
studies have confirmed that this is not the case. Though particularly reactive to HCMV 
antigens, ‘adaptive’ NK cells have also demonstrated increased IFN-γ production in 
response to other targets such as K562 tumour cells, suggesting that while HCMV may 
drive the development and expansion of these cells the mechanisms by which they 
become activated afterwards may be more generalised 135.   
Studies by Schlums et al and Lee et al in 2015 demonstrated that these changes in 
adaptive NK receptor expression and subsequent function are due to underlying 
epigenetic modifications that downregulate the expression of various intracellular 
adaptor molecules. Hypermethlyation of promoter regions within the genome leads to 
silencing of certain genes, and subsequent altered function of the NK cell 136 137.  
The resulting modifications include downregulated expression of the transmembrane 
adaptor molecule FcεRIγ, which is involved in regulating the activity of various NK 
receptors. Conversely, adaptive NK cells maintain normal expression levels of the 
alternative adaptor molecule CD3ζ which is involved in regulating the activity of many 
of the same receptors. FcεRIγ and CD3ζ have been shown to associate with the NK 
activating receptors NKp46 and NKp30 as either homodimers or a heterodimer 
including both proteins 138, 139, 5. Additional studies have shown that FcεRγ1- NK cells 
express lower levels of NKp46 and NKp30, and demonstrate consequent reduced 
activation in the presence of certain tumour lines 140.  
The NK cell Fc receptor CD16 also associates with FcɛRIγ and CD3ζ, and 
demonstrates an increased activating capacity on FcεRIγ- cells. Several studies have 
demonstrated that FcεRIγ- NK cells have increased degranulation and IFN-γ production 
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when stimulated with antibodies directed against cells infected with viruses such as 
HCMV, HSV-1 and influenza 141,142. Preliminary published abstracts have also 
suggested potentially greater antibody-dependent responses against intracellular 
parasites 143,144.  
The downregulation of FcɛRIγ in adaptive NK cells is driven by reduced expression of 
the transcription factor PLZF, which initiates changes in DNA methlylation 145. PLZF has 
been shown to bind to the promotor region of  FcɛRIγ, in addition to other NK adaptor 
molecules such as SYK  and EAT2 that are also frequently downregulated through 
hypermethylation in adaptive NK cells 137.  
In addition to reduced expression of natural cytotoxicity receptors such as NKp30, 
NKp44 and NKp46, ‘adaptive’ NK cells exhibit reduced responsiveness to pro-
inflammatory cytokines such as IL-2, IL-12 and IL-18 when provided without other forms 
of activation. DNA analysis has suggested that this may be driven by downregulated 
transcription of the genes encoding the receptors for these cytokines 137. However, 
recent evidence has shown that IL-18 can upregulate IFN-γ and TNFα production of 
adaptive NK cells in the presence of cancer cells, indicating that the cytokine 
responsiveness of ‘adaptive’ NK cells may be rescued in the presence of alternate 
forms of activation 146.  
Though previously thought to be a purely NKG2C+ population, studies have identified 
the presence of FcεRγ1- NK cells in individuals with inactivating mutations in the 
NKG2C gene locus 147. Additional studies have also suggested that in NKG2C- donors 
specifically, these responses are mediated partly through the engagement of the NK 
cell surface receptor CD2. CD2 is known to bind a range of ligands expressed on both 
target cells and accessory PBMCs, such as the lymphocyte differentiation marker 
CD48, the adhesion molecule CD58 and the glycoprotein CD59 which protects against 
activation of the complement pathway 148. Binding of CD2 to CD58 in particular has 
been shown to synergise with antibody crosslinking of CD16, leading to enhanced 
cytotoxic reactions through increased phosphorylation of intracellular signalling 
molecules 149. 
It is worth noting that whilst these particular NK cells are referred to as ‘adaptive’, they 
have globally enhanced ADCC responses to a range of antigenic targets and as such 
they cannot be said to have clonal antigen specificity in the sense of an adaptive T-cell 
or B-cell. This does however raise the interesting possibility that the development of 
adaptive NK cells in response to HCMV may have the potential to shape the NK cell 
response not only to this specific pathogen, but to any future infectious or cancerous 
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target antigens NK cells encounter. It is also possible that the antibody-dependent 
activity of these cells against different pathogens may vary due to synergistic effects of 
cytokines such as IL-18 or engagement of modulatory receptors such as CD2 or 
NKG2C, the costimulatory effects of which may be more prominent in certain infection 
models than others.  
Whilst most studies have identified HCMV as the primary driver of adaptation in NK 
cells, more recent research has suggested that this adaptive state can also be induced 
by exposure to cells infected with HIV, suggesting that there may be other sources of 
adaptive differentiation signals beyond HCMV 150. 
 
1.4 Malaria; biology, symptoms and transmission 
1.4.1 Developmental cycle of the malaria parasite 
Malaria is a severe insect-borne infectious disease most commonly found in developing 
African and Asian countries 151. The causative agents of malaria are members of the 
Plasmodium genus of protozoan parasites, capable of infecting a diverse range of 
mammalian and non-mammalian hosts, from humans to lizards 152, 153. Female 
members of the Anopheles genus of mosquitoes transmit the parasites while they feed 
on the blood of host animals. During a single bite, anywhere between a dozen and 
several hundred motile and infectious malaria sporozoites can be transmitted into the 
skin of the host from the salivary glands of the mosquito 154. The parasites then migrate 
to the blood stream to initiate development within the non-Anopholean host 155. 
The developmental pathway of the Plasmodium parasite within vertebrate hosts 
consists of several life stages. After sporozoites enter the blood, they travel to the liver 
and enter the hepatocytic cells where they then begin to develop into large 
multinucleated schizonts. These eventually divide into dozens of smaller merozoites, 
which then lyse the hepatic cells and enter the bloodstream to infect erythrocytes. Once 
inside erythrocytes the parasites undergo asexual replication. Merozoites develop over 
~48 hours from adolescent trophozoites into more schizonts, which then divide and 
repeat the merozoite cycle, constantly lysing and invading new erythrocytes (Fig. 1.5). 
Some blood stage parasites differentiate instead into male and female gametocytes 
that, when ingested in the mosquito blood meal, are activated to produce gametes and 
initiate a sexual replication cycle inside the Anopheles host (reviewed in 156). These 
stages exhibit both conserved and stage-specific proteomic expression 157.  
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1.4.2 Global malarial epidemiology and the importance of research 
At present an estimated 3 billion people are at risk of developing malaria, the majority 
of whom live in Sub-Saharan African and South Asia. In 2016 alone there were an 
estimated 216 million cases of malaria worldwide leading to just under half a million 
deaths, with children under 5 years old accounting for the vast majority 151. Africa 
overwhelming experiences the most malarial deaths worldwide, accounting for 91% of 
all malaria deaths in 2016, followed by South-East Asia with 6% of all deaths 151.   
The most common methods used to manage malarial infection include long-lasting 
insecticides used to treat bed nets and spray housing, chemoprevention in at-risk 
individuals and the use of combination drug cocktails to treat individuals already 
infected 151. Efforts to develop a viable malarial vaccine are also ongoing, though these 
have experienced recent setbacks with the publication of disappointing clinical trial 
results for the RTS-S vaccine previously considered to be the most promising candidate 
for a commercial vaccine 158 
Regardless, it is generally recognised by researchers in this area that development of 
a viable vaccine is desirable for use in addition to other pre-existing methods of malarial 
control, and will require continued research into the interaction between the human 
immune system and Plasmodium parasites. Of particular interest are the species 
Plasmodium falciparum and Plasmodium vivax, as together these species are 
responsible for the majority of lethal malaria cases worldwide. Plasmodium falciparum 
is the most prevalent species in sub-Saharan Africa (and consequently the most 
prevalent worldwide given the global burden of the disease primarily falls in this region), 
accounting for 99% of estimated malaria cases in Africa in 2016. Outside of Africa, 
Plasmoidum vivax is the most common species in the Americas, representing 64% of 
malaria cases, and represents above 30% of cases in South-East Asia and the Eastern 
Mediterranean 151. In this thesis I will focus on investigating human natural killer cell 
interactions with P. falciparum. 
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1.4.3 Malarial pathology and immunology 
1.4.3.1 Innate immunity and the pro-inflammatory balance 
 
The complex nature of the Plasmodium life cycle dictates an equally complex anti-
malarial immune response from the human host. The initial stages of infection in the 
skin and liver provoke a relatively muted immune response in humans, with minimal 
innate involvement and limited production of antibody even in individuals with prior 
exposure 159. Though the reasons for this are not definitively understood, it is suspected 
that the relatively high proportion of regulatory T-cells present in the skin under normal 
homeostatic conditions may inhibit early immune responses to the sporozoite stage of 
Plasmodium 160. Meta-analyses of malarial vaccine studies have also suggested that 
Plasmodium-specific regulatory T-cells are induced during initial infection, potentially 
inhibiting early responses to sporozoites as well as later stages of infection 161. 
In human hosts the most pathogenic stage of the malaria developmental cycle is the 
intra-erythrocyte asexual cycle resulting in the repetitive infection and lysis of red blood 
cells (Fig. 1.5). Structural changes in the surface membrane of infected erythrocytes 
can cause the cells to become sequestered in the vascular endothelium, blocking off 
small blood vessels. Rupturing of erythrocytes during merozoite release can also 
significantly reduce the number of circulating erythrocytes in the blood stream, causing 
anaemia. Reduced oxygen supply to the tissue due to blockage of vessels and anaemia 
can in turn lead to systemic lactic acidosis in the body, and in the brain can lead to 
severe symptoms such as seizures and coma (reviewed in 162). A cyclical fever is also 
indicative of the condition, roughly correlating with the parasite’s own ~48 hour asexual 
developmental cycle 163.  
In addition to being the most clinically problematic, asexual blood-stage malaria is by 
far the most immunogenic. Studies conducted in both human and animal models have 
shown a role for various innate immune cells in the response to early blood-stage 
infection, inhibiting the growth of parasites and promoting inflammation. Plasmodium 
pathogen associated molecular patterns such as GPI glycolipid anchors 164) and 
malarial DNA 165 can bind to host toll-like receptors such as TLR-2 and TLR-9 
respectively, while parasite-derived hemozoin binds to NOD-like receptors present in 
the myeloid inflammasome 166. Interactions between parasite-derived ligands such as 
these and their cognate host receptors induce pro-inflammatory responses in innate 
immune cells, including phagocytosis of infected erythrocytes and production of 
reactive oxygen species by macrophages, production of pro-inflammatory IL-12 and IL-
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18 by dendritic cells, and production of pro-inflammatory IFN- by γδ T-cells 167. NK cells 
have also been shown to play an important role in shaping the early immune response 
to blood-stage malaria, as will be discussed in more detail in a later section. 
Many studies conducted over the last 20 years have indicted a vital role for pro-
inflammation in controlling parasitaemia. An early study by Luty et al on discovered an 
association in African children between higher IFN- levels and increased resistance to 
reinfection after a mild episode of malaria 168. Later studies published by Roestenberg 
et al have also found associations between production of IFN- and IL-2 and protection 
against infectious challenge in experimental human models of infection involving 
vaccination with whole sporozoites 169,170. Additional studies have also indicated that 
excessive regulatory immune responses lead to negative clinical outcomes. In 2005 
Walther et al discovered that increased frequency of regulatory T-cells producing anti-
inflammatory cytokines such as IL-10 was associated with higher parasitaemia in 
humans 171, whilst in 2006 Prakash et al suggested that anti-inflammatory cytokines 
were associated with increased susceptibility to cerebral malaria in Indian patients 172. 
While it has been demonstrated that pro-inflammatory immunity is vital for promoting 
clearance of parasites, excessive inflammatory immune responses to infected cells 
have also been suggested to exacerbate the symptoms of infection. High levels of pro-
inflammatory cytokines such as IL-1, IL-6, IL-12, IFN-γ, and TNFα have been 
specifically implicated in this respect 172. An early study by Riley et al. in 1991 
demonstrated an association between IFN-γ production after in vitro stimulation with 
malaria antigens and an increased likelihood of developing fever and malaise during in 
vivo infection in a sample of African children 173. A later study by Walther et al. also 
found a similar association between IFN-γ levels in blood plasma and fever in an 
experimental model of malarial infection 171. Additional studies conducted by our own 
lab group on children from Ghana have also suggested that TNFα and IL-12 production 
by various peripheral blood mononuclear cell types are associated with increased 
incidence of fever 174, 175. 
These studies suggest that an optimal response to malarial infection requires a delicate 
balance of pro-inflammatory and anti-inflammatory activity designed to prevent parasite 
replication without provoking a pathological autoimmune response. 
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1.4.3.2 Acquired immunity and the importance of antibody 
 
In instances of chronic or secondary infection with malarial the adaptive immune system 
becomes active, leading to gradually increasing protection against re-infection. This is 
often reflected in the demographics of malarial infection, as typically most infections 
occur in the young, who also generally suffer the most severe symptoms and 
consequently make up the majority of malarial deaths worldwide 151. In the case of 
Plasmodium falciparum specifically most infections in holoendemic areas occur in 
childhood, characterised by high parasitaemia and clinical symptoms such as fever and 
severe anaemia. With age, semi-protective immunity develops with repeated 
exposures, resulting in a reduced likelihood of infection if bitten and asymptomatic 
infections if exposed 176.  
It has been known for many decades that production of anti-malarial antibodies is a vital 
component of blood-stage immunity, as several early studies have demonstrated that 
the passive transfer of anti-malarial immunoglobulin G from malaria-immune adults to 
partially immune children can rapidly reduce parasitaemia and symptoms of fever 177. 
Anti-malarial antibodies can confer protection through several mechanisms which can 
involve either direct complement-mediated destruction of parasitised cells or the 
neutralisation of pathogenic effects. In passive transfer studies anti-malarial antibodies 
acquired from immune donors have been shown to induce antibody-dependent cellular 
cytotoxicity of infected cells by monocytes in partially immune recipients 178. In cellular 
studies opsonisation of infected erythrocytes with anti-malarial IgG1 and IgG3 have 
been shown to induce phagocytosis of infected cells 179. Antibodies targeting the 
parasite-derived protein PfEMP1 have also been shown to be able to block binding of 
infected erythrocytes to host-express adhesion molecules such as CD36, 
thrombosponsin and ICAM-1, and therefore may play a role in inhibiting the 
sequestration of infected erythrocytes in the vascular endothelium which is typically 
considered a major contributor to pathology 180. Additionally, antibodies targeting 
parasite-derived molecules such as GPI glycolipid anchors have been shown to 
neutralise the pro-inflammatory activity of Plasmodium falciparum in cellular models, 
whilst also minimising pathogenic effects of infection such as malarial acidosis, 
pulmonary oedema and cerebral malaria in murine models infected with Plasmodium 
berghei 181. 
Over time and with repeated infectious exposures, individuals can achieve an 
increasing natural immunity to malaria with increasing breadth and depth of the anti-
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malarial immunoglobulin repertoire. Consequently, the symptoms of clinical malaria are 
most common in children, as adults who have survived multiple exposures display 
increased resistance to the development of severe symptoms. True sterilising immunity 
is largely considered unlikely however, as parasites can continue to be detected in the 
blood up until at least 60 years old, even in asymptomatic adults [162]. 
Many studies have indicated that antibody-independent acquired immune mechanisms 
also contribute protection against malaria. In ex vivo studies conducted on human 
volunteers inoculated with low doses of live falciparum-infected erythrocytes, secondary 
challenge with malarial antigens can result in a Th1-biased CD4+ and CD8+ T cell 
response involving proliferation of T cells, production of pro-inflammatory IFN- and 
increased nitric oxide synthesis in peripheral blood mononuclear cells 182. Similar results 
have also been observed in murine models infected with Plasmodium yoelii 183. 
Additional studies have also suggested that the acquired T cell response to malaria can 
help shape the innate NK cell response through production of IL-2, as will be discussed 
later in more detail in section 1.5 184 185. 
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Figure 1.5 The intra-erythrocytic asexual replication cycle of malaria parasites 
After initial infection of the host and replication in the liver, merozoites are released into the blood stream where they 
penetrate healthy erythrocytes. The merozoite will then metabolize host haemoglobin to fuel its own development 
into the mature schizont stage while restructuring the erythrocytic membrane to aid in nutrient transfer, rosetting 
and sequestration. Parasite proteins such as PfEMP1 are produced, some of which are exported to the erythrocyte 
surface. The mature schizont will then undergo replicative fission, forming 8–32 merozoites which lyse the cell 
membrane and re-enter the bloodstream. In in the case of P. falciparum, this entire process will take approximately 
48 hours, corresponding with the cyclical fever indicative of malarial infection.  
Figure republished with permission from Wolf, Sherratt and Riley (2017) Frontiers in Immunology 246 
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1.5 Natural killer cells and malaria 
1.5.1 Production of anti-malarial pro-inflammatory cytokines by NK cells 
Multiple studies conducted over the last few decades have suggested there may be a 
vital role for the production of IFN-γ in mounting an early successful immune response 
against malaria. In children, IFN-γ production has been found to associate with 
protection against severe malarial symptoms as well as delayed incidence of re-
infection within one year of initial contraction of the disease 168. In experimental models 
of vaccination with Plasmodium falciparum sporozoites, production of IFN-γ by PBMCs 
has also been found to associate with long-term protection against malaria 169,170. In 
cellular studies, production of IFN-γ in addition to other pro-inflammatory cytokines such 
as TNF has also been associated with lower parasite burden and high haemoglobin 
concentration in the blood, suggesting specific mechanisms for these protective effects 
174,175. 
Evidence for a beneficial effect of IFN-γ production is mixed however, as research has 
also suggested that excessive production of pro-inflammatory cytokines may contribute 
to the autoimmune pathology believed to contribute to clinical symptoms. Several 
studies have suggested an association between production of IFN-γ during either 
natural or experimental infection with malaria and increased likelihood of developing 
fever and fatigue 173, 171. Additional studies have suggested a link between higher levels 
of several pro-inflammatory cytokines, including IFN-γ, and increased frequency of 
febrile episodes in young patients 175, 174. Taken together, these studies suggest that 
while IFN- is necessary for a robust anti-malarial response excessive production may 
contribute to autoimmune pathology. 
Given that one of the primary functions of NK cells is the production of IFN-γ, there has 
naturally been significant interest in studying the activities of this particular cell type in 
instances of malarial infection. Early studies typically assumed that classical CD4+ 
helper and CD8+ cytotoxic T-cells were the predominant source of malaria-induced 
IFN-γ as a consequence of researchers utilizing techniques that could not differentiate 
between T-cells and NK cells 186,187.  
More recent studies by both our own lab group and others have confirmed that NK cells 
produce significant quantities of IFN-γ in response to erythrocytes infected with 
Plasmodium falciparum in both in vitro cellular models of infection and controlled human 
infection models 188, 189. These models have suggested that NK cells may be particularly 
important in providing an early source of IFN-γ during infection, with cellular studies 
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previously published by our own research group indicating that NK cells begin to 
produce IFN-γ within only 6 hours of co-culture with infected erythrocytes 82, though this 
response varies significantly between individuals 190. Some studies have suggested that 
the optimal production of IFN-γ by NK cells in response to malaria parasites is 
dependent on physical contact with infected target cells 188. The heterogeneity in IFN- 
responses may therefore be a result of variation in the NK germline receptors expressed 
by different individuals, though this is somewhat speculative as the specific receptor-
ligand pairings that mediate interactions between NK cells and malaria-infected targets 
are largely unknown.  
Additional signals such as pro-inflammatory cytokines and physical contacts with 
accessory peripheral blood mononuclear cells have also been demonstrated to 
upregulate NK production of IFN-γ in response to malaria. Our own research group has 
demonstrated that in cellular models soluble signals such as IL-12 and IL-18 produced 
by myeloid accessory cells during initial infection 45 188 and IL-2 produced by memory 
CD4+ T-cells later on during the adaptive immune response have both been shown to 
upregulate cytokine production by NK cells (Fig. 1.6) 184. In controlled human infection 
models the presence of T-cells appears particularly crucial to induce IFN- production 
by NK cells in response to malaria, with depletion of the CD3 subset leading to 
significant downregulation of the NK response through a partially IL-2 dependent 
mechanism 185. 
The specific physical contacts that occur between NK cells and accessory cells in 
instances of malarial infection are largely uncharacterised, but include binding of LFA-
1 expressed on the NK cell surface to ICAM-1 expressed on PBMCs 103. 
Transpresentation of IL-15 to NK cells by dendritic cells is also speculated to occur as 
soluble IL-15 has been demonstrated to upregulate NK IFN-γ cells to falciparum-
infected erythrocytes 191.  
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Figure 1.6 Established model for the production of IFN-γ by natural killer cells during malarial infection 
During the asexual erythrocytic stage of infection, NK cells are activated by cytokines such as IL-12, IL-15 
and IL-18 produced by macrophages and dendritic cells. Some evidence also suggests NK cells are activated 
by direct contact with infected erythrocytes. NK cells in turn release IFN-γ to stimulate the pro-inflammatory 
activity of other immune cells. Examples include activation of macrophages that subsequently phagocytose 
infected erythrocytes. Once the adaptive immune response has developed, T-cells contribute IL-2 to enhance 
the ongoing NK cell response.  
Figure adapted with permission from Wolf, Sherratt and Riley (2017) Frontiers in Immunology 246 
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1.5.2 Natural killing of malaria-infected erythrocytes through cytotoxic 
activity 
A growing body of research has also suggested that NK cells can form direct functional 
contacts with erythrocytes infected with Plasmodium falciparum, facilitating their 
activation and subsequent cytotoxic activity and cytokine production. Early flow 
cytometry studies conducted by our lab have suggested that direct conjugates may form 
between NK cells stained for the CD56 marker and infected erythrocytes stained for 
glycophorin A after as little as 30 minutes of co-culture 188. Immortalised NK92 cell lines 
have also been imaged forming so called ‘rosettes’ consisting of one NK cell bound to 
many infected erythrocytes 103, while additional studies have also observed purified NK 
cells forming what appear to be functional cytotoxic contacts with erythrocytes infected 
with Plasmodium falciparum as determined by the apparent reorganisation of 
cytoskeletal F-actin within the conjugated NK cells 190. More recently, studies utilising 
video microscopy have shown NK cells forming conjugates and apparently killing 
malaria-infected erythrocytes in a humanised mouse model of malarial infection 40. 
Additional studies conducted using controlled human infection models have also 
demonstrated a significant decrease in the proportion of NK cells found in the blood 
after early malarial infection, potentially due to migration to the afflicted tissues 192. 
Whilst these studies have presented convincing evidence that NK cells can form 
functional conjugates with malaria-infected erythrocytes, there are significant gaps in 
our current knowledge both regarding the receptors that facilitate these interactions and 
whether there is any significant variance in the ability of different NK cell subsets to form 
these conjugates.  
Erythrocytes typically do not express classical or non-classical HLA class I molecules 
that act as ligands for inhibitory NK cell receptors such as the KIRs, or do so at very low 
levels 193. Despite this, healthy erythrocytes remain unchallenged by NK cells due to a 
simultaneous lack of ligands for activating NK cell receptors such as the NCRs or 
activating KIRs, allowing them remain immunological ‘silent’. This raises questions as 
to which altered-host or parasite-derived ligands bind to which NK receptors in order for 
NK cells to recognise and respond to erythrocytes after they are infected with malaria.  
Several research groups have attempted to block various NK receptors and surface 
molecules during malarial cytotoxicity assays to assess their contribution to the anti-
malarial response; but few of the receptors tested have demonstrated any significant 
role in conjugate formation or subsequent cytotoxicity. One study has suggested that 
the NK receptor NKp30 can bind the Duffy binding-like domain of Plasmodium 
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falciparum erythrocyte membrane protein-1 (PfEMP-1), a protein widely expressed on 
parasitized erythrocytes 38, though subsequent studies have thoroughly disputed this 
result 40. PfEMP-1 has also been found to bind to chondroitin sulfate A (CSA), a 
glycosaminoglycan modification of many cell surface proteins, including those found on 
NK cells. However, whilst it has been shown that binding of PfEMP1 to CSA appears to 
mediates adhesion of infected erythrocytes to NK92 cell lines, it does not seem to be 
required to induce NK cell activation, refuting its importance 103.  
Currently the only NK receptor that has been repeatedly suggested to play an important 
role in the formation of conjugates with infected erythrocytes is the activating receptor 
and adhesion molecule LFA-1, and to a lesser extent the costimulatory receptor DNAM-
1 40,103. However, studies disagree on whether LFA-1 binds directly to an unknown 
ligand on infected erythrocytes 40 or simply facilitates the activation of NK cells by 
binding ICAM-1 present on the surface of accessory cells within PBMC 103.  
Adding to these complexities, most if not all of the studies that have thus far been 
performed in this area have failed to take into account any variability in receptor 
repertoire that may occur between different subsets of primary NK cells. NK cell 
receptor expression is known to vary considerably as NK cells differentiate from Brights 
to Mature Dims, and several studies have subsequently noted a significant difference 
in the ability of these subsets to respond to physical contact with infected targets 128,194 
(reviewed in 127). In the case of studies utilising NK92 cell lines any diversity amongst 
NK receptor repertoires is simply not represented, as these cells are clonal and typically 
present as undifferentiated Brights. Some results acquired using this cell line have also 
failed to hold true when experiments are repeated using primary NK cells 103, and in 
other cases have proven difficult to replicate even using the same line 195. In other 
studies which use primary NK cells for imaging, whilst there is presumably considerable 
diversity present amongst the NK cells in terms of differentiation and receptor 
expression, this is generally not noted or analysed 40,196.  
Furthermore, several of these studies utilise models of infection that are 
unrepresentative of malarial infection in vivo. In particular, most studies use NK92 
tumour cell lines or purified NK cells where accessory cells are absent. These cannot 
be assumed to provide a realistic representation of conjugate formation due to the lack 
of potential interactions with accessory PBMCs that have been demonstrated by both 
our own group and others to provide essential costimulatory signals for NK cells in 
instances of malarial infection, such as pro-inflammatory cytokines and physical 
contacts 45,103,184,188,191. Additional studies also utilise NK cells grown under extremely 
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unusual conditions, such as humanised mouse models that require contact 
supplementation with high dose cytokine in order to keep the NK cells viable 40.  
Given these issues, it would be helpful for future research in this area to develop an 
experimental in vitro imaging system, which allows us to assess whether NK cells 
preferentially form conjugates with malaria-infected erythrocytes whilst using NK cells 
obtained from human donors with representative subset diversity and allowing for 
potential co-stimulatory signals from autologous accessory PBMCs. Such a system 
would allow us to determine whether different NK subsets preferentially form conjugates 
under representative conditions. If so, this may help identify additional receptor-ligand 
pairings involved in these interactions.  
Developing such a system is therefore one of the aims of this thesis, and the subject 
will therefore be discussed in greater detail in the relevant chapter. 
 
1.5.3 Antibody-dependent responses to malaria in NK cells 
Whilst there are an increasing number of studies investigating cytokine and innate 
receptor induced IFN-γ production and cytotoxic conjugate formation by NK cells in 
response to malaria-infected erythrocytes, with the exception of a few published 
abstracts investigating antibody-dependent responses in cellular models of naïve 
subjects, there are currently no full published studies investigating antibody-dependent 
NK cell responses to malaria in naturally-exposed individuals 143,144. Given the 
continued focus of the global research community on development of an effective anti-
malarial vaccine 158 the importance of NK cell IFN-γ production and cytotoxic activities 
in controlling malarial infection 40,173, and recent studies indicating the existence of 
adaptive NK cells with enhanced antibody-dependent activity 137,141,142, this seems an 
important omission. There is a need both to evaluate the generic NK cell response to 
malaria through antibody-dependent mechanisms in a representative model of 
exposure, as well as to evaluate the specific role of adaptive NK cells in mounting these 
responses.  
A primary aim of this thesis will therefore be to investigate antibody-dependent IFN-γ 
and cytotoxic activity of NK cells in response to malaria-infected erythrocytes, with 
specific focus on the activity of adaptive NK cells. This subject will therefore be 
discussed in greater detail in the relevant chapter. 
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CHAPTER 2 
Materials and Methods 
In this chapter, I will give generic descriptions of the methods used in this thesis. 
Experiment-specific methods will be described in the relevant chapters with more 
detailed information. 
 
2.1 Cell and plasma donors 
2.1.1 European donors for malaria and influenza vaccine studies 
50 healthy volunteers were recruited from within the London School of Hygiene and 
Tropical Medicine (LSHTM) through an anonymised blood donation system operated 
by Carolynne Stanley, a trained phlebotomist. Ethical approval for this system was 
acquired from the LSHTM Ethics Committee under the ethics reference numbers 5520 
and 6237, and informed consent was obtained from all donors as stipulated by LSHTM 
and the appropriate regulatory bodies. 50ml of venous blood was collected in sterile 
Falcon tubes with 2 I.U. per ml of sodium heparin added to prevent coagulation. Plasma 
and peripheral blood mononuclear cells (PBMCs) from these donors were isolated from 
venous blood by myself, Dr Martin Goodier and Dr Carolyn Nielsen and either used 
immediately or cryopreserved for cold storage and later use. 40 of these donors had 
been previously tested for HCMV exposure prior to this study by Dr Carolyn Nielsen 
using an ELISA assay testing for the presence of anti-HCMV antibodies.   
 
2.1.2 Gambian donors for malaria studies 
641 donors were recruited from sites of known high-malarial transmission in the 
Gambia. Ethical approvals to collect samples were acquired from the Gambian 
Government and Medical Research Council Gambian joint ethics committee (reference 
numbers SCC 1269 and SCC 1449) as well as the LSHTM ethics committee (ethics 
reference number 6034). Informed consent was also obtained from all donors as 
required by local regulations. Plasma and PBMCs from these donors were isolated from 
venous blood and cryopreserved in Gambia before shipment to LSHTM for later use. 
The previous malarial exposure of these donors was determined by ELISA assay 
P a g e  | 47 
 
assessing the presence of antibodies in blood plasma directed against apical merozoite 
antigen (AMA-1) and 66 positive donors selected for inclusion in experiments. Due to 
the high prevalence of HCMV in the Gambia, all of these individuals tested positive for 
anti-HCMV IgG. 
 
2.1.3 Anti-AMA1 ELISA of plasma samples 
Gambian plasma samples were tested for the presence of antibodies targeting AMA1, 
a malarial antigen expressed by infectious merozoites. The presence of anti-AMA1 
antibodies is a commonly used criterion to confirm previous exposure to malaria. 
Selected plasma samples were diluted 1 in 200 with reconstitution buffer (PBS, 0.05% 
Tween 20, 1g/L sodium azide) in 96-well flat-bottom deep well plates.  
AMA1 stock antigen consisting of 0.5 μg AMA1 protein per ml  was diluted 1/5836 in 
coating buffer (distilled water, 1.59g/L Na2CO3, 2.93g/L NaHCO3) and 50ul of the 
resulting solution added to wells of 96-well flat-bottom Immulon 4 HBX plates 
(Thermofisher). These plates were covered to prevent evaporation and left to incubate 
overnight at 4oC.  
ELISA plates were then washed three times in washing solution (PBS, 0.05% Tween 
20) and allowed to dry. 150ul of blocking solution (PBS, 0.05% Tween 20, 1% skimmed 
milk powder) was added to each well and allowed to incubate at room temperature for 
3 hours. Plates were then washed three more times in washing solution and allowed to 
dry. 
45ul of blocking solution was then added to each well, followed by 5ul of the previously 
diluted 1 in 200 plasma samples to form a final dilution of 1 in 2000. Positive and 
negative control plasmas were added to each ELISA plate to generate a standard 
reference curve. Plates were then covered and incubated overnight at 4oC to allow 
binding of antibody to AMA1-coated wells. 
Plates were then washed 5 more times in washing buffer and allowed to dry. 
Horseradish peroxidase-conjugates rabbit anti-human immunoglobulin G stock was 
then diluted in washing solution 1 in 15000. 50ul of this solution was then added to each 
well of the ELISA plates and incubated at room temperature for 3 hours. Plates were 
then washed again 5 times in washing solution and allowed to dry. 100ul of 
Tetramethylbenzidine (TMB) Liquid Substrate (Sigma) was then added to each well and 
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incubated at room temperature in the dark for 15 minutes. The ELISA reaction was then 
halted by adding 50ul of 0.2M sulphuric acid to each well.  
Plates were read immediately using a Dynex Technologies MRX II Microplate 
Absorbance Reader run at 450nm. Standard curves and positive/negative cutoffs were 
determined by Dr Joe Biggs, with the positive cutoff based on the mean optical density 
plus two standard deviations.  
 
2.2 PBMC purification, freezing, and thawing 
2.2.1 PBMC purification 
Peripheral blood mononuclear cells (PBMCs) were purified from whole blood samples 
by slowly layering 25ml of blood onto 15ml of Histopaque 1077 (Sigma-Aldrich) in a 
50ml sterile tube before centrifugation at 500g for 25 minutes with the centrifuge brake 
turned off. Once these cells formed a visibly distinct layer between Histopaque 1077 
and blood plasma, they were transferred to a fresh tube using a 25ml stripette and 
washed twice with RPMI 1640 (Thermofisher), centrifuging at 500g for 10 minutes with 
maximum braking. Viable cells were then mixed at a 1:1 dilution with Trypan blue dye 
and then counted using a FastRead 102 haemocytometer (Immune Systems). Cells 
were then resuspended in a culture medium consisting of RPMI 1640 (Thermofisher) 
supplemented with 2mM L-glutamine at the desired cell concentration. 
 
2.2.2 PBMC freezing for nitrogen storage 
PBMCs were suspended at a concentration of 2 × 107 cells/ml in RPMI 1640 
(Thermofisher) with 10% FCS and 2mM L-glutamine. Cells were diluted 1:1 with 
freezing medium consisting of 80% FCS with 20% DMSO (Sigma) and aliquoted into 
1.5ml cryotubes which were then placed in pre-chilled cryogenic freezing containers 
filled with isopropyl alcohol (Nalgene). Cells were frozen and allowed to reach a 
temperature of -80oC before being transferred to long-term liquid nitrogen storage. (N.B. 
Research has indicated that cryopreservation in DMSO and sera has no significant 
effects on NK phenotype when performed correctly 197) 
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2.2.3 Recovery of frozen PBMCs 
Cryopreserved PBMCs were thawed for use by pipetting warm RPMI 1640 onto the 
frozen cells and transferring the thawed cells into 20ml warm RPMI quickly to avoid cell 
death by prolonged exposure to unfrozen DMSO. Cells were centrifuged at 500g for 10 
minutes and washed again with RPMI 1640 before being resuspended in RPMI 1640 
supplemented with 2mM l-glutamine at the required cell concentration. 
2.2.4 NK cell enrichment 
When necessary, NK cells were enriched from PBMC mixtures using a MACS NK Cell 
Isolation Kit (Miltenyi Biotec) according to the manufacturer’s instructions. PBMCs were 
suspended in PBS supplemented with 1% bovine serum albumin (BSA) and 1% EDTA 
at a concentration of 2.5 x 108 cells/ml. Cells were incubated with 20ul of NK Cell Biotin-
Antibody Cocktail per 40ul of cell suspension (per 107 cells) for 5 minutes at 4oC. 60ul 
of PBS buffer was then added per 60ul of cell suspension (per 107 cells). 40ul of NK 
Cell MicroBead Cocktail was then added per 120ul of cell suspension of cells (per 107 
cells) and incubated for 10 minutes at 4oC. The resulting cell suspension was then 
topped up with PBS buffer to a final volume of 2ml, and run through an MS MACs 
Separator column placed within a magnetic field. The enriched runoff was collected and 
washed twice with RPMI 1640 before being resuspended in the appropriate cell 
medium. 
 
2.3 Culture of asexual-stage Plasmodium falciparum 
2.3.1 Thawing frozen erythrocytes infected with ring-stage Plasmodium 
falciparum 
Cryopreserved erythrocytes infected with ~3% ring-stage Plasmodium falciparum 
(either 3D7-strain or transgenic 3D7-strain tagged with GFP) were thawed for use by 
briefly warming the cells in a 37oC water bath for approximately 30 seconds until the 
frozen cell mass liquefied. Filtered deionised water supplemented with 3.5% NaCl was 
then added drop-wise to the thawed cell suspension until reaching a 1:1 ratio. The cells 
were then spun at 800g for 2 minutes with a slow brake and the supernatant removed 
and discarded. This process was repeated once more before resuspending the 
remaining infected erythrocytes in 10mls of parasite culture medium consisting of RPMI 
1640 (Life Technologies) with the following modifications: 2.3 g/L sodium bicarbonate, 
4 g/L dextrose, 5.957 g/L Hepes, 0.05 g/L hypoxanthine, 5 g/L AlbuMAX II (Thermo 
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Fisher Scientific) and 0.292 g/L L-glutamine. Parasitised erythrocytes were then 
cultured at 37oC in an incubator supplied with a 5% CO2, 5% O2 and 90% N2 gas 
mixture. 
 
2.3.2 Routine culturing of Plasmodium falciparum 
Erythrocytes infected with Plasmodium falciparum were cultured in 23.25ml of parasite 
culture medium (as above) supplemented with 1.25ml of packed fresh red blood cells 
to form a final culture of 25mls at 5% haematocrit kept in a 75ml filtered top flask (Nunc). 
Red blood cells were obtained from the National Blood Service, London on a weekly 
basis and kept at 4oC for storage. Parasitaemia was kept at between 0.5-2.5% for 
routine culture to prevent excessive depletion of culture nutrients. For cultures at the 
correct parasitaemia, culture medium was changed every day by spinning entire 
cultures at 800g for 2 minutes with a slow brake before removing the supernatant and 
resuspending cells in fresh medium. For cultures with parasitaemia >2.5%, 5mls of 
infected culture were removed and added to 19mls of fresh culture medium 
supplemented with 1ml fresh packed red blood cells to form a 1:5 dilution with 5% 
haematocrit. For experiments requiring high parasitaemia cultures were allowed to 
continue replicating to the required point, taking care to change culture medium 
regularly. Cultures were tested regularly for Mycoplasma contamination with a LookOut 
Mycoplasma QPCR Detection Kit (Sigma-Aldrich). Parasitaemia was monitored by 
blood films fixed with methanol and stained using 0.2µm filtered 10% giemsa solution 
(VWR Chemicals) for 10 minutes at room temperature. 
 
2.3.3 Percoll purification of late-stage Plasmodium falciparum schizonts for 
synchronisation and experiments 
In order to obtain purified cultures of late-stage schizonts for creation of synchronised 
cultures and experimentation, 25ml Plasmodium falciparum cultures were allowed to 
reach a parasitaemia of ~10-12%. 60% Percoll solution was made using 30mls Percoll 
plus 17 mls RPMI 1640 supplemented with 3ml 10X PBS. This solution was filter 
sterilised using 0.25 micron syringe filters before use. Parasite cultures were then spun 
at 800g for 2 minutes with slow brake and resuspended in culture medium at a 
haematocrit of ~40%. 2mls of 40% parasite culture were then slowly layered onto 4mls 
of prewarmed 60% Percoll solution before being spun at 800g for 10 minutes with no 
brake. Erythrocytes infected with late-stage schizonts formed a distinct layer above 
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uninfected erythrocytes and erythrocytes infected with early ring and trophozoite stage 
parasites, allowing them to be pipetted off. The late-stage schizonts were then washed 
twice in culture medium to remove any traces of Percoll, and are either recultured to 
form a synchronised culture or used directly in experiments requiring purified schizonts. 
2.3.4. Culturing uninfected erythrocytes for experiments 
Uninfected erythrocytes from pooled donors were obtained from the National Blood 
Service, London on a weekly basis and kept at 4oC for storage. Uninfected 
erythrocytes were cultured under the same conditions using the same culture media 
as described for infected erythrocytes so as to control for environmental variables that 
could affect erythrocyte phenotype. 
 
 
2.4 PBMC/NK cell assays 
2.4.1 Assessing NK cell functional markers through flow cytometry 
For functional assays PBMCs were either thawed or purified using the protocols 
described in sections 2.2.1 and 2.2.3. PBMCs were either used directly or used to 
collected enriched NK cells using the protocol described in section 2.2.4. Either PBMCs 
or enriched NK cells were incubated at 37oC with 5% CO2 in wells of 96-well U-bottom 
plates (ThermoFisher) under the required conditions for each experiment, specified in 
the relevant chapters. FCS was used as a control for Ig-free human plasma in order to 
maintain consistency with our previous publications, where we have shown that FCS is 
a viable substitute for Ig-free human plasma in NK cell culture 198. GolgiStop containing 
Monensin (BD Biosciences) was added to cultures to form a final 1/1500 concentration 
and GolgiPlug containing Brefeldin A (BD Biosciences) added to form a 1/1000 final 
concentration after either 15 hours (for 18 hour assays) or 1 hour (6 hour assays) to 
prevent protein trafficking from the endoplasmic reticulum and allow a measurable 
build-up of intracellular IFN-γ. Anti-CD107a antibody (ef660-conjugated, clone 1D4B, 
BD Biosciences) was added during culturing at 1µl per 100ul of culture suspension to 
allow sufficient staining of recycled CD107a.  
After the required period of incubation, cells were centrifuged at 500g for 5 minutes at 
maximum brake and the resulting supernatant removed by flicking the plate over a 
waste container. The cells were then washed twice with 200ul cold FACS buffer (PBS 
supplemented with 1% FCS, 1% EDTA and 0.01% sodium azide). Cells were then 
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incubated for 30 minutes at 4oC in the dark with 10µl total of the required surface 
antibody cocktail made up with FACS buffer. Cells were then rewashed with 200ul 
FACS buffer, taking care to avoid excessive exposure to light. Cells were then 
incubated in 75µl Foxp3/Transcription Factor Staining Buffer (eBioscience) for 25 
minutes at room temperature in the dark. Cells were then washed with 200ul 1X 
Permwash (BD Biosciences) twice at 500g with maximum brake and the supernatant 
again removed by flicking. Cells were then stained with 10µl total of the required 
intracellular antibody cocktail made up with Permwash for 30 minutes at 4oC in the dark. 
Cells were then washed again with 200ul Permwash, then resuspended in 300µl FACS 
buffer, transferred to alpha tubes (Alpha labs) and stored at 4oC until run on a BD LSRII 
Flow Cytometer (BD Biosciences) using the appropriate laser set.  Data was collected 
using the complementary FACSDiva software (BD Biosciences) and analysed using 
FlowJo, v.10 (FlowJo LLC). Fluorescence compensation was carried out using 
OneComp eBeads Compensation Beads (eBioscience) stained with single antibodies 
Cell samples were run until a minimum of 1000 CD56+ CD3- events were acquired. 
FMO controls were run for all staining panels in order to determine background 
fluorescence and allow accurate discrimination of positive versus negative signals. 
 
2.4.2 Assessing NK cell conjugate formation with PRBCs through imaging flow 
cytometry 
For conjugation assays PBMCs were purified from whole blood using the protocol 
described in section 2.2.1. PBMCs were then incubated at 37oC with 5% CO2, 5% O2 
and 90% N2 in 100ul wells of 96-well U-bottom plates (ThermoFisher) with either healthy 
erythrocytes or erythrocytes infected with transgenic GFP-expressing Plasmodium 
falciparum schizonts purified using the Percoll method described in section 2.3.5 (GFP 
parasites originally obtained from Professor BM Cooke, University of Monash). PBMC 
and erythrocytes were cultured under the required conditions for each experiment, 
specified in the relevant chapter.  
After the required period of incubation, cells were centrifuged at 500g for 5 minutes at 
maximum brake and the resulting supernatant removed by gentle aspiration. The cells 
were then washed once with 200ul cold FACS buffer (PBS supplemented with 1% FCS, 
1% EDTA and 0.01% sodium azide). Cells were then incubated in 75ul of 4% 
paraformaldehyde for only 15 minutes at room temperature to allowing fixation of 
conjugates whilst preventing erythrocyte lysis. Cells were then washed again with 200ul 
FACS buffer once at 500g with maximum brake and the supernatant removed by gentle 
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aspiration. Cells were then incubated for 30 minutes at 4oC in the dark with 12µl total of 
the required surface antibody cocktail. Cells were then rewashed with 200ul FACS 
buffer, taking care to avoid excessive exposure to light. Cells were then resuspended 
in 50μl FACS buffer at a final concentration of 8 x 107/ml PBMCs and erythrocytes 
combined, transferred to 1.5ml Eppendorf tubes (Sigma) and run immediately on an 
ImageStreamX Mark II Imaging Flow Cytometer (Amnis) using the appropriate lasers 
to induce fluorescence. Data was collected using INSPIRE acquisition software (Amnis) 
and analysed using IDEAS analytical software (Amnis). CD56+ CD3- events were gated 
using IDEAS, sorted based on level of GFP or glycophorin A expression and inspected 
visually to confirm whether the gated events were in fact NK-RBC conjugates based on 
the proximity of CD56+ CD3- NK cells to glycophorin A+ erythrocytes. Fluorescence 
compensation was carried out using cells stained with single antibodies to avoid conflict 
with the tracking beads used in the ImageStream sheath fluid. Cell samples were run 
until a minimum of 1000 CD56+ CD3- events were acquired. FMO controls were run for 
all staining panels in order to determine background fluorescence and allow accurate 
discrimination of positive versus negative signals. 
 
 
 
2.4.3 Assessing mechanisms of CD16 downregulation on NK cells exposed to 
flu antigen-antibody complexes through imaging flow cytometry 
For CD16 imaging assays PBMCs were purified from whole blood using the protocol 
described in section 2.2.1. PBMCs were then incubated for 5 hours at 37oC with 5% 
CO2 in 100ul wells of 96-well U-bottom plates (ThermoFisher) with trivalent flu vaccine 
supplemented with either 5% FCS or 1% pooled immune plasma collected by Dr Martin 
Goodier and Helen Wagstaffe as described in section 2.1.1.  
After the required period of incubation, cells were centrifuged at 500g for 5 minutes at 
maximum brake and the resulting supernatant removed by flicking plates. The cells 
were then washed once with 200ul cold FACS buffer (PBS supplemented with 1% FCS, 
1% EDTA and 0.01% sodium azide). Cells were then incubated for 30 minutes at 4oC 
in the dark with 12µl total of the required surface antibody cocktail. Cells were then 
rewashed with 200ul FACS buffer, taking care to avoid excessive exposure to light. 
Cells were then incubated in 75µl Foxp3/Transcription Factor Staining Buffer 
(eBioscience) for 25 minutes at room temperature in the dark. Cells were then washed 
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with 200ul 1X Permwash (BD Biosciences) twice at 500g with maximum brake and the 
supernatant again removed by flicking. Cells were then stained with 10µl total of the 
required intracellular antibody cocktail made up with Permwash for 30 minutes at 4oC 
in the dark. Cells were then washed again with 200ul Permwash, then resuspended in 
50µl FACS buffer and,run immediately on an ImageStreamX Mark II Imaging Flow 
Cytometer (Amnis) using the appropriate lasers to induce fluorescence. Data was 
collected using INSPIRE acquisition software (Amnis) and analysed using IDEAS 
analytical software (Amnis). CD56+ CD3- events were gated using IDEAS and 
inspected visually to assess CD16 staining. Fluorescence compensation was carried 
out using cells stained with single antibodies to avoid conflict with the tracking beads 
used in the ImageStream sheath fluid. Cell samples were run until a minimum of 1000 
CD56+ CD3- events were acquired. FMO controls were run for all staining panels in 
order to determine background fluorescence and allow accurate discrimination of 
positive versus negative signals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 55 
 
CHAPTER 3 
Developing an in vitro system to image conjugate formation 
between natural killer cells and erythrocytes infected with 
Plasmodium falciparum 
3.1 Introduction 
3.1.1 NK cell conjugate formation with malaria-infected erythrocytes 
Several studies have provided evidence that NK cells are able to discern the difference 
between uninfected erythrocytes and erythrocytes infected with malaria parasites, 
forming stable conjugates with the latter.  
In early flow cytometry studies conducted by Artavanis-Tsakonas et al. in 2003, 
fluorescent events positive for both NK markers and erythrocyte markers were found to 
occur more frequently when the erythrocytes were infected with Plasmodium 
falciparum, suggesting the preferential formation of conjugates with infected cells. 
Physical contact between NK cells and infected erythrocytes was also found to be 
necessary for production of IFN-γ by NK cells 188.  
In 2005 Korbel et al. directly observed physical conjugates forming between purified 
human NK cells and P.falciparum-infected erythrocytes after as little as 15 minutes co-
culture using confocal microscopy 190. In 2007, Baratin et al. similarly observed the 
formation of ‘rosettes’ between immortalised NK92 clonal NK cells and P. falciparum-
infected erythrocytes using light microscopy, each rosette consisting of multiple 
erythrocytes bound to a single NK92 cell. However, these rosettes could not be 
observed forming between infected erythrocytes and NK cells derived from peripheral 
blood 103. 
More recently in 2014, Chen et al. directly observed purified NK cells interacting with 
and killing P. falciparum-infected erythrocytes using live video microscopy. On average, 
NK cell conjugates with infected erythrocytes lasted 11-fold longer with than with 
uninfected erythrocytes, indicating an ability for NK cells to discern between the two 40. 
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3.1.2 Evidence for cytotoxic killing of infected erythrocytes as a result of 
conjugation 
 
In additional to observing NK cells preferentially forming conjugates with Plasmodium 
falciparum-infected erythrocytes versus uninfected, several studies have suggested 
that these conjugates lead to killing of infected erythrocytes through NK cell cytotoxic 
activity.  
An early in vitro study by Orago and Facer in 1991 demonstrated that erythrocytes 
infected with the blood-stage parasite can induce production of cytotoxic mediators from 
purified peripheral NK cells, leading to apparent killing of infected erythrocytes as 
determined by chromium release assays 55. A later study by Hermsen et al. in 2003 
showed that there are significantly higher levels of cytotoxic granzymes A and B in the 
plasma of individuals infected with Plasmodium falciparum in both natural and 
experimental models of infection. This latter study suggests parasitised cells also 
provoke cytotoxic functions in immune cells in vivo, though NK cells were not 
specifically implicated in this response 199.  
In 2005 Korbel et al. observed the reorganisation of cytoskeletal F-actin in purified NK 
cells bound to P. falciparum-infected erythrocytes, indicating the formation of an active 
immune synapse between NK cells and parasitised cells. This response varied 
considerable between donors however, with some individuals displaying no 
reorganisation of F-actin in response to infected erythrocytes 190. 
More recently, Chen et al. demonstrated that co-incubation of purified NK cells with 
Plasmodium falciparum-infected erythrocytes leads to significantly reduced 
parasitaemia, suggesting NK cells have an inhibitory effect on parasite replication. 
Video microscopy assays conducted in the same study also suggested that direct 
conjugate formation between purified NK cells and infected erythrocytes led to 
‘flattening’ of the erythrocytes, suggested they had been killed through cytotoxic activity 
40. 
 
3.1.3 Receptors involved in mediating conjugates 
While there is a growing body of evidence suggesting that NK cells can conjugate with 
and cytotoxically kill malaria-infected erythrocytes, the receptor-ligand interactions that 
mediate this process are not well understood. Erythrocytes do not express MHC-I (HLA) 
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molecules, and as such it is generally assumed that any interactions between NK cells 
and falciparum-infected erythrocytes must involve NK cell receptors that do not bind 
HLA.  
One early study has suggested that the NK receptors NKp30 and NKp46 may bind 
Duffy binding-like (DBL) domain of P. falciparum erythrocyte membrane protein-1 
(PfEMP-1), expressed on the surface of parasitized erythrocytes 38. However, this result 
has since been disputed by a study by Baratin et al. suggesting that PfEMP-1 is not 
required to induce NK cell activation in the presence of parasites 103. 
More recently in 2014 Chen et al. performed a systematic assay utilising antibodies to 
block the activity of various NK receptors on purified NK cells co-incubated with 
falciparum-infected erythrocytes; including NKG2D, NKp30, NKp44, NKp46, 2B4, CD2, 
DNAM-1, and LFA-1. Of these, only the blocking of DNAM-1 and LFA-1 led to any 
significant increase in subsequent parasitaemia, suggesting these co-receptors may be 
involved in mediating NK cell conjugation with infected erythrocytes 40. These results 
concur with earlier work by Baratin et al. which suggested that blocking of LFA-1 
significantly reduced NK cell activity in the presence of PRBCs, though Baratin et al. 
suggested that this was due to its role in binding ICAM-1 expressed on accessory 
PBMCs such as macrophages 103. Additional work by Baratin et al. has suggested 
macrophages provide co-stimulatory signals to NK cells in in vitro models of falciparum 
infection 105, and it may be possible that LFA-1 is involved in both direct conjugation to 
parasitised cells and indirect activation of NK cells through binding of activated 
accessory PBMCs. However, the ligand(s) for LFA-1/DNAM-1 on PRBCs are currently 
unknown. 
Additional work by Baratin et al. has suggested than the proteoglycan molecule 
chondroitin sulphate A (CSA) expressed on the surface of NK92 cells, an NK cell tumour 
line, mediates conjugation of these cells to PRBCs, potentially by binding to the 
parasite-expressed molecule PfEMP-1, although this appeared not to be required to 
induce NK cell activation. These results could not be replicated with purified NK cells 
obtained from peripheral blood however, suggesting this result may not be 
representative of in vivo infections 103. 
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3.1.4 Limitations of current methodologies 
While there is a growing body of research indicating that NK cells may be able to form 
functional cytotoxic conjugates with erythrocytes infected with Plasmodium falciparum, 
there are several limitations of the models currently in use by researchers. 
Firstly, several studies utilise models that exclude the possibility of co-stimulatory 
interactions between NK cells and accessory PBMCs such as macrophages. Many of 
the conjugation studies conducted thus far utilise NK cell lines such as NK92 or purified 
peripheral NK cells incubated alone with parasitised cells 103, 40, 55. Several studies have 
suggested that production of IFN-γ by NK cells in the presence of PRBCs is induced in 
part by direct contact with accessory PBMCs 45, 105, and it is possible that cytotoxic 
responses may be similarly regulated. 
Secondly, many of these studies fail to take into account the diversity in receptor 
expression and consequent function of different NK cell subsets. NK cells in peripheral 
blood occupy a spectrum of maturity, from undifferentiated CD56bright NK cells to the 
differentiated CD56dim CD57+ cells. These cells exhibit varied expression of natural 
cytotoxicity receptors such as the NCR family, as well as CD16 and KIR receptors 127. 
Several studies have also suggested that CD56dim NK cells express higher levels of 
LFA-1, a receptor suggested to be involved in mediating cytotoxic conjugate formation 
between NK cells and PRBCs 200,201. Studies utilising NK92 cell lines fail to account for 
this diversity as these cells are clonal and typically considered to be CD56bright 195. Other 
studies utilising purified peripheral NK cells can be assumed to have a better 
representation of NK diversity, but this is generally not accounted for during imaging or 
cytometric assays, and is not considered as a variable in any analyses of conjugate 
formation with parasitised cells 40. 
It would be of value for future research in this area to develop an in vitro imaging system 
that would take these issues into consideration. 
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3.2 Aims, Hypotheses and Objectives 
The aim of the study in this chapter was to develop an in vitro imaging system that 
would facilitate imaging of conjugates between erythrocytes and primary peripheral NK 
cells. This system would then be used to assess whether NK cells preferentially form 
conjugates with Plasmodium falciparum-infected erythrocytes versus healthy, whilst 
allowing for a) possible co-stimulatory interactions with accessory PBMCs, and b) 
categorisation of conjugates based on NK cell CD56 and CD57 expression, or 
‘maturity’.  
My hypotheses were that CD56+ human NK cells preferentially form conjugates with 
infected erythrocytes versus uninfected, and that the frequency of conjugation would 
vary depending on the differentiation status of NK cells. 
My objectives were to purify peripheral blood mononuclear cell mixtures containing NK 
cells from the whole blood of healthy donors, co-incubate them for varying time periods 
with either infected or uninfected erythrocytes, fix the cells to stabilise any conjugates 
that have formed, and then stain and image the cells using an ImageStreamX Mark II 
Imaging Flow Cytometer (Amnis). 
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3.3 Methods  
3.3.1 PBMC donors 
Five healthy volunteers were recruited from within the London School of Hygiene and 
Tropical Medicine (LSHTM) through an anonymised blood donation system operated 
by Carolynne Stanley, a trained phlebotomist. Donors are summarised in Table 3.1 by 
age, sex, nationality and malarial status. Ethical approval for this system was acquired 
from the LSHTM Ethics Committee under the ethics reference number 5520, and 
informed consent was obtained from all donors as stipulated by LSHTM and the 
appropriate regulatory bodies. 50ml of venous blood from each donor was collected in 
sterile Falcon tubes with 2 I.U. per ml of sodium heparin added to prevent coagulation. 
 
Age/Years Nationality Sex Malarial Status 
Mean              28 
Median           27 
Range          18-42 
White British  5 
Other             0 
Male              2 
Female          3 
Naïve            5 
Exposed        0 
 
 
3.3.2 Incubating PBMCs with uninfected or infected erythrocytes 
PBMCs were isolated from whole blood using the Histopaque 1077 method described 
in Section 2.2.1. PBMCs were washed and resuspended in parasite culture medium 
consisting of RPMI 1640 with 5% Albumax II and 1% Hypoxanthine (Gibco) 
supplemented with 2mM L-glutamine. Erythrocytes infected with a schizont-stage 
transgenic GFP-expressing 3D7 strain of Plasmoidum falciparum were purified to a 
parasitaemia of >95% using the Percoll method described in Section 2.2.5 and 
resuspended in parasite culture medium. 
Table 3.1 Age, nationality, sex and malarial status of donors for this study  
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PBMCs and either Plasmoidum-infected (PRBC) or uninfected (URBC) erythrocytes 
were then incubated at either a 1:1, 1:3 or 1:9 ratio for either 60, 120 or 180 minutes in 
100ul total medium in wells of a 96-well U-bottom plate as described in Section 2.4.2. 
Cell mixtures were then fixed and stained with 12ul of the antibody cocktail described 
in Table 3.2 using the method described in Section 2.4.2; 
 
 
 
3.3.3 ImageStreamX Mark II data acquisition 
After fixation and staining PBMC and erythrocyte cell mixtures were resuspended in 
50μl FACS buffer at a final concentration of 8 x 107/ml cells, transferred to 1.5ml 
Eppendorf tubes (Sigma) and run immediately on an ImageStreamX Mark II Imaging 
Flow Cytometer (Amnis) using the appropriate lasers to induce fluorescence. Single-
stained cell preparations were used to compensate for spectral overlap. Fluorescence 
positive events were collected using INSPIRE acquisition software (Amnis) and 
analysed using IDEAS analytical software (Amnis).  
Events were first gated on above average Gradient Root Mean Square (RMS) value. 
High Gradient RMS indicates that an image has a high number of different pixel shades, 
indicating that it is in focus (Fig. 3.1A). CD56+ CD3- events were then gated to identify 
NK cells, and then subsequently gated again on levels of CD56 and CD57 expression 
to categorise NK cells by into three ‘maturity’ subsets; CD56bright CD57-, CD56dim CD57-
, and CD56dim CD57+ (Fig. 3.1A). CD56+ CD3- events were then sorted and ranked 
based on levels of GFP-parasite expression (Fig. 3.1B) or glycophorin A-erythrocyte 
membrane expression (Fig. 3.1C) to assess the presence of infected or healthy 
erythrocytes. ‘Double positive’ events with at least one NK cell and one erythrocyte 
were then inspected visually to confirm whether the cells were directly conjugated. 
 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human CD56 NCAM16.2 PE-Cy7 BD Biosciences 3μl 
Mouse Anti-Human CD3 SK7 APC- eFluor® 780 eBioscience 3μl 
Mouse Anti-Human CD57 TB01 eFluor® 450 eBioscience 3μl 
Recombinant Human  
Anti-Human Glycophorin A 
REA175 PE Miltenyi Biotec 3μl 
Table 3.2 List of fluorescent antibodies used to stain the surface of NK cells for Imagestream  
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3.4 Results 
 
3.4.1 CD56+ NK cells preferentially form conjugates with erythrocytes 
infected with Plasmodium falciparum schizonts versus healthy 
erythrocytes 
PBMCs were incubated with either medium alone, healthy erythrocytes or parasitized 
erythrocytes at a 1:3 ratio in parasite culture medium for 60 minutes before being fixed, 
stained and imaged using an ImageStreamX Mark II. The percentage of CD56+ NK 
cells forming conjugates with erythrocytes was assessed via the method described in 
section 3.3.3. The gating strategy used to categorise NK subsets is shown in Figure 
3.1A, while the ranking strategy used to determine the presence or absence of 
conjugates is shown in Figures 3.1B and 3.1C. Representative examples of a non-
conjugated NK cell and conjugated NK cell are shown in Figures 3.2A and 3.2B 
respectively. 
No conjugates were found in medium controls as expected, confirming that the 
Histopaque 1077 PBMC purification had adequately removed all erythrocyte 
contamination (Fig. 3.2C). 
CD56+ CD3- NK cells cell were observed forming conjugates with uninfected 
erythrocytes in all but one of the individuals tested, with a mean of 1.05% of NK cells 
forming conjugates after 60 minutes incubation (Fig. 3.2C). However in all individuals 
tested there was a distinct increase in the frequency of CD56+ CD3- NK cells forming 
conjugates when incubated with erythrocytes parasitised with schizont-stage 
Plasmodium falciparum, with a mean of 2.54% of NK cells forming conjugates (Fig. 
3.2C). This suggested that the NK cells of all donors were able to distinguish between 
infected and uninfected cell targets. The frequency of conjugation remained 
unexpectedly low however, so it was decided to further optimise this assay. 
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Figure 3.1. Representative IDEAS analysis of NK cells and erythrocytes imaged using confocal flow cytometry      
PBMCs were purified from whole blood and incubated with either healthy or parasitized erythrocytes at a 1:3 ratio in 
parasite culture medium for 60 minutes before being fixed, stained and imaged using an ImageStreamX Mark II. (n = 5) 
A) Flow diagram demonstrating method of identifying in-focus CD56dim CD3- NK cells belonging to 3 CD56/CD57 subsets 
in ascending order of differentiation, or ‘maturity’; CD56bright CD57-, CD56dim CD57-, and CD56dim CD57+. The blue arrow 
on the third diagram shows the pathway of differentiation from least differentiated CD56bright cells to most differentiated 
CD56dim CD57+. 
B-C) Representative example of CD56+ CD3- events from one donor being ranked by B) parasite GFP expression or C) 
erythrocyte membrane glycophorin A expression to assess frequency of conjugates  
C 
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Figure 3.2. Results of conjugation assays between CD56+ NK cells and either uninfected or infected erythrocytes 
A-B) Representative images of CD56+ NK cells incubated with A) unconjugated healthy erythrocytes or B) conjugated 
erythrocytes infected with Plasmodium falciparum schizonts. (BF = bright field; GFP = parasite expressing green fluorescent 
protein; Gly A = erythrocyte membrane stained with anti-glycophorin A antibody; CD56 = NK cell membrane stained with 
anti-CD56 antibody)  
C) PBMCs were incubated with either medium alone, healthy erythrocytes or parasitized erythrocytes at a 1:3 ratio for 60 
minutes before imaging to assess conjugate frequency. Each line represents one donor without replicates. 
D-E) PBMCs were purified from whole blood and incubated with either D) PRBCs or E) healthy erythrocytes at a 1:3 ratio 
for 60, 120 or 180 minutes before imaging to assess conjugate frequency. Each line represents one donor without 
replicates. 
F-G) PBMCs were incubated with either F) PRBCs or G) healthy erythrocytes at a 1:1, 1:3 or 1:9 ratio for 60 minutes 
before imaging to assess conjugate frequency. Each line represents one donor without replicates. 
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3.4.2 The percentage of CD56+ NK cells forming conjugates with erythrocytes 
infected with Plasmodium falciparum schizonts declines over time 
In a time course assay conducted over 180 minutes, PBMCs from all donors were 
incubated with either healthy or parasitized erythrocytes at a 1:3 ratio. Samples were 
taken after 30, 60, 120 and 180 minutes before being fixed, stained and imaged as 
previously described.  
Conjugates were observed forming between CD56+ CD3- NK cells and infected 
erythrocytes at all time points, but were most frequent at the second earliest time point 
of 60 minutes incubation with a mean conjugate frequency of 2.54%, though conjugate 
frequency was almost as high after only 30 minutes with a mean of 2.44% (Fig. 3.2D). 
After 120 minutes the mean conjugate frequency declined to 1.61%, and finally to 1.1% 
after 180 minutes (Fig. 3.2D). No such effect was observed with uninfected 
erythrocytes, where the frequency of conjugation remained low throughout the assay 
with a mean frequency of 0.93% after 30 minutes incubation, 1.05% after 60 minutes, 
1.12% after 120 minutes and 0.97% after 180 minutes (Fig. 3.2E). This suggested that 
the NK cells of all donors were able to distinguish between infected and uninfected cell 
targets until at least 180 minutes after incubation, at which point the frequency of 
conjugates was similar for both infected and uninfected erythrocytes. 
 
3.4.3 The percentage of CD56+ NK cells forming conjugates with erythrocytes 
infected with Plasmodium falciparum schizonts increases with increased ratio 
of erythrocytes  
In a titration assay conducted over 60 minutes, PBMCs from all donors were incubated 
with parasitized erythrocytes at either a 1:1, 1:3 or 1:9 ratio before being fixed, stained 
and imaged as previously described.  
Conjugates were observed forming between CD56+ CD3- NK cells and infected 
erythrocytes at all ratios, but were infrequent at a PBMC to PRBC ratio of 1:1 with only 
a mean of 1.27% of CD56+ CD3- NK cells forming conjugates with parasitised targets 
(Fig. 3.2E). This increased to a mean of 2.54% at a ratio of 1:3, indicating a titre 
dependent effect. However, at a ratio of 1:9 the mean frequency of NK cells forming 
conjugates with parasitised targets remained relatively steady at 2.47%, indicating this 
effect is saturated beyond a certain ratio (Fig. 3.2E).  
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A similar effect was observed with uninfected erythrocytes, with the mean frequency of 
conjugation increasing from 0.34% at a 1:1 ratio to 1.05% at a 1:3 ratio before declining 
slightly to 0.64% at 1:9 (Fig. 3.2F). However, the mean frequency of conjugation with 
uninfected erythrocytes was lower than with PRBCs for all ratios, with a difference of 
0.93-1.9% in mean conjugate frequency between uninfected and infected erythrocytes 
(Fig. 3.2F). This provided further evidence that the NK cells of all donors were able to 
distinguish between infected and uninfected cell targets.  
 
3.4.4 Conjugates form between Plasmodium falciparum-infected erythrocytes 
and all NK cell differentiation stages 
PBMCs were purified from whole blood and incubated with parasitized erythrocytes at 
a 1:3 ratio in parasite culture medium for 60 minutes to optimise conjugate formation 
according to previous results (Fig. 3.2D, Fig. 3.2F). Cells were then fixed, stained 
subgated into three differentiation subsets ascending from least to most differentiated; 
CD56bright CD57-, CD56dim CD57- and CD56dim CD57+ (gating strategy shown in Fig. 
3.1A).  
Conjugates could be seen forming between PRBCs and CD56bright CD57- NK cells (Fig. 
3.3A), CD56dim CD57- NK cells (Fig. 3.3B) and CD56dim CD57+ NK cells (Fig. 3.3C), 
indicating the potential of NK cells at all differentiation stages to interact with PRBCs. 
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A 
B 
C 
Figure 3.3. Representative images of CD56+ CD3- NK cell subsets forming conjugates with Plasmodium falciparum-infected erythrocytes 
A-C) Representative images of erythrocytes infected with schizont-stage Plasmodium falciparum forming conjugates with; A) CD56bright CD57- NK cells; B) CD56dim CD57- NK cells; 
C) CD56dim CD57+ NK cells (BF = bright field; GFP = parasite expressing green fluorescent protein; Gly A = erythrocyte membrane stained with anti-glycophorin A antibody; CD56 = 
NK cell membrane stained with anti-CD56 antibody; CD57 = NK cell membrane stained with anti-CD57 antibody) (n = 5) 
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3.4.5 ImageStream has limited application for enumeration of NK cell subset 
specific conjugates  
The initial aim of this assay was to determine whether any of the aforementioned NK 
differentiation subsets are more or less likely to form conjugates with PRBCs in 
comparison to the other subsets. If so, this would potentially indicate selective 
expression of receptors on certain subsets that mediate conjugate formation. 
Unfortunately, the ImageStreamX Mark II imaging flow cytometer assay established in 
this study proved an inviable method to determine this. The reasoning for this will be 
discussed in greater detail in the relevant discussion section. 
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3.5 Discussion 
A number of studies conducted by various research groups over the years have 
suggested that NK cells are able to preferentially form conjugates with erythrocytes 
infected with malaria parasites in comparison to uninfected erythrocytes cultured under 
the same conditions 40,103,188,190. However, many of these studies utilise purified NK cells 
[61] or NK92 cell lines 103 when conducting conjugation assays, ignoring the potential 
role of cytokine exposure or physical contact with accessory cells in upregulating 
conjugate formation. Numerous studies conducted in viral and cancer models have 
indicated that NK cell cytotoxic activity against targets is enhanced when cultured in 
contact with accessory cells within PBMCs such as macrophages and dendritic cells, 
involving both enhanced presentation of cytokines such as IL-15, IL-12, IL-18 and IFN-
β 52, 47, 60, as well as direct activation of NK cell receptors by PBMC-expressed ligands 
such as MICA and MICB 60, 62. 
Additionally, though the role of accessory cell contact in mediating cytotoxic responses 
against malaria-infected cells has not been fully explored, several studies have 
indicated that IFN-γ production by NK cells in response to malaria is upregulated by 
physical contact between PBMCs 103, 105. Given that many of the signals required for 
IFN-γ production by NK cells are also necessary for cytotoxic activity, it is reasonable 
to assume that optimal cytotoxic responses against malaria may also require such 
contact-dependent signals.  
Most if not all of the aforementioned conjugation studies also do not distinguish between 
different NK cell subsets. In peripheral blood NK cells fall along a spectrum of cytotoxic 
‘maturity’; ranging from undifferentiated, or ‘naïve’, CD56bright CD57- NK cells 
expressing low levels of activating NK cell receptors such as NKG2C, KIRS and CD16 
(reviewed in 119), and differentiated CD56dim CD57+ NK cells expressing higher levels 
of CD16 and KIRs and lower levels of inhibitory NKG2A (reviewed in in 119). 
Consequently the latter are typically considered to be the most efficient at antibody-
independent cytotoxic killing of cancerous and virally-infected cellular targets. It 
therefore seems plausible that these cells could form cytotoxic conjugates more 
frequently with targets infected with an intracellular parasite such as Plasmodium. 
In this study I therefore set out to develop an in vitro imaging assay that would permit 
imaging of primary NK cells obtained from human peripheral blood forming conjugates 
with Plasmodium falciparum-infected erythrocytes whilst allowing for accessory cell 
contact during incubation. I also set out to stain and image these conjugates using 
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markers of NK cell maturity to assess whether different NK subsets varied in their ability 
to form conjugates. 
 
3.5.1 Primary human CD56+ NK cells preferentially form conjugates with 
erythrocytes infected with Plasmodium falciparum schizonts, but this occurs 
less frequently than previously reported 
Numerous studies conducted over the previous few decades by various research 
groups have suggested that NK cells are able to discern the difference between 
uninfected erythrocytes and erythrocytes infected with malaria parasites. In flow 
cytometry studies using peripheral PBMCs incubated with either healthy or infected 
cells, fluorescent events positive for both NK markers and erythrocyte markers are 
much more frequent when erythrocytes are infected with P. falciparum schizonts 188. In 
confocal imaging studies using purified NK cells conjugates can also be seen forming 
between purified human NK cells and infected erythrocytes after a short time in co-
culture 190. Additional imaging studies using NK92 cell lines have observed ‘rosettes’ 
consisting of multiple erythrocytes bound to a single NK92 cell forming with infected 
erythrocytes but not uninfected, though these rosettes could not be observed forming 
between infected erythrocytes and NK cells derived from peripheral blood 103. 
In this study PBMCs were purified from whole blood and incubated with either healthy 
erythrocytes or parasitized erythrocytes under optimal conditions in parasite culture 
medium. Cell mixtures were then imaged using an ImageStreamX Mark II to determine 
the percentage of CD56+ NK cells forming conjugates with erythrocytes. In keeping 
with expectations, in all individuals tested there was a noticeable increase in the 
frequency of NK cells forming conjugates when incubated with erythrocytes parasitised 
with schizont-stage Plasmodium falciparum (Fig. 3.2C). This suggested that the NK 
cells of all donors were able to distinguish between infected and uninfected cell targets 
in keeping with prior published results obtained by other researchers 40,103,188,190.  
However, the frequency of conjugation between infected erythrocytes and NK cells 
remained surprisingly low even under optimised conditions, as previous researchers 
have repeatedly reported much higher values. In 2003 Artavanis-Tsakonas et al. 
suggested that NK cells can form what appear to be conjugates with infected 
erythrocytes at a frequency of near 60% when co-cultured for 30 minutes at a 1:3 ratio 
(PBMCs:PRBCs) 188. These conjugates were defined as any event testing ‘double-
positive’ using flow cytometry with CD56 as an marker for NK cells and glycophorin A 
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as a marker for erythrocytes 188. However, as Artavanis-Tsakonas et al noted 
themselves in their study, these events could not be confirmed definitively as 
conjugates as the events were not imaged directly. Prior research by other imaging 
groups has indicated that there is transfer of cellular membrane material from target 
cells to NK cells during the formation of an immune synapse 202. It is therefore possible 
that the high frequency of CD56+ glycophorin A+ events found by Artavanis-Tsakonas 
et al using cytometry may have been due in part to transfer of glycophorin A+ 
erythrocyte membrane material to NK cells after conjugation. This would still suggest a 
high degree of conjugation had taken place between NK cells and infected erythrocytes, 
though it creates difficulty in using cytometry alone to distinguish between active 
conjugates consisting of NK and target cell bound together and NK cells that have 
retained prior membrane material from previous encounters. 
In 2005 Korbel et al also noted a high frequency of conjugate formation between NK 
cells and infected erythrocytes when imaged using confocal microscopy, with conjugate 
frequencies of between 40-50% after only 15 minutes incubation at a 1:3 ratio (NK cells 
:PRBCs) 190. Though confocal imaging can be considered a more reliable technique 
than flow cytometry, it is worth noting that this study utilised purified primary NK cells 
for assays rather than mixed PBMCs. The absence of physical interference from 
accessory cells and relatively high ratio of NK cells to infected targets may have resulted 
in greater physical contact between NK cells and targets in comparison to the assay 
described in this thesis, leading to artificially higher frequencies.  
In 2007 Baratin et al reported a similar result as Korbel et al, observing NK cells forming 
rosettes with infected erythrocytes at the relatively high frequency of 26.7% after one 
hour of co-culture at a 1:10 ratio (NK92s:PRBCs) 103. However, these results suffer from 
similar issues to those reported by Korbel et al, as Baratin et al utilised a NK92 cell line 
rather than primary PBMCs which may have overinflated the frequency of conjugation. 
Furthermore, NK92 cells are a tumour line derived from early stage NK cells, and do 
not truly reflect the functional differentiation of primary NK cells found in blood. 
Regardless of variation between the absolute frequency of conjugation found in this 
study and the results of other researchers, this study confirms prior observations that 
CD56+ CD3- NK cells preferentially form conjugates with erythrocytes infected with 
Plasmodium falciparum compared to uninfected erythrocytes. 
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3.5.2 Conjugation between primary human CD56+ NK cells and erythrocytes 
infected with Plasmodium falciparum schizonts occurs rapidly but declines 
over time 
 
Previous studies investigating conjugate formation between NK cells and infected 
erythrocytes have suggested that this process occurs fairly rapidly in co-culture, with 
some studies suggesting that NK cells are able to begin forming conjugates in less than 
an hour of co-culture 190. The results of the assays described in this thesis support these 
conclusions, as conjugates between primary NK cells and infected erythrocytes could 
be observed forming between primary NK cells and infected erythrocytes within only 30 
minutes co-culture and at a higher frequency than with uninfected control erythrocytes 
(Fig. 3.2D). 
Prior research has suggested that the frequency of conjugates forming between NK 
cells and infected erythrocytes declines rapidly in co-culture. In their 2003 flow 
cytometry study, Artavanis-Tsakonas et al found that the frequency of conjugation 
between NK cells and infected erythrocytes declined by over 50% after only two hours 
of co-culture, eventually reaching frequencies similar to with uninfected control cells by 
150-180 minutes 188. During the study described in this thesis it was decided to evaluate 
whether this result could be replicated using high-throughput imaging as a more reliable 
technique of assessing conjugate formation over time. 
 
A time course assay was carried out where PBMCs were purified from whole blood and 
incubated with parasitised erythrocytes for either 30, 60, 120 or 180 minutes. At the 
earlier time points of 30 and 60 minutes the mean frequency of conjugation was roughly 
equivalent but began to decline after 120 minutes. After 180 minutes co-culture 
conjugate frequency between NK cells and infected erythrocytes declined to a level on 
par with uninfected erythrocytes, similar to the effect seen by Artavanis-Tsakonas et al 
188.  
There are several potential explanations for these results. Perhaps the simplest 
explanation may be that as time passes, NK cells lyse infected erythrocytes through 
cytotoxic activity and consequently there are fewer and fewer erythrocytes are available 
for conjugation at later time points. In prior studies cytotoxic mediators have been 
detected in cellular supernatants after co-culture of NK cells with Plasmodium-infected 
erythrocytes 55, and at least one research group has observed NK cells directly lysing 
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infected erythrocytes after conjugation 40 which would seem to support this 
interpretation. 
Several studies have also demonstrated that NK cells participate in ‘serial killing’, 
conjugating to and killing up to 5 separate target cells sequentially before being 
depleted of cytotoxic capacity unless restimulated with cytokine or antibody 203 204. This 
can involve both depletion of cytotoxic mediators such as perforin and granzymes 204, 
as well as downregulation of receptors used to form activating contacts such as CD16, 
2B4 and DNAM-1 205. Additional studies have suggested that once NK cells have 
exhausted their killing capacity they may become apoptotic 206. The decline in conjugate 
frequency between NK cells and infected erythrocytes seen in this study may therefore 
be a result of serial lysis of infected erythrocytes by NK cells, leading to both fewer 
viable erythrocyte targets and fewer effectors as NK cells become anergic or die 
through apoptosis.  
 
3.5.3 Conjugate formation by distinct CD56/CD57 NK cell subsets  
One of the initial aims of this study was to determine whether different CD56/CD57-
defined NK cell subsets are more likely to form conjugates with parasitised erythrocytes. 
If so, this would potentially indicate selective expression of receptors on certain subsets 
that mediate conjugate formation. This could then be investigated with conjugation 
assays utilising blocking antibodies against receptors that are known to vary between 
subsets to determine their role in conjugate formation 126. Unfortunately, the 
ImageStreamX Mark II imaging flow cytometer assay study proved to be an impractical 
method to determine this. 
Acquisition of fluorescent events is considerably slower using ImageStream relative to 
conventional flow cytometry due to the need to image each event as it passes through 
the flow cell using a set of confocal cameras. Renting the ImageStream equipment is 
also a far more expensive technique than in-house flow cytometry, with per-hour costs 
in excess of seven times higher than conventional techniques. The combination of these 
factors prohibited a thorough investigation into the relative ability of different NK cell 
maturity subsets to form conjugates with parasitised cells, as acquiring a sufficiently 
high number of CD56+ events for each maturity subset to perform a valid comparison 
could not be achieved within an acceptable budget.  
Distinct CD56/CD57 maturity subsets are clearly present in these data (Fig. 7A), and 
conjugates could be observed forming between NK cells of each of these subsets and 
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infected erythrocytes (Fig. 9A-9C). However, comparing the absolute frequency of 
conjugates between subsets becomes unreliable when subsets comprise of only a 
hundred or few hundred total acquired events, particularly when conjugates are 
infrequent. Under these conditions, a difference of only a few events can translate into 
large percentage differences. As with all techniques utilising fluorescence, 
ImageStream is vulnerable to the effects of cellular autofluorescence or non-specific 
antibody staining resulting in a certain level of fluorescent noise 207. Whilst with high 
event numbers these issues are generally considered negligible, their capacity to skew 
the interpretation of data is much higher with low event numbers. Given these issues, it 
was decided that ImageStream is an unreliable technique to evaluate this hypothesis 
under our original parameters. 
Previous researchers have reported observing much higher frequencies of conjugate 
formation when using purified NK cells or NK cell lines rather than mixed peripherical 
blood mononuclear cells, with frequencies often in the double-digits 188, 190, 103. 
Consequently, one possible method of compensating for the issue of low conjugate 
frequency in future work with ImageStream may be to abandon the concept of allowing 
for accessory PBMC contact and cytokine production and simply use purified peripheral 
NK cells or an NK92 cell line. Whilst this would diminish the extent to which the results 
could be extrapolated to real in vivo infections, it would perhaps allow for more efficient 
data acquisition and subsequent analysis of the relative conjugation frequencies of 
CD56/CD57 subsets. Additionally, whilst physical accessory cell contact with PBMCs 
would be difficult to mimic under these conditions, the effect of cytokines such as IL-12 
and IL-18 produced by accessory cells could perhaps be simulated by supplementation 
of culture medium with soluble cytokines. 
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CHAPTER 4 
 Investigating mechanisms of CD16 downregulation during 
antibody-dependent natural killer cell responses  
4.1 Introduction 
4.1.1 CD16: function and expression on NK cells 
CD16 (FcγRIII) is an activating receptor belonging to the immunoglobulin superfamily 
of proteins. It is ubiquitously expressed on CD56dim NK cells, and its expression is 
upregulated alongside increased expression of CD57 as NK cells differentiate into a 
more differentiated  state, resulting in significantly enhanced antibody-dependent 
responses in this subset 126. CD16 binds the Fc region of immunoglobulin G molecules 
produced by B-lymphocytes. When multiple CD16 molecules bind immunoglobulin in 
proximity the receptors become cross-linked, activating NK cells to direct cytotoxic 
activities against opsonised cellular targets, and in some circumstances, to produce 
pro-inflammatory cytokines such as IFN-γ and TNFα 208,209.  
Signalling through CD16 occurs by association with either CD3ζ or FcɛRIγ, 
transmembrane protein chains containing immunoreceptor tyrosine-associated 
activation motifs (ITAMs) used to initiate signalling cascades 66, 210. Cross-linking of 
CD16 and subsequent phosphorylation of ITAM residues results in increased 
intracellular calcium levels, inducing the activity of nuclear factors NFATp and NFATc 
which initiate DNA transcription 211. 
 
4.1.2 Downregulation of CD16 after ligation of immunoglobulin G 
Once CD16 has been cross-linked by antibody and has successfully transduced an 
activating signal to the NK cell, it is rapidly downregulated on the surface of the cell 212. 
ADAM17, a metalloproteinase expressed by the majority of leukocytes, mediates this 
process. ADAM17 plays a broad role in shedding of leukocyte receptors such as TNFRI 
and adhesion molecules such as CD62L in addition to CD16 213. After CD16 ligation by 
IgG, ADAM17 cleaves CD16 at a membrane proximal cleavage region, leading to 
reduced sensitivity to antibody-dependent activation 214 
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4.1.3 CD16 downregulation:  a role for internalisation 
Several studies have validated the role of ADAM17 in CD16 cleavage from the NK 
surface resulting in downregulated antibody-sensitivity 213,214. However, there are 
sporadic reports indicating that a second mechanism of CD16 downregulation involving 
internalisation into the cell may also be involved.  
In 2007 Cecchetti et al performed a series of experiments utilising confocal microscopy 
to image NK cells after stimulation with antibody, and reported seeing CD16 enter the 
cytoplasm from the cell surface 215. This process was dependent on a functional actin 
cytoskeleton, and Cecchetti et al therefore theorised that CD16 may also be internalised 
into the cell for recycling or degradation via actin-dependent endocytosis as is the case 
with many other NK receptors 215, 216.  
Subsequent attempts to replicate these results have seemingly contradicted these 
findings, though a limited number of studies have investigated the issue 212 213. There 
remains a valid question therefore whether CD16 downregulation on antibody-
stimulated NK cells is purely a result of shedding by ADAM17, or whether a secondary 
mechanism exists by which CD16 is internalised for possible recycling or degradation. 
 
4.2 Aims, Hypotheses and Objectives 
The aims of the study in this chapter were to establish a reliable assay that induces 
downregulation of CD16 and degranulation in NK cells in response to influenza antigen 
and immune plasma. This assay will then be used to investigate whether the 
downregulation of CD16 seen on NK cells after this stimulation is purely a result of 
metalloprotease-mediated shedding from the cell surface, or whether a second 
mechanism exists by which CD16 is internalised into the cell.  
My hypotheses were that influenza antigen-antibody complexes would induce 
significant downregulation of CD16 on NK cells leading to degranulation, and that this 
downregulation would be partly a result of internalisation of CD16 into NK cells. 
My objectives were to purify NK cells from the whole blood of healthy donors, incubate 
them in the presence of influenza-immune serum acquired from vaccinated donors and 
trivalent influenza vaccine antigen, stain and fix the cells, and then run the resultant cell 
mixtures through either an LSRII flow cytometer (BD Biosciences) to assess CD16 
downregulation and functional activity, or through an ImageStreamX Mark II Imaging 
Flow Cytometer (Amnis) to image the spatial distribution of CD16.  
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4.3 Methods  
4.3.1 European PBMC donors for Imagestream 
5 healthy volunteers were recruited from within the London School of Hygiene and 
Tropical Medicine (LSHTM) through an anonymised blood donation system operated 
by Carolynne Stanley, a trained phlebotomist. Donors are summarised in Table 4.1 by 
age, nationality and sex. Ethical approval for this system was acquired from the LSHTM 
Ethics Committee under the ethics reference number 6237, and informed consent was 
obtained from all donors as stipulated by LSHTM and the appropriate regulatory bodies. 
50ml of venous blood from each donor was collected in sterile Falcon tubes with 2 I.U. 
per ml of sodium heparin added to prevent coagulation. Peripheral blood mononuclear 
cells were purified for use in imaging experiments. 
 
Age/Years Nationality Sex 
Median             34 
Range           27-53 
White British              5 
Other                         0 
Male              1 
Female          4 
 
 
4.3.2 Influenza-immune European PBMC and plasma donors for flow cytometry 
Prior to the current study, 17 healthy volunteers had been recruited from within the 
London School of Hygiene and Tropical Medicine (LSHTM) through an anonymised 
blood donation system operated by Carolynne Stanley, a trained phlebotomist. Donors 
are summarised in Table 4.2 by age and vaccination status. All donors received a single 
dose of 2012–2013 seasonal trivalent influenza vaccine (TIV) by the intramuscular 
route (Split Virion BP, Sanofi Pasteur MSD), performed by the study clinician Dr Ron 
Behrens who provided medical supervision for the original visit as well as follow-up care 
in the event of side effects. Ethical approval for this system was acquired from the 
LSHTM Ethics Committee under the ethics reference number 6237, and informed 
consent was obtained from all donors as stipulated by LSHTM and the appropriate 
regulatory bodies. 50ml of venous blood from each donor was collected in sterile Falcon 
tubes with 2 I.U. per ml of sodium heparin added to prevent coagulation. Blood samples 
were collected immediately after vaccination and at various time points after 
vaccination. Purification and storage of frozen PBMC and plasma for use in future 
Table 4.1 Age, nationality and sex of donors for this assay  
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experiments and quantitation of anti-TIV IgG was coordinated Dr Martin Goodier at 
LSHTM. 
 
Age/Years Influenza Vaccines Received 
Prior to Study 
Vaccines Received 
During Study 
Median           37.5 
Range          21-63 
None                                17 
Intramuscular TIV             0 
Intranasal TIV                   0 
Intramuscular TIV      17   
Other                          0 
 
 
4.3.3 Incubating PBMCs with trivalent flu vaccine for imaging flow cytometry 
PBMCs were isolated from whole blood using the Histopaque 1077 method described 
in Section 2.2.1. PBMCs were washed and resuspended in RPMI 1640 supplemented 
with 2mM L-glutamine. 2 × 106 freshly isolated PBMC were then cultured for a total of 5 
hours with inactivated TIV (Split Virion BP, Sanofi Pasteur MSD) in 100ul total medium 
supplemented with either 5% fetal calf serum or 1% pooled immune plasma acquired 
from influenza-exposed donors (PIP) diluted with FCS to give a total concentration of 
5% serum in wells of a 96-well U-bottom plate as described in Section 2.4.3. PBMCs 
were then stained with 12ul of the antibody cocktail described in Table 4.3 using the 
method described in section 2.4.3. 
 
 
After staining cells were washed twice in FACS buffer (PBS, 1% EDTA, 1% FCS, 0.01% 
sodium azide) a blocking step was performed for an additional 15 minutes with 3ul of 
unconjugated Mouse Anti-Human CD16 (Clone:3G8, BD Biosciences) diluted in 12ul 
total volume of FACS buffer to ensure all remaining CD16 surface epitopes were bound 
by antibody. Cells were then fixed, permeabilised and stained for a further 30 minutes 
with 3ul of Mouse Anti-Human CD16 PE-Dazzle 594 (Clone:3G8, Biolegend) diluted in 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human CD56 B159 PE-Cy7 BD Biosciences 3μl 
Mouse Anti-Human CD3 UCHT1 PE BD Biosciences 3μl 
Mouse Anti-Human CD16 3G8 APC Biolegend 3μl 
Mouse Anti-Human CD57 TB01 E450 eBioscience 3μl 
Table 4.3. List of fluorescent antibodies used to stain the surface of NK cells for ImageStream  
Table 4.2 Donor age, prior vaccine status and vaccines received for this assay  
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12ul total volume of FACS buffer to stain intracellular CD16 before being washed as 
described in Section 2.3.4. 
 
4.3.4 ImageStreamX Mark II data acquisition 
After staining and fixation PBMC were resuspended in 50μl FACS buffer at a final 
concentration of 8 x 107 cells/ml, transferred to 1.5ml Eppendorf tubes (Sigma) and run 
immediately on an ImageStreamX Mark II Imaging Flow Cytometer (Amnis) using the 
appropriate lasers to induce fluorescence. Single-stained cell preparations were used 
to compensate for spectral overlap. Fluorescence positive events were collected using 
INSPIRE acquisition software (Amnis) and analysed using IDEAS analytical software 
(Amnis). Cell samples were run until a minimum of 1000 CD56+ CD3- events were 
acquired. 
Events were first gated on above average Gradient Root Mean Square (RMS) value. 
High Gradient RMS indicates that an image has a high number of different pixel shades, 
indicating that it is in focus (Fig. 4.1A). CD56+ CD3- events were then gated to identify 
NK cells, and then subsequently gated again on levels of surface CD16 expression to 
categorise NK cells by into three functional subsets; CD16negative, CD16reduced, and 
CD16strong (Fig. 4.1A). Events were inspected visually to determine the presence or 
absence of internalized CD16. 
 
4.3.5 Incubating PBMCs with trivalent flu vaccine for functional flow cytometry 
Frozen PBMC samples from European donors were thawed using the protocol 
described in section 2.2.3. PBMCs were thawed from unimmunised donors and the 
same donors 2, 4, 6 or 12 weeks after immunisation with the 2012–2013 seasonal 
trivalent influenza vaccine (TIV) by the intramuscular route (Split Virion BP, Sanofi 
Pasteur MSD). 2 x 105 PBMCs from each donor and timepoint were incubated for 6 
hours at 37oC with 5% CO2 in wells of 96-well U-bottom plates (ThermoFisher) with 
autologous plasma alone or autologous plasma with TIV. GolgiStop containing 
Monensin (BD Biosciences) was added to cultures to form a final 1/1500 concentration 
and GolgiPlug containing Brefeldin A (BD Biosciences) added to form a 1/1000 final 
concentration after 1 hour of incubation. Anti-CD107a antibody (FITC-conjugated, clone 
H4A3, BD Biosciences) was added during culturing at 1µl per 100ul of culture 
suspension.  
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After the required period of incubation, cells were washed and stained for 30 minutes 
at 4oC in the dark with 10µl total of the surface antibody cocktail described in Table 4.4 
using the protocol as described in section 2.4.1. Dead and dying cells were excluded 
using APC-efluor780-conjugated fixable viability dye (eBioscience).  
 
 
 
 
 
 
Cells were then washed, fixed, rewashed and resuspended in 300µl FACS buffer. Cells 
were transferred to alpha tubes (Alpha labs) and stored at 4oC until run on a BD LSRII 
Flow Cytometer (BD Biosciences) using the appropriate laser set.  Data was collected 
using the complementary FACSDiva software (BD Biosciences) and analysed using 
FlowJo, v.10 (FlowJo LLC). Fluorescence compensation was carried out using 
OneComp eBeads Compensation Beads (eBioscience) stained with single antibodies. 
This assay was performed in collaboration with Dr Martin Goodier and Chiara Lusa, an 
MSc student. 
 
4.3.6 Statistical analyses 
Statistical analyses were performed with Prism 7.03 (Graphpad), as specified for each 
experiment. Data were excluded when the gated cell subset contained fewer than the 
required minimum number of cells. All statistical tests are two-sided, with p values 
stated as follows; **** <p 0.0001; *** p< 0.001; ** p< 0.01; * p< 0.05. Specific statistical 
tests and sample sizes are stated in the relevant figure legends. 
 
 
 
 
 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human CD56 B159 PE-Cy7 BD Biosciences 1ul 
Mouse Anti-Human CD3 UCHT1 V500 BD Biosciences 1ul 
Mouse Anti-Human CD57 TB01 eFluor® 450 eBioscience 1ul 
Mouse Anti-Human CD16 CB16 APC eBioscience 1ul 
Mouse Anti-Human CD69 FN50 PE eBioscience 1ul 
Table 4.4. List of fluorescent antibodies used to stain the surface of NK cells for flow cytometry  
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4.4 Results 
 
4.4.1 CD56+ CD3- NK cells downregulate CD16 after stimulation with influenza 
trivalent vaccine antigen and immune plasma but not with either alone 
Before conducting CD16 internalisation experiments, we first attempted to establish a 
reliable assay that induces downregulation of CD16 and subsequent degranulation in 
NK cells in response to influenza antigen and immune plasma. We used a combination 
of imaging and conventional flow cytometry to establish this assay. 
For imaging experiments, PBMCs were purified from whole blood and incubated with 
trivalent flu vaccine containing influenza antigen supplemented with either 5% fetal calf 
serum or 1% pooled immune plasma (PIP) for 6 hours. Cells were then stained, fixed 
and imaged using an ImageStreamX Mark II. CD56+ CD3- NK cells were gated based 
on CD16 surface expression level as described in section 4.3.4. (gating shown in Fig. 
4.1A and 4.1B) 
All donors tested demonstrated a distinct decrease in the proportion of CD56+ CD3- 
NK cells expressing ‘strong’ levels of surface CD16 after treatment with TIV and PIP in 
comparison to TIV with control FCS (Fig.4.1C). The percentage of cells expressing 
strong levels of CD16 decreased from a mean of 47.8% in response to FCS to mean of 
20.2% in response to PIP. All donors demonstrated a decrease in NK cells expressing 
strong levels of CD16, though there was some degree of heterogeneity in this response 
with a decrease of between 7.6-47.7% for all donors. 
At the same time CD56+ CD3- NK cells were observed in all donors exhibiting a 
complementary reduction in the levels of surface CD16 after treatment with TIV in the 
presence of PIP, but not with FCS (Fig. 4.1D). The percentage of cells expressing 
‘reduced’ levels of CD16 increased from a mean of 19% in response to FCS to mean 
of 44.2% in response to PIP. Interestingly, substantial heterogeneity was observed in 
the extent of CD16 down-regulation responses despite the same pooled immune 
plasma being used in the different individuals tested. This indicated that cell intrinsic 
factors may influence the extent of the antibody-dependent response in different 
individuals. 
A representative example of an NK cell stained and imaged for CD16 is shown in Figure 
4E. 
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Figure 4.1 Representative ImageStream gating and imaging of TIV-exposed NK cells  
PBMCs incubated with trivalent influenza vaccine (TIV) supplemented with either 5% fetal calf serum (FCS) or 1% pooled 
immune plasma (PIP) in RPMI 1640 with 2mM L-glutamine for 5 hours before imaged using an ImageStreamX Mark II.  
A) Flow diagram demonstrating method of identifying in-focus CD56dim CD3- NK cells  
B) Examples of CD56+ CD3- events being gated by surface CD16 expression into 3 CD16 subsets; negative, reduced and 
strong, after incubation with TIV and either FCS (left) or PIP (right) 
C-D) PBMCs were incubated with TIV supplemented with either 5% FCS or 1% PIP for 5 hours before flow imaging to assess 
the percentage of CD56+ CD3- NK cells in either the A) CD16strong or B) CD16reduced subsets 
E) Representative image of unstimulated CD56+ CD3- CD57+ CD16strong NK cell (BF = bright field; CD3 = marker for T cells 
[absent]; CD56 = anti-CD56 antibody; CD57 = anti-CD57 antibody; CD16 internal = internal anti-CD16 antibody [absent]; 
CD16 external = surface anti-CD16 antibody 
E 
C D 
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For conventional flow cytometry experiments plasma from 17 donors at 7 time points 
(immediately after vaccination; or 2, 4, 6, 12. 24 or 36 weeks after intramuscular 
influenza vaccination) were thawed from frozen stocks. Median anti-influenza antibody 
titres in the plasma were assessed via ELISA by Dr Martin Goodier and Chiara Lusa, a 
MSc student, and were found to significantly increase shortly after vaccination, before 
declining slowly over the following weeks (Fig. 4.2A). Median baseline antibody titres in 
the study group were 429.9 (IQR = 299.4-767.2) Arbitrary Elisa Units (AEU), while the 
highest median anti-influenza antibody titres were found 2 weeks after vaccination 
(1027.0 AEU, IQR:742-1089). It was decided to use plasma from this time point in future 
experiments assessing functional responses to antibody.  
PBMCs from the 17 donors were incubated with 1% autologous plasma collected 
immediately after vaccination or 2 weeks after vaccination; either alone or with TIV. 
PBMCs were incubated under these conditions for 6 hours before being stained, fixed 
and imaged using an LSRII flow cytometer as described in section 4.3.5. 
Total CD56dim as well as CD56dim CD57- and CD56dim CD57+ NK cells significantly 
downregulated CD16 in response to TIV and immunised plasma collected immediately 
after vaccination in comparison to cells incubated with plasma alone, though this effect 
was relatively small (p< 0.05 for both subsets, Fig. 4.2D).  
In contrast, downregulation of CD16 was much more pronounced in all subsets in 
response to TIV and immunised plasma collected 2 weeks after vaccination in 
comparison to plasma alone (p<0.001 for all subsets, Fig. 4.2D). CD16 MFI was 
significantly lower in all subsets when incubated with plasma collected 2 weeks post 
vaccination than plasma collected immediately (p<0.001 for all subsets, Fig. 4.2D).  
Downregulation of CD16 in the presence of immune plasma and trivalent influenza 
vaccine antigen was dependent on the presence of antibody, as pooled immune plasma 
depleted of IgG (7.6 AEU anti-TIV IgG) was unable to induce significant downregulation 
of CD16 compared to IgG replete pooled immune plasma (413.4 AEU). Trivalent 
influenza vaccine antigen alone was also unable to induce CD16 downregulation in the 
absence of immune plasma, indicating the need for antigen-antibody complexes to 
induce this effect (Fig. 4.2E). 
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Figure 4.2 Representative flow cytometry gating of TIV-exposed NK cells and graph of anti-influenza ELISA titres 
over time 
A) Graph showing median anti-influenza antibody titres with interquartile ranges at various timepoints after vaccination 
with intramuscular influenza vaccine (n = 17, one-way repeated measures ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001) 
B) Diagram of gating strategy, including NK cell gate (left), and NK maturity subset gate (right).  
C) Diagram of gating strategy for NK CD16 expression. PBMCs incubated with 1% pooled immune plasma either with 
(right) or without (left) trivalent influenza vaccine (TIV) for 6 hours.  
D) PBMCs incubated with 1% pooled plasma collected either prior to vaccination (x-axis = 0) or two weeks post vaccination 
(x-axis = 2) with (shaded bars) or without (white bars) trivalent influenza vaccine for 6 hours (n = 17, Mann–Whitney U 
test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data represent median values with interquartile ranges. 
E) PBMCs incubated with either FCS, IgG depleted plasma or immune plasma in either the presence or absence of 
trivalent influenza vaccine antigen (TIV) for 5 hours (n = 10, Mann–Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001) 
These assays were performed in collaboration with Dr Martin Goodier and Chiara Lusa, an MSc student. Figures adapted 
from Goodier, Lusa and Sherratt et al (2016) Frontiers in Immunology 
 
D 
E 
C 
P a g e  | 85 
 
4.4.2 CD56+ CD3- NK cells degranulate after stimulation with TIV antigen and 
immune plasma and this effect is most prominent in highly differentiated cells 
In conventional flow cytometry experiments, PBMCs from 17 donors were incubated 
with 1% pooled plasma collected immediately after intramuscular vaccination or 2 
weeks after vaccination; either alone or with TIV. PBMCs were incubated under the 
conditions as described in section 4.3.5. 
CD56dim NK cells and CD56dim CD57- and CD56dim CD57+ subsets significantly 
upregulated presentation of CD107a in response to TIV antigen combined with either 
baseline (week 0) or post- vaccination plasma (week 2) collected immediately after 
vaccination in comparison to parallel cultures with no antigen. However, this effect was 
relatively small (p< 0.05 for both subsets, Fig. 4.3A).  
However, while CD56dim NK cells and differentiation subsets responded to TIV and 
plasma collected at either time point, the degranulation response was significantly 
higher in both subsets in response to TIV and immunised plasma collected 2 weeks 
after vaccination in comparison to plasma collected at baseline (week 0) (p<0.05 for all 
subsets, Fig. 4.3A).  
The degranulation response was also noticeably stronger in the CD57+ subset, both 
when incubated with TIV and plasma collected immediately or TIV and plasma collected 
after two weeks. After incubation for 6 hours with TIV and plasma collected immediately 
after vaccination 18% of CD57+ cells begun degranulating in comparison to 10% of 
CD57-, while after incubation with TIV and plasma collected after 2 weeks 22% of 
CD57+ cells begun degranulating in comparison to 12% of CD57- (Fig. 4.3A). 
Downregulation of CD16 MFI and percentage of NK cells degranulating were 
significantly inversely correlated in both the CD56dim CD57- (p< 0.01, Fig. 4.3B) and 
CD56dim CD57+ (p<0.001, Fig. 4.3B) subsets. Interestingly, this correlation was 
stronger for the more differentiated CD57+ subset. Increasing immune plasma 
concentration was also associated with both increased downregulation of CD16 and 
increased degranulation, most prominently in CD57+ cells which constitutively have 
higher expression of CD16 (Fig. 4.3C-D). This correlation could indicate that 
downregulation of CD16 
 was due to binding of anti-influenza antigen-antibody complexes to NK cells and 
subsequent degranulation of those cells. This would be consistent with the increased 
capacity of highly differentiated CD56dimCD57+ NK cells to respond to antigen-antibody 
complexes. 
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Figure 4.3 Reciprocal loss of CD16 and  activation of degranulation in response to immune plasma and TIV 
A) PBMCs were thawed from frozen stocks and incubated with 1% pooled plasma collected either prior to vaccination (x-axis 
= 0) or two weeks post vaccination (x-axis = 2) in RPMI 1640 with 2mM L-glutamine either with (shaded bars) or without 
(white bars) trivalent influenza vaccine (TIV) for 6 hours before being stained for CD107a. Cells were then fixed and run 
through an LSRII flow cytometer (n = 17, Mann–Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Data 
represent median values with interquartile ranges. 
B) Correlation plots of average NK cells CD16 MFI (y-axis) versus percentage of NK cells presenting CD107a (x-axis) after 
stimulation with TIV and pooled immune plasma in either CD56dim CD57- NK cells (left plot) or CD56dim CD57+ NK cells (right 
plot) (n = 17, linear regression) 
C-D) Plots of median NK cell CD16 MFI (C) or mean percentage of NK cells expressing CD107a (D) for 3 NK cell 
differentiation subsets after stimulation with TIV and plasma, vs plasma concentration (x-axis) (n = 17, p-values refer to 
comparisons between CD56dimCD57− and CD56dimCD57 + NK cell subsets using Mann–Whitney U test. *p < 0.05, **p < 0.01, 
***p < 0.001) 
These assays were performed in collaboration with Dr Martin Goodier and Chiara Lusa, an MSc student. Figures adapted 
from Goodier, Lusa and Sherratt et al (2016) Frontiers in Immunology 
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4.4.3 Downregulation of CD16 on CD56+ CD3- NK cells stimulated with 
antibody-influenza antigen complexes does not involve internalisation of CD16 
 
For imaging experiments, PBMCs were purified from whole blood and incubated with 
trivalent flu vaccine containing influenza antigen supplemented with either 5% fetal calf 
serum or 1% pooled immune plasma as described in section 4.3.4. Cells were run 
through an ImageStreamX Mark II imaging flow cytometer and gated on CD16 surface 
expression level, then examined visually for CD16 internal fluorescence. 
No visible internalisation of CD16 was seen in the CD16reduced subset after treatment 
with TIV and PIP despite visible downregulation of CD16 on the surface of the cells 
(Fig. 4.4B) in comparison to the CD16strong subset (Fig. 4.4A). Additionally, no 
internalisation of CD16 was seen in either the CD16negative (Fig. 4.4C) or CD16strong 
subsets (Fig. 4.4A). These results were consistent in the control FCS treatment, with 
no internalisation of CD16 seen in any subset after treatment with TIV and FCS. These 
results suggested no apparent mechanism for CD16 internalisation after stimulation 
with influenza antibody-antigen complexes. 
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CD16strong CD56+ CD57- CD3- NK cell after TIV + 1% PIP 
CD16reduced CD56+ CD57- CD3- NK cell after TIV + 1% PIP 
CD16negative CD56+CD57- CD3- NK cell after TIV + 1% PIP 
Figure 4.4 Representative IDEAS analysis of TIV-exposed NK cells  
PBMCs were incubated with trivalent influenza vaccine (TIV) supplemented with either 5% fetal calf serum (FCS) ot 1% 
pooled immune plasma (PIP) in RPMI 1640 with 2mM L-glutamine for 5 hours before being stained, fixed and imaged using 
an ImageStreamX Mark II (n = 5 donors). A minimum of 5000 NK cells were analysed per donor. 
A-C) Representative images of CD56+ NK cells incubated with TIV supplemented with 1% PIP in either the C) CD16strong 
D) CD16reduced or E) CD16negative subsets (BF = bright field; CD3 = marker for T cells [absent]; CD56 = NK cell membrane 
stained with anti-CD56 antibody; CD57 = NK cell membrane stained with anti-CD56 antibody [absent in these examples]; 
CD16 internal = internal anti-CD16 marker [absent]; CD16 external = NK cell membrane stained with anti-CD16 antibody 
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4.5 Discussion 
It has been observed repeatedly by several research groups that CD56+ CD3- NK cells 
downregulate surface expression of the Fc receptor CD16 after it binds antibody-
antigen complexes 212. It has also been firmly established that this process of 
downregulation involves the metalloprotease ADAM17, which cleaves CD16 at a 
membrane proximal cleavage region, leading to reduced sensitivity to antibody-
dependent activation 214. However, it has also been suggested that a second 
mechanism for downregulation of CD16 may exist, involving internalisation into the cell 
for recycling or degradation via actin-dependent endocytosis 216. This hypothesis is 
based on the results of imaging studies purporting to demonstrate CD16 being 
internalised into NK cells after stimulation 215, though subsequent efforts to replicate 
these results have been conflicting 212.  
Consequently, it was decided to investigate this hypothesis using high-throughput 
imaging flow cytometry to assess definitively whether such a secondary mechanism of 
downregulating CD16 exists. An influenza vaccine model of antibody-dependent 
activation was used to test the mechanisms of CD16 downregulation, as our group has 
previously established that a combination of trivalent influenza vaccine and immune 
plasma produce significant antibody-dependent responses in NK cells 217. However, as 
the CD16 cellular machinery is largely invariant and does not require antigen-specificity, 
it is assumed that these results can be generalised to the generic antibody-dependent 
response 66,210. 
 
4.5.1 CD56+ CD3- NK cells downregulate surface-expressed CD16 after 
stimulation with influenza antigen-antibody complexes 
In this study, two separate but complementary methods were used to assess whether 
CD16 is downregulated on the surface of NK cells after stimulation with influenza 
antigen-antibody complexes; conventional flow cytometry and imaging cytometry. 
In imaging experiments, donor PBMCs stimulated with trivalent influenza vaccine 
antigen (TIV) and pooled immune plasma (PIP) had higher proportions of NK cells 
expressing reduced levels of CD16 and lower proportions of NK cells expressing high 
levels of CD16 in comparison to controls (Fig. 4.1C-D). 
In keeping with previously published results, this suggested that NK cells in all donors 
tested has downregulated CD16 on their NK cells in response to antibody-antigen 
P a g e  | 90 
 
complexes formed by mixing immune plasma with influenza vaccine antigen 217. This 
suggested that CD16 had either been shed from the surface of NK cells by the action 
of ADAM17 metalloprotease 213 or possibly internalised after binding antibody-antigen 
complexes and transducing an activation signal to the cells.  
In conventional flow cytometry experiments stimulation with TIV and plasma caused 
both CD56dim CD57- and CD56dim CD57+ NK cells to significantly reduce in median 
CD16 MFI in comparison to cells incubated with plasma alone (Fig. 4.2C). This 
suggested that NK cells of both subsets downregulate CD16 on their cell surface in 
response to antibody-antigen complexes formed in the presence of both flu antigen and 
immune plasma, as our research group has previously seen in our published work 217. 
This response was also significantly greater when using plasma collected 2 weeks after 
intramuscular vaccination rather than plasma collected immediately (Fig. 4.2C), likely a 
result of the significantly higher anti-influenza antibody titres detected at the 2 week 
timepoint leading to a greater concentration of antibody-antigen complexes (Fig. 4.2A).  
It must be noted however that the apparent downregulation in CD16 seen in these 
experiments may also be due to experimental errors, such as antigen-antibody 
complexes blocking access to CD16 by anti-CD16 labelling antibodies, or fixation and 
permeabilization of cells prior to staining leading to deformation of the CD16 surface 
receptor and potentially preventing binding of anti-CD16 labelling antibody. In future 
experiments these possibilities could be accounted for by using multiple staining panels 
utilising different clones of anti-CD16 designed to bind to different sites on the receptor. 
If CD16 downregulation is consistent regardless of the site targeted for labelling, this 
would indicate that downregulation is due to genuine downregulation of CD16 rather 
than methodological issues arising from blocking or deformation of any one specific 
binding site. Alternatively, the amount of CD16 receptor present in the surrounding 
surface medium could be quantified using proteomic techniques. A greater quantity of 
soluble CD16 present in surrounding medium after stimulation would also indicate 
CD16 had been downregulated through shedding rather than simply being unlabelled. 
 
4.5.2 Downregulation of CD16 after stimulation with flu antigen-antibody 
complexes leads to degranulation, and this is more prominent in CD57+ cells 
In conventional flow cytometry experiments, both CD56dim CD57- and CD56dim CD57+ 
cells demonstrated significantly higher presentation of CD107a on their cell surface 
after stimulation with TIV and plasma, indicating they had begun degranulating (Fig. 
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4.3A). Linear regression analysis revealed a significant inverse correlation between 
average CD16 MFI and the percentage of NK cells presenting CD107a, suggesting that 
binding of flu antigen-antibody complexes to NK cells is associated with degranulation 
by NK cells (Fig. 4.3B).  
This result is in keeping with the established literature on the subject. Several research 
groups have published data in cellular, animal and human ex vivo models indicating 
that NK cells exhibit degranulation and subsequent cytotoxic activity in response to 
influenza antigen-antibody complexes binding and crosslinking CD16, leading to 
transduction of activation signals into the cell 218–220. Our own results further validate 
this model. 
Whilst both CD56dim CD57- and CD56dim CD57+ cells demonstrated significantly higher 
presentation of CD107a on their cell surface after stimulation with TIV and immunised 
plasma, this response was noticeably higher in CD57+ cells (Fig. 4.3A). This was also 
in keeping with our expectations based on the established literature on NK maturity 
subsets. CD57+ NK cells are known to express significantly higher levels of CD16 than 
their CD57- counterparts, leading to enhanced antibody-dependent cytotoxic responses 
and cytokine production 126,127. Our own results confirm this, as CD57+ cells expressed 
noticeable higher levels CD16 at baseline in response to negative control stimuli than 
CD57- whilst also demonstrating higher levels of degranulation and CD16 
downregulation as a consequence of antibody-dependent activation (Fig. 4.3A-C) 
 
4.5.3 Downregulation of CD16 on CD56+ CD3- NK cells stimulated with 
antibody-influenza antigen complexes does not involve internalisation of CD16 
Various studies conducted over the years have confirmed that the downregulation in 
CD16 seen on NK cells stimulated by antibody-antigen complexes is due at least in part 
to the activity of metalloprotease molecules such as ADAM17. These molecules cleave 
CD16 from from the NK surface, resulting in downregulated responsiveness to antibody 
stimulation 213,214. 
However, there have been occasional reports suggesting that a second mechanism of 
CD16 downregulation may exist, by which CD16 is internalised into the cell for possible 
degradation or recycling. Most prominently, in 2007 Cecchetti et al performed a series 
of confocal microscopy experiments imaging NK cells after stimulation with anti-CD16 
antibody, and reported CD16 entering the cytoplasm from the cell surface 215. This 
process appeared to be dependent on a functional actin cytoskeleton, leading to the 
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theory that in adding to being shed from the surface via metalloprotease activity CD16 
may also be internalised into the cell via actin-dependent endocytosis 215. Subsequent 
attempts to replicate these results have seemingly contradicted Cecchetti et al’s 
findings, though the number of studies investigating the issue is minimal 212 213. 
Sadly our own results also contradict these findings. After stimulating NK cells with 
influenza antigen-antibody complexes we were able to visualise a reduction in surface 
CD16 as expected, but no CD16 was detected inside cells after intracellular staining 
(Fig. 4.4A-C).  
A possible explanation for this discrepancy may the difference in methods used by 
researchers investigating this issue. In Cecchetti et al’s study NK cells were stimulated 
directly with a fluorescent anti-CD16 antibody designed to induce activation and 
internalisation of CD16 without the need for antigen. The presence of the fluorescent 
anti-CD16 antibody inside the cell after incubation was considered to be evidence that 
the receptor had been internalised through actin dependent endocytosis 215. In our own 
study NK cells were stimulated with influenza antigen-antibody complexes, perhaps 
representing a more realistic approximation of CD16 activation in vivo, and did not 
internalise CD16 (Fig. 4.4A-C). It may be that stimulating CD16 directly with the Fab 
region of an antibody induces internalisation of CD16 or the antibody itself through a 
mechanism not involved in the usual process of CD16 activation, whereby it binds the 
Fc region of antibody-antigen complexes.  
It should noted however that subsequent attempts to replicate Cecchetti et al’s results 
using a variety of methods have also failed to result in detectable internalisation of 
CD16. In 2013 Romee et al published a study where anti-CD16 antibodies were used 
to directly activate CD16, similar to the technique used by Cecchetti et al. Subsequent 
immunoblotting revealed little to no evidence of CD16 internalisation 213. Also in 2013, 
Peruzzi et al published a study utilising phorbol 12-myristate 13-acetate (PMA) as an 
inducer of CD16 downregulation, and reported seeing no internalisation of CD16 
through confocal microscopy 212. Peruzzi et al have also reported that downregulation 
of CD16 also appears to be unaffected by exposure to endocytic pathway inhibitors 
such as phenylarsine oxide (PAO), suggesting internalisation of CD16 does not occur 
through actin-dependent endocytosis 212. Additional work by our own group has also 
demonstrated that inhibition of the metalloprotease ADAM17 in the presence of the 
ADAM17 inhibitor TAPI-1 results in significant reduction of CD16 shedding after 
stimulation with flu antibody-antigen complexes, indicating that shedding of CD16 on 
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NK cells in instances of viral infection is largely mediated by metalloprotease cleavage 
198.  
Recently published evidence by Srpan et al has also indicated that shedding of CD16 
from the surface of NK cells after engagement with opsonised targets results in 
increased motility, promoting serial engagement of NK cells with multiple targets. 
Inhibition of this process through the use of pharmacological inhibitors and NK cells 
transfected to express a noncleavable form of CD16 resulted in decreased motility of 
NK cells with subsequent negative consequences on the strength of observed immune 
responses. This perhaps offers an explanation as to why CD16 is preferentially shed 
from the surface of NK cells post-engagement rather than internalised, as the former 
may promote faster disengagement of NKs from target cells, allowing for more efficient 
serial killing 221. 
Our data lend support to the mechanism of downregulation of CD16 on NK cells post-
activation is largely the result of cleavage rather than internalisation. Regardless, we 
were able to establish a robust assay to detect CD16 downregulation and degranulation 
in response to antigen and immune plasma. These studies also indicate a stronger and 
more rapid downregulation of CD16 is achieved in the presence of antigen-antibody 
complexes than in response to previously tested forms of activation, such as high 
concentrations of cytokines. The influence of NK cell differentiation on these responses 
has also been demonstrated. In the next chapter these assays will be applied to assess 
NK cell antibody-dependent responses to malaria with further investigation of the 
impact of NK cell differentiation status. 
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CHAPTER 5 
Investigating antibody-dependent adaptive natural killer cell 
responses to erythrocytes infected with Plasmodium falciparum 
 
5.1 Introduction 
5.1.1 Development of a malarial vaccine and the importance of antibody 
An estimated 3 billion people are currently at risk of developing malaria, the majority of 
whom live in Sub-Saharan African and South Asia. Each year the disease results in 
hundreds of thousands of deaths, the majority of which are in children 151.  
At present the most widely used methods to manage malarial infection include long-
lasting insecticides along with combination drug therapies used for chemoprevention 
and treatment of infected patients 151. Whilst these methods have met with considerable 
success the past few decades, it is widely recognised that future effects to curb and 
eventually eradicate malaria as a public health concern would be greatly aided by 
development of an effective vaccine. Efforts to develop such a vaccine have been 
ongoing for many years now, with variable success (reviewed in 222). The most 
promising candidate for a viable vaccine in recent years is RTS,S/AS01, a recombinant 
protein vaccine consisting of Plasmodium falciparum circumsporozoite protein (CSP) 
fused to hepatitis B surface antigen, combined with the AS01 adjuvant 223. 
Implementation of this vaccine has experienced recent setbacks however, particularly 
with the publication of Phase 3 results for RTS,S/AS01 where protective efficacy 
amongst children was shown to wane relatively rapidly 224 158.  
Nonetheless, development of an effective and safe malaria vaccine remains a primary 
goal of the public health community 158. As with all vaccines, the goal of an efficient anti-
malarial vaccine is to illicit strong antibody-dependent responses targeted against 
malarial epitopes 225 226 227. Consequently, it is of considerable interest to the research 
community to continue studying the adaptive antibody-dependent response of the 
immune system to the most problematic species of malaria. 
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5.1.2 Antibody-dependent responses to malaria in NK cells; a dearth of research 
As of 2018 there is a considerable body of research on the antibody-independent 
response of human natural killer cells to malaria. Studies have confirmed that NK cells 
produce significant quantities of IFN-γ in response to erythrocytes infected with 
Plasmodium falciparum in in vitro cellular models of infection in the absence of antibody 
188, with previously studies published by our own lab indicating that NK cells begin to 
produce IFN-γ within only 6 hours of co-culture with infected erythrocytes 82. Production 
of IFN-γ in stances of malarial infection has also been found to associate with protection 
against severe symptoms as well as delayed incidence of re-infection 168. 
Additional studies have confirmed that NK cells are able to mount cytotoxic responses 
against malaria-infected erythrocytes in the absence of antibody. Imaging studies 
performed by several groups have seen the formation of an active immune synapse 
between NK cells and parasitised cells 190 40 whilst some have claimed to see direct 
killing of parasitized erythrocytes by NK cells as indicated by ‘flattening’ of infected cells 
after incubation with NK cells 40. Others have demonstrated that erythrocytes infected 
with the blood-stage parasite can induce production of cytotoxic mediators from NK 
cells both in vitro 55, and in vivo 199.  
In contrast, with the exception of a few published abstracts, there is little to no published 
research investigating antibody-dependent NK cell responses to malaria 143,144. Given 
the continuing focus of the global research community on development of an effective 
malaria vaccine designed to trigger potent anti-malarial antibody production, this would 
seem to be an important lapse. 
 
5.1.3 Adaptive NK cells and the coincidence of HCMV and malaria 
Recent research performed in the last few years has indicated that NK cells are capable 
of differentiating into a functionally active ‘adaptive’ phenotype in response to cells 
infected with certain viruses, predominantly human cytomegalovirus (HCMV) 131,132. 
Though originally these cells were considered to have adapted to HCMV specifically, 
subsequent studies have confirmed that these cells have both increased antibody-
independent response to certain tumour lines 135 as well as increased antibody-
dependent responses to cells infected with viruses such as HSV-1 and influenza 141,142. 
Preliminary published abstracts have also suggested potentially greater antibody-
dependent responses against intracellular parasites, though as of yet there are no full 
published studies on the subject 143,144.  
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This altered ‘adaptive’ functionality appears to be driven by epigenetic modifications 
resulting in altered function. Several studies have confimed that ‘adaptive’ NK cells have 
reduced expression of the transcription factor PLZF, leading to hypermethylation of 
certain promotor DNA regions 145. This leads to downregulated expression of adaptor 
molecules such as FcεRγ1, SYK and EAT2 137, leading to enhanced antibody-
dependent responses through as-of-yet unclear mechanisms. Additional studies have 
also suggested that demethylation of cytokine promoter regions also occurs as a result 
of differentiation down the adaptive pathway, leading to enhanced production of IFN- 
in response to ligation of receptors such as NKG2C and 2B4 228. 
Many of the areas of the world where malaria is still present also have high rates of 
HCMV infection, most prominently in Africa, South-East Asia and South America 151. In 
Africa in particular HCMV is endemic in many countries, with 85% of infants infected by 
one year of age in countries such as Gambia 229 and Zimbabwe 230. Some studies 
estimate that by the time of adolescence, HCMV infection is virtually universal in Sub-
Saharan Africa 231.  
If the assumption that HCMV drives expansion of adaptive NK cells is correct, and that 
these cells exhibit increased ability to respond to pathogens via antibody-dependent 
mechanisms, it would be a reasonable hypothesis that individuals from these areas 
could demonstrate increased antibody-dependent responses to pathogens such as 
malaria. Given this prospect, research into the NK cell antibody-dependent response to 
malaria becomes even more imperative. Consequently, in this study I have set out to 
investigate the antibody-dependent response to malaria in NK cells, with a specific 
focus on the adaptive NK cell activity of HCMV-exposed Africans. 
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5.2 Aims, Hypotheses and Objectives 
The primary aims of the study in this chapter were fourfold; 
1) To investigate the magnitude of the antibody-dependent NK cell response to malaria 
in comparison to the antibody-independent response, with a specific focus on IFN-γ 
production and degranulation given the importance of these activities in mounting an 
effective anti-malarial immune defence 
2) To investigate the effect of co-stimulatory factors such as cytokines and accessory 
cell contact on antibody-dependent NK cell response to malaria 
3) To evaluate the contribution of ‘adaptive’ FcεRIγ- NK cells and differentiated CD57+ 
NK cells to the antibody-dependent anti-malarial response 
4) To investigate the specific effects of co-stimulatory factors on the antibody-
dependent response of FcεRIγ- and CD57+ NK cells  
My hypotheses were that NK CD56dim NK cells would be significantly activated into 
producing IFN- and degranulating by the presence of malaria-infected erythrocytes 
and malaria exposed plasma; that these responses would be mediated primarily 
through anti-malarial antibody-dependent mechanisms but may involve additional co-
factors; that adaptive and/or differentiated NK cells subsets would respond significantly 
differently to this stimuli than canonical and/or undifferentiated subsets, and that the 
precise combination of stimuli that activate these subsets may vary due to phenotypic 
differences. 
My objectives were to purify peripheral blood mononuclear cell mixtures containing NK 
cells from the whole blood of either malaria-exposed Gambians or malaria-naïve 
Europeans, as well as autologous plasma from both groups. I would then incubate these 
cells either with or without matched autologous plasma in the presence of either 
uninfected erythrocytes or erythrocytes infected with Plasmodium falciparum.  I would 
then stain and fix the cells using markers that would allow me to parse CD56dim NK cells 
by adaptive and differential subsets, and use flow cytometry to assess antibody-
dependent functional activity with an emphasis on degranulation and IFN- production. 
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5.3 Methods 
 
5.3.1 European PBMC and plasma donors 
Prior to the current study, several hundred healthy malaria-naive volunteers were 
recruited from within the London School of Hygiene and Tropical Medicine (LSHTM) 
through an anonymised blood donation system operated by Carolynne Stanley, a 
trained phlebotomist. Donors are summarised in Table 5.1 by age, nationality, sex, 
malarial status and HCMV status. Ethical approval for this system was acquired from 
the LSHTM Ethics Committee under the ethics reference numbers 5520 and 6237, and 
informed consent was obtained from all donors as stipulated by LSHTM and the 
appropriate regulatory bodies. 50ml of venous blood from each donor was collected in 
sterile Falcon tubes with 2 I.U. per ml of sodium heparin added to prevent coagulation. 
Peripheral blood mononuclear cells and plasma were purified and frozen for use in 
experiments by Dr Martin Goodier, Dr Asia Wolf and Dr Carolyn Nielsen. Prior to the 
current study, plasma samples were tested via ELISA for the presence of antibodies 
against human cytomegalovirus by Dr Carolyn Nielsen. 20 HCMV+ donors and 20 
HCMV- donors were selected for use in this study, with a total of 40 European donors 
in total.   
Age/Years Ethnicity Sex Malarial Status HCMV Status 
Mean              38.5 
Median           48 
Range          21-63 
White British    40 
Other                0 
Male              
12 
Female          
28 
Naïve            40 
Exposed         0 
Negative       20 
Positive         20 
 
 
5.3.2 Gambian PBMC and plasma donors 
Prior to the current study, 641 volunteers were recruited from malaria-exposed sites in 
Gambia. Ethical approval for this system was acquired from the Gambian Government/ 
MRC Gambia joint ethics committee (ethics reference numbers SCC 1269 and SCC 
1449) and the LSHTM ethics committee (ethics reference number 6034) and informed 
consent was obtained from all donors as stipulated by LSHTM and the appropriate 
regulatory bodies. 50ml of venous blood from each donor was collected in sterile Falcon 
tubes with 2 I.U. per ml of sodium heparin added to prevent coagulation. Peripheral 
blood mononuclear cells and plasma were purified frozen and shipped to LSHTM by Dr 
Table 5.1 Age, nationality, sex, malarial status and HCMV status of donors for this assay  
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Martin Goodier, Dr Carolyn Nielsen and Dr Asia Wolf for use in experiments. Plasma 
samples were then tested via ELISA for the presence of antibodies against apical 
membrane antigen 1 (AMA1), a malaria-derived protein. 66 donors who tested positive 
for prior malarial exposure were selected for use in this study. Donors are summarised 
in Table 5.2 by age, nationality, malarial status and HCMV status.  
Age/Years Nationality Malarial Status HCMV Status 
Mean                18 
Median             16 
Range           1-49 
Gambian       66 
Other              0 
Naïve               0 
Exposed         66 
Negative         0 
Positive         66 
 
 
5.3.3 Anti-AMA1 ELISA of Gambian plasma 
Plasma samples from 641 Gambian donors were diluted 1 in 200 with reconstitution 
buffer (PBS, 0.05% Tween 20, 1g/L sodium azide) in 96-well flat-bottom deep well 
plates.  
AMA1 antigen-coated Immulon ELISA plates were prepared as described in section 
2.1.3. 45ul of blocking solution (PBS, 0.05% Tween 20, 1% skimmed milk powder) was 
then added to each well, followed by 5ul of the previously diluted 1 in 200 plasma 
samples to form a final dilution of 1 in 2000. Positive and negative control plasmas were 
added to each ELISA plate to generate a standard reference curve. ELISA plates were 
then incubated, washed and activated using the HRP-TMB system described in section 
2.1.3. 
Plates were read immediately using a Dynex Technologies MRX II Microplate 
Absorbance Reader run at 450nm. Standard curves and positive/negative cut-offs were 
determined by Dr Joe Biggs, with the positive cut-off based on the mean optical density 
plus two standard deviations. 
 
5.3.4 Assessing NK cell antibody-independent responses to Plasmodium 
falciparum-infected erythrocytes through flow cytometry 
Frozen PBMC samples from Gambian and European donors were thawed using the 
protocol described in section 2.2.3. 2 x 105 PBMCs were incubated for 18 hours at 37oC 
with 5% CO2 in wells of 96-well U-bottom plates (ThermoFisher) under the conditions 
Table 5.2 Age, nationality, sex, malarial status and HCMV status of donors for this assay  
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described in Table 5.3. GolgiStop containing Monensin (BD Biosciences) was added to 
cultures to form a final 1/1500 concentration and GolgiPlug containing Brefeldin A (BD 
Biosciences) added to form a 1/1000 final concentration after 15 housr of incubation. 
Anti-CD107a antibody (ef660-conjugated, clone 1D4B, BD Biosciences) was added 
during culturing at 1µl per 100ul of culture suspension.  
 
After the required period of incubation, cells were washed and stained for 30 minutes 
at 4oC in the dark with 10µl total of the surface antibody cocktail described in Table 5.4 
using the protocol as described in section 2.4.1.  
 
 
Dead and dying cells were also stained using APC-conjugated fixable viability dye 
(eBioscience). Cells were then washed thoroughly with buffer, fixed and stained 
intracellularly with 10µl of the intracellular antibody cocktail described in Table 5.5 using 
the protocol described in section 2.4.1.  
 
 
Cells were then washed, resuspended in 300µl FACS buffer, transferred to alpha tubes 
(Alpha labs) and stored at 4oC until run on a BD LSRII Flow Cytometer (BD Biosciences) 
using the appropriate laser set.  Data was collected using the complementary 
FACSDiva software (BD Biosciences) and analysed using FlowJo, v.10 (FlowJo LLC). 
PBMCs per well Incubated with; Total volume per well 
2 x 105 Culture medium alone 100μl 
2 x 105 High Dose Cytokines (Il-12 and IL-18) 100μl 
2 x 105 6 x 105 uninfected erythrocytes (URBCs) 100μl 
2 x 105 6 x 105 P. falciparum-infected erythrocytes (PRBCs) 100μl 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human CD56 B159 BV605 Biolegend 0.5μl 
Mouse Anti-Human CD3 UCHT1 V500 BD Biosciences 0.5μl 
Mouse Anti-Human CD57 TB01 ef450 eBioscience 0.5μl 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human IFN-γ 4S.B3 BV785 Biolegend 0.25μl 
Table 5.3. List of PBMC culture conditions used for functional flow cytometry  
Table 5.4. List of fluorescent antibodies used to stain the surface of NK cells for flow cytometry  
Table 5.5. List of fluorescent antibodies used to internally stain NK cells for flow cytometry  
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Fluorescence compensation was carried out using OneComp eBeads Compensation 
Beads (eBioscience) stained with single antibodies.  
 
5.3.5 Assessing NK cell antibody-dependent responses to Plasmodium 
falciparum-infected erythrocytes through flow cytometry 
Frozen PBMC samples from Gambian and European donors were thawed using the 
protocol described in section 2.2.3. 2 x 105 PBMCs were incubated for 6 hours at 37oC 
with 5% CO2 in wells of 96-well U-bottom plates (ThermoFisher) under the conditions 
described in Table 5.6. GolgiStop containing Monensin (BD Biosciences) was added to 
cultures to form a final 1/1500 concentration and GolgiPlug containing Brefeldin A (BD 
Biosciences) added to form a 1/1000 final concentration after 1 hour of incubation. Anti-
CD107a antibody (ef660-conjugated, clone 1D4B, BD Biosciences) was added during 
culturing at 1µl per 100ul of culture suspension.  
 
After the required period of incubation, cells were washed and stained for 30 minutes 
at 4oC in the dark with 10µl total of the surface antibody cocktail described in Table 5.7 
using the protocol as described in section 2.4.1.  
 
 
 
 
 
PBMCs per well Incubated with; Total volume per well 
2 x 105 Culture medium alone 100μl 
2 x 105 4 x 104 K562 cells 100μl 
2 x 105 4 x 104 Raji cells with 1μg/ml IgG1 isotype  100μl 
2 x 105 4 x 104 Raji cells with 1μg/ml Rituximab 100μl 
2 x 105 6 x 105 uninfected erythrocytes (URBCs) 100μl 
2 x 105 6 x 105  (URBCs) with 1% autologous plasma 100μl 
2 x 105 6 x 105 P. falciparum-infected erythrocytes (PRBCs) 100μl 
2 x 105 6 x 105 (PRBCs) with 1% autologous plasma 100μl 
Table 5.6. List of PBMC culture conditions used for functional flow cytometry  
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Dead and dying cells were also stained using APC-conjugated fixable viability dye 
(eBioscience). Cells were then stained with 10µl of the intracellular antibody cocktail 
described in Table 5.8 using the protocol described in section 2.4.1.  
 
Cells were then washed and run on a BD LSRII Flow Cytometer (BD Biosciences) using 
the appropriate laser set.  Data was collected using FACSDiva software (BD 
Biosciences) and analysed using FlowJo, v.10 (FlowJo LLC). Compensation was 
carried out using OneComp eBeads Compensation Beads (eBioscience) stained with 
single antibodies. A representative gating strategy is outlined in Figure 5.1. 
 
 
 
 
 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human CD56 B159 BV605 Biolegend 0.5μl 
Mouse Anti-Human CD3 UCHT1 V500 BD Biosciences 0.5μl 
Mouse Anti-Human CD57 TB01 ef450 eBioscience 0.5μl 
Mouse Anti-Human NKG2C FAB138P PE R&D Systems 0.5μl 
Mouse Anti-Human CD16 3G8 PE/Dazzle Biolegend 0.5ul 
Mouse Anti-Human CD94 REA113 PE/Vio770 Miltenyi Biotec 1ul 
Mouse Anti-Human CD2 RPA-2.10 PerCP/Cy5.5 Biolegend 0.5ul 
Antibody Clone Fluorophore Supplier Volume per well 
Mouse Anti-Human IFN-γ 4S.B3 BV785 Biolegend 0.25μl 
Anti-Human FcεRIγ Polyclonal FITC MIllipore 0.15ul 
Table 5.7. List of fluorescent antibodies used to stain the surface of NK cells for flow cytometry  
Table 5.8. List of fluorescent antibodies used to internally stain NK cells for flow cytometry  
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Figure 5.1 Representative FACS plots of NK cells stimulated by PRBCs and 1% autologous plasma.      
PBMCs were stained and fixed as described in section 3.3.4 
A) Flow diagram demonstrating method of identifying viable CD56dim CD3- NK cells 
B) FACS plots demonstrating method of assessing expression of functional markers on CD56dim CD3- NK 
cells; (top row, left to right) IFN-γ, CD107a, CD16, NKG2C, (bottom row, left to right) CD94, CD2 
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5.3.6 Statistical analyses 
Statistical analyses were performed with Prism 7.03 (Graphpad), as specified for each 
experiment. Data were excluded when the gated cell subset contained fewer than the 
required minimum number of cells. All statistical tests are two-sided, with p values 
stated as follows; **** <p 0.0001; *** p< 0.001; ** p< 0.01; * p< 0.05. Specific statistical 
tests and sample sizes are stated in the relevant figure legends. Two-way paired or 
unpaired t-tests were used to compare control and experimental data when sample 
sizes were sufficiently large, or two-way paired or unpaired Wilcoxon tests when not. 
Pearson’s correlations were used to determine trends between data. For data sets 
where n =<10 no formal analyses were performed as the data lacked sufficient 
statistical power. 
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5.3 Results 
 
5.3.1 Both Gambian and European CD56dim NK cells produce IFN- and 
degranulate after long-term incubation with erythrocytes infected with 
Plasmodium falciparum 
Previous research by both our own lab group and others has indicated that European 
NK cells are induced to produce IFN-γ and degranulate in response to long-term 
incubation with Plasmodium falciparum-infected erythrocytes (PRBCs) through 
cytokine and potentially germline-receptor mediated mechanisms 82,184,188,190. Before 
assessing antibody-dependent responses over a shorter period of incubation, we 
decided to validate these prior observations in both Gambian and European control 
individuals by incubating them either with medium alone, with a high dose concentration 
of cytokines IL-12 and IL-18 (HDC) as a positive control, with uninfected erythrocytes 
(URBCs) or with parasitised erythrocytes (PRBCs) as described in section 5.3.4. 
When incubated with HDC there was a large significant increase in the frequency of 
both European and Gambian CD56dim NK cells producing IFN-γ than when incubated 
with medium alone (Fig. 5.2A-B, p<0.0001 for both).  
When incubated with PRBCs there was a small but highly significant increase in the 
frequency of both European and Gambian CD56dim NK cells producing IFN-γ than when 
incubated with URBCs (Fig. 5.2A-B, p<0.0001 for both). 
Similar responses were observed with degranulation. When incubated with HDC there 
was a large significant increase in the frequency of both European and Gambian 
CD56dim NK cells degranulating than when incubated with medium alone (Fig. 5.2C-D, 
p<0.0001 for both).  
When incubated with PRBCs there was a small significant increase in the frequency of 
both European and Gambian CD56dim NK cells degranulating than when incubated with 
URBCs (Fig. 5.2C-D, p<0.0001 for both). 
Having confirmed our prior observations that CD56dim NK cells are capable of producing 
pro-inflammatory cytokine and degranulating in response to parasitised cells over 
prolonged incubation, we then moved on to evaluating antibody-dependent responses 
to this stimulation after short-term incubation with or without the presence of immune 
plasma. 
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Figure 5.2 Gambian and European antibody-independent CD56dim NK responses to control treatments and PRBCs 
A-B) PBMCs were thawed and incubated with; (bars, left to right) culture medium alone, High Dose Cytokines (HDC), URBCs 
or, PRBCs for 18 hours. Cells were stained and fixed for IFN-γ; A) Europeans B) Gambians; (Gambian n value=48, paired t-
tests, European n value=16, paired Wilcoxon tests, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
C-D) PBMCs were thawed and incubated with; (bars, left to right) culture medium alone, High Dose Cytokines (HDC), URBCs 
or, PRBCs for 18 hours. Cells were stained and fixed for CD107a as a marker of degranulation; C) Europeans D) Gambians 
value=48, paired t-tests, European n value=16, paired Wilcoxon tests, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
A B 
C D 
= Europeans = Gambians 
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5.3.2 Gambian CD56dim NK cells produce IFN- in response to short-term 
incubation with erythrocytes infected with Plasmodium falciparum, but 
European CD56dim NK cells do not 
 
PBMCs isolated from European individuals (n=40) were incubated at a 1:3 ratio for 6 
hours with either URBCs or PRBCs. Cells were then stained and fixed for cellular and 
functional markers, then compared to Gambian cells treated under the same conditions 
(n=66). 
When incubated with PRBCs alone, there was no significant increase in the frequency 
of European CD56dim NK cells producing IFN- than when incubated with URBCs (Fig. 
5.3A). In contrast, a mean of 1.48% (SD±2.52)  of Gambian CD56dim NK cells produced 
IFN- in response to PRBCs versus a mean of 0.41% (SD±0.38)  in response to URBCs 
(p=0.001, Fig. 5.3B). 
 
5.3.3 The short-term IFN- response of CD56dim NK cells from malaria exposed 
Gambian individuals produce IFN- response to short-term incubation with 
PRBCs is upregulated in the presence of autologous plasma  
 
When PBMCs from Gambians were incubated with PRBCs in the presence of 
autologous plasma, the percentage of CD56dim NK cells producing IFN- was also 
significantly higher in contrast to incubation with URBCs with autologous plasma. A 
mean of 2.77% (SD±4.06) of CD56dim NK cells produced IFN- in response to PRBCs 
with plasma versus a mean of 0.47% (SD±0.46) in response to URBCs with plasma 
(p<0.0001, Fig. 5.3B). The response to PRBCs and autologous plasma was 
heterogenous, with some donors expressing no IFN- at all in response to this 
combination of stimuli, while in at least one individual up to 28.3% of CD56dim NK cells 
expressed IFN- (Fig. 5.3B). 
Overall, the frequency of CD56dim NK cells producing IFN- in Gambian individuals was 
significantly higher in response to PRBCs in the presence of autologous plasma than 
with PRBC alone (p<0.05, Fig 5.3B). This suggested that the production of IFN- was 
upregulated by the presence of autologous plasma beyond what was seen in response 
to parasitised cells alone.  
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In contrast there was no significant difference in the percentage of CD56dim NK cells 
expressing IFN- when incubated with URBC alone or URBC with autologous plasma, 
suggesting that autologous plasma in the absence of malarial antigens was not 
sufficient to provoke increased production of IFN- (Fig. 5.3B). 
 
5.3.3 Autologous plasma promotes higher frequencies of CD56dim NK cells to 
produce IFN-  in response to PRBCs in Gambians than in European individuals 
Europeans donors demonstrated no significant IFN- in response to incubation with 
PRBCs alone in comparison to URBCs. However, when incubated with PRBCs and 
autologous plasma, there was a significant increase in the frequency of European 
CD56dim NK cells producing IFN- than when incubated with URBCs and autologous 
plasma. A mean of 1.26% (SD±2.62) of European CD56dim NK cells produced IFN- in 
response to PRBCs in the presence of autologous plasma versus a mean of 0.35% 
(SD±0.34) in response to URBCs in the presence of plasma (p=0.05, Fig. 5.3A).  
While this response was relatively minimal it was nonetheless unexpected given the 
malaria-naïve status of our European donors, perhaps indicating that expression of  
IFN- in these donors in response to parasitised cells and plasma may be due to 
unknown antibody-independent mechanisms. These will be discussed in the relevant 
section. 
The frequency of CD56dim NK cells from European individuals producing IFN- was still 
significantly lower than Gambian individuals however, where 2.77% of CD56dim NK cells 
produced IFN- in response to PRBCs in the presence of plasma in comparison to 
1.26% in Europeans (p<0.05, Fig. 5.3C). This difference in responsiveness was also 
obiovus when observed as fold-change in interferon production (Fig. 5.4D). There was 
no significant difference between Gambians and Europeans in the percentage of 
CD56dim NK cells producing IFN- in response to URBCs and plasma (Fig. 5.3C).  
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Figure 5.3 European and Gambian  CD56dim NK IFN-γ responses to control treatments and PRBCs with autologous 
plasma.  
A-B) European (A) or Gambian (B) PBMCs were thawed and incubated with; (bars, left to right) culture medium alone, K562 
cells, Raji cells with IgG1 isotype control antibody, Raji cells with Rituximab antibody, URBC, URBC with 1% autologous 
plasma, PRBC, or PRBC with 1% autologous plasma. Cells were stained and fixed for IFN-γ. (European n value = 40; 
Gambian n value = 66, paired t-tests, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
C) European (left bars) and Gambian (right bars) PBMCs were thawed and incubated with URBCs, URBCs 1% 
autologous plasma, PRBCs, or PRBCs with 1% autologous plasma. Cells were stained and fixed for IFN-γ; (European n 
value = 40; Gambian n value = 66, within-group paired t-tests and between-group unpaired t-tests, **** p<0.0001, *** 
p<0.001, ** p<0.01, * p<0.05).  
D) Fold change in the percentage of Gambian and European CD56dim NK cells expressing IFN-y in response to either 
PRBCs vs URBCs (left bars) or PRBCs + 1% autologous plasma vs URBCs + 1% autologous plasma (right bars) 
(Gambian n value= 66, European n value=40, within-group paired and between-group unpaired t-tests, **** p<0.0001, *** 
p<0.001, ** p<0.01, * p<0.05). 
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5.3.4 CD56dim NK cells mount weak antibody-independent degranulation 
responses to PRBCs 
PBMCs isolated from European individuals (n=40) were incubated at a 1:3 ratio for 6 
hours with either healthy erythrocytes or erythrocytes infected with schizont-stage 
Plasmodium falciparum. Cells were then stained and fixed for cellular and functional 
markers, then compared to Gambian cells treated under the same conditions (n=66). 
When incubated with PRBCs, the frequency of European CD56dim NK cells 
degranulating was significantly higher than when incubated with URBCs, with a mean 
of 9.01% (SD±7.23) CD56dim NK cells presenting CD107a in response to infected cells 
versus a mean of 8.01% (SD±5.64) in response to URBCs (p>0.05, Fig. 5.4A). A 
similarly upregulated degranulation response was seen in Gambian CD56dim NK cells, 
where a mean of 4.62% (SD±3.51)   of CD56dim NK cells degranulated in response to 
parasitised cells in comparison to a mean of 3.52% (SD±2)   in response to URBCs 
(p=0.001, Fig. 5.4B).  
The mean degranulation response was relatively small in both Europeans and 
Gambians, though considerably heterogenous between individuals, with between 
0.88% and 9.73% of CD56dim NK cells degranulating for most Gambian donors. In at 
least one individual the percentage of CD56dim NK cells degranulating reached 25%, 
though this was considerably higher than all other donors and may be anomalous (Fig. 
5.4B). 
 
5.3.5 Upregulation of PRBC-induced NK cell degranulation in the presence of 
autologous plasma 
When PBMC from Gambians donors were incubated with PRBC in the presence of 
autologous plasma, the frequency of CD56dim NK cells expressing CD107a was 
significantly higher in contrast to cells incubated with URBC under the same conditions, 
with a mean of 19% (SD±11.8) of CD56dim NK cells degranulating versus a mean of 
4.36% (SD±3.38) respectively (p<0.0001, Fig. 5.3B). The range of degranulation 
responses to infected erythrocytes with autologous plasma was extremely 
heterogenous within the group, ranging from 3.35% of CD56dim NK cells in the weakest 
responders to  51.1% in the strongest responders. (Fig. 5.4B). 
The frequency of CD56dim NK cells degranulating in Gambian donors was also 
significantly higher in response in the presence of autologous plasma than with PRBCs 
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alone, equating to an increase in mean frequency of 13.38% (p<0.0001, Fig. 5.4B). This 
suggested that degranulation of CD56dim NK cells was mediated by the presence of 
autologous plasma and not simply due to parasitised cells alone. 
In contrast there was no significant difference in the percentage of CD107a+ CD56dim 
when comparing URBCs alone or with autologous plasma, suggesting that autologous 
plasma alone without the presence of malarial antigens was not sufficient to provoke a 
degranulation response in Gambian individuals (Fig.5.4B). 
 
5.3.6 Stronger plasma-dependent degranulation responses in Gambian 
individuals compared to European control subjects 
In response to incubation with PRBCs and autologous plasma, there was a significant 
increase in the frequency of European CD56dim NK cells degranulating than when 
incubated with URBCs and autologous plasma. A mean of 14.08% (SD±10.56) of 
European CD56dim NK cells degranulated in response to parasitised cells with plasma 
versus a mean of 10.03% (SD±10.23) in response to URBCs with plasma (p=0.05, Fig. 
5.4A).  
While this increase was relatively small, it was nonetheless unexpected given the 
malaria-naïve status of our European donors. This could perhaps indicate that 
expression of IFN- in these donors in response to parasitised cells and plasma may 
be due to unknown antibody-independent mechanisms, which will be discussed in the 
relevant section of the discussion. 
The European degranulation response to parasitised cells and plasma was also 
significantly lower than in Gambian donors, where 19.04% (SD±11.8) of CD56dim NK 
cells produced plasma in response to parasitised cells and plasma in comparison to 
14.08% (SD±10.56) in Europeans (p<0.05, Fig. 5.4C).  
Unexpectedly, there was a significant difference in the frequency of CD56dim NK cells 
producing IFN- in response to URBCs and plasma between Gambians and Europeans, 
with Europeans far more likely to degranulate in response to this control. 10.03% 
(SD±10.23) of European CD56dim NK cells degranulated in response to URBCs and 
plasma in comparison to only 4.36% (SD±3.38) in Gambians (Fig. 5.4C).  
Given the relatively high background degranulation of European CD56 NK cells in 
response to uninfected controls, we decided to perform an additional analysis of these 
results as a function of fold-change in the percentage of cells degranulating in response 
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to experimental stimuli versus controls (Fig. 5.4D). This allowed us to compensate for 
high background degranulation in Europeans by expressing results as a measure of 
change from background values rather than absolute values. When analysed in this 
format, it became clear that CD56dim NK cells from Gambian individuals are far more 
responsive to cytotoxically PRBCs and plasma than those from Europeans donors. 
CD56dim NK cells from Gambians demonstrated a mean x6.22 fold-change in the 
percentage of cells degranulating in response to PRBCs with plasma versus URBCs 
with plasma, in comparison to a mean of only x1.78 fold-change in Europeans 
(p<0.0001, Fig. 5.4D). 
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Figure 5.4 European and Gambian  CD56dim NK degranulation responses to control treatments and PRBCs with 
autologous plasma.  
A-B) European (A) or Gambian (B) PBMCs were thawed and incubated with; (bars, left to right) culture medium alone, 
K562 cells, Raji cells with IgG1 isotype control antibody, Raji cells with Rituximab antibody, URBC, URBC with 1% 
autologous plasma, PRBC, or PRBC with 1% autologous plasma. Cells were stained and fixed for CD107a as a marker 
of degranulation. (European n value = 40; Gambian n value = 66, paired t-tests, **** p<0.0001, *** p<0.001, ** p<0.01, * 
p<0.05).  
C) European (left bars) and Gambian (right bars) PBMCs were thawed and incubated with URBCs, URBCs 1% 
autologous plasma, PRBCs, or PRBCs with 1% autologous plasma. Cells were stained and fixed for CD107a; 
(European n value = 40; Gambian n value = 66, within-group paired t-tests and between-group unpaired t-tests, **** 
p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
D) Fold change in the percentage of Gambian and European CD56dim NK cells expressing CD107a in response to 
either PRBCs vs URBCs (left bars) or PRBCs + 1% autologous plasma vs URBCs + 1% autologous plasma (right bars) 
(Gambian n value= 66, European n value=40, within-group paired and between-group unpaired t-tests, **** p<0.0001, 
*** p<0.001, ** p<0.01, * p<0.05). 
 
P a g e  | 114 
 
5.3.7 Shedding of CD16 from CD56dim NK cells from malaria-exposed Gambian 
donors is strongly upregulated by autologous plasma 
A significantly reduced frequency of CD56dim NK cells from Gambian individuals 
expressed CD16 after 6 hours of incubation with PRBCs in comparison to cells 
incubated with URBCs, indicating activation-induced background shedding of CD16 in 
the absence of autologous plasma. A mean of 76.46% (SD±13.3) of CD56dim NK cells 
expressed CD16 when incubated with URBCs versus 71.45% (SD±17.1) when 
incubated with parasitized cells (p=0.001, Fig. 5.5A).  
Whilst this decrease was statistically significant, in absolute terms it was relatively small, 
with the percentage of CD56dims expressing CD16 only decreasing by a mean of 5.01% 
when exposed to infected erythrocytes versus uninfected.  
However, when PBMCs from Gambian individuals were incubated with infected 
erythrocytes in the presence of autologous plasma, the frequency of CD56dim NK cells 
shedding CD16 was far greater.  A mean of 74.89% (SD±14.9) of CD56dim NK cells 
expressed CD16 when incubated with URBCs versus 41.6% (SD±29.66) when 
incubated with PRBCs, representing a mean decrease of 33.29% in the percentage of 
CD56dim NK cells expressing when exposed to PRBCs vs URBCs in the presence of 
autologous plasma (p<0.0001, Fig. 5.5A). This strong response could indicate that 
Gambian CD56dim NK cells could be responding to PRBCs through an antibody-
dependent mechanism in the presence of autologous plasma, perhaps due to anti-
malarial immunoglobulins present in malaria-exposed Gambian plasma. 
 
5.3.8 The frequency of CD56dim NK cells downregulating CD16 in response to 
PRBCs and autologous plasma is significantly higher in Gambian individuals 
 
In response to incubation with PRBCs and autologous plasma, CD56dim NK cells from 
European individuals were significantly more likely to downregulate CD16 than when 
incubated with URBCs and autologous plasma. A mean of 71.41% (SD±19.2) of 
CD56dim NK cells expressed CD16 in response to parasitised cells with plasma versus 
a mean of 81.49% (SD±10.7) in response to URBCs with plasma (p=0.05, Fig. 5.5B).  
This response was unexpected given the malaria-naïve status of our European donors. 
This could perhaps indicate that expression of IFN- in these donors in response to 
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parasitised cells and plasma may be due to unknown plasma-dependent mechanisms, 
to be discussed in the relevant section. 
The mean downregulation of CD16 by NK cells from European donors was also 
significantly lower than that seen in Gambian donors, where only a mean of 41.6% of 
CD56dim NK cells expressed CD16 after incubation with parasitised cells and plasma in 
comparison to 71.41% in Europeans (p<0.05, Fig. 5.5C). This difference was far more 
apparent when observed as fold-change in CD16 expression (Fig. 5.5D).  
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Figure 5.5 European and Gambian CD56dim NK CD16 responses to control treatments and PRBCs with 
autologous plasma.  
A-B) European (A) or Gambian (B) PBMCs were thawed and incubated with; (bars, left to right) culture medium alone, 
K562 cells, Raji cells with IgG1 isotype control antibody, Raji cells with Rituximab antibody, URBC, URBC with 1% 
autologous plasma, PRBC, or PRBC with 1% autologous plasma. Cells were stained and fixed for CD16. (European 
n value = 40; Gambian n value = 66, paired t-tests, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
C) European (left bars) and Gambian (right bars) PBMCs were thawed and incubated with URBCs, URBCs 1% 
autologous plasma, PRBCs, or PRBCs with 1% autologous plasma. Cells were stained and fixed for CD16; 
(European n value = 40; Gambian n value = 66, within-group paired t-tests and between-group unpaired t-tests, **** 
p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
D) Fold change in the percentage of Gambian and European CD56dim NK cells expressing CD16 in response to 
either PRBCs vs URBCs (left bars) or PRBCs + 1% autologous plasma vs URBCs + 1% autologous plasma (right 
bars) (Gambian n value= 66, European n value=40, within-group paired and between-group unpaired t-tests, **** 
p<0.0001, *** p<0.001, ** p<0.01, * p<0.05). 
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5.3.9 Downregulation of CD16 on Gambian CD56dim NK cells in response to 
incubation with PRBCs and malaria-exposed plasma correlates with 
degranulation  
 
The percentage of Gambian CD56dim NK cells downregulating CD16 when incubated 
with PRBCs and autologous plasma was plotted against the percentage of cells 
producing IFN- and presenting CD107a under the same culture conditions in order to 
determine whether antibody-dependent activation and shedding of CD16 was 
associated with CD56dim functional activity.  
A significant positive correlation was found between the downregulation in CD16 and 
CD107a presentation, suggesting the degranulation of Gambian CD56dim NK cells in 
response to parasitised cells and plasma was perhaps mediated by binding of anti-
malarial antibody-antigen complexes to the NK cell (p<0.0001, Fig. 5.6A).  
No significant correlation was found between decrease in CD16 expression and IFN- 
production, indicating that while the presence of autologous plasma does significantly 
increase IFN- production by CD56dim NK cells from Gambian individuals, this may 
involve multiple co-stimulatory factors (Fig. 5.6B). 
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Figure 5.6 Correlations of Gambian CD56dim NK responses to PRBCs with autologous plasma.  
A-B) Correlations of change in the percentage of CD56dim NK cells expressing CD16 (PRBCs vs PRBCs + 1% 
autologous plasma) against; A) change in percentage of CD56dim NK cells producing CD107a; B) change in percentage 
of CD56dim NK cells presenting IFN- (Gambian n value=66, Pearson correlation coefficients, **** p<0.0001, *** p<0.001, 
** p<0.01, * p<0.05) 
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5.3.10 IFN-γ production by Gambian CD56dim NK cells in response to PRBCs and 
malaria-exposed plasma is upregulated by the cytokines IL-12 and IL-18, as well 
as ligation of the CD2 receptor 
 
No significant correlation was found between the percentage of Gambian CD56dim NK 
cells producing IFN- and the percentage of cells shedding CD16 after stimulation with 
PRBCs and autologous plasma (Fig. 5.6B). However, the percentage of CD56dim NK 
cells producing IFN- was still significantly upregulated when cultured with parasitised 
cells and plasma versus parasitised cells alone (Fig. 5.3B).  
There were two potential explanations for this result.  IFN- production by CD56dim NK 
cells could be completely unrelated to anti-malarial antibody-antigen complexes binding 
to CD16 present on NK cells, and instead be the result of an alternative pathway of 
activation induced by autologous plasma. Alternatively, IFN- production under these 
conditions could still involve binding of antibody-antigen complexes to NK cells, but also 
involve additional sources of co-stimulation that confound an absolute direct correlation 
between downregulation of CD16 and IFN- production. 
We hypothesised that autologous plasma may synergise with the early production of 
pro-inflammatory cytokines by accessory cells present in the PBMC cultures, leading to 
indirect activation of CD56dim NK cells. We therefore elected to test the effect of 
neutralising or blocking antibodies to inhibit potential sources of NK cell co-stimulation 
on the immune plasma-dependent response.  
Inhibition assays utilised neutralising antibodies against  cytokines IL-2, IL-12 and IL-
18 which are known to  co-stimulate NK cells and have previously been shown to be 
induced in response to PRBC alone. , Blocking antibodies against the pro-inflammatory 
cytokine receptor IFNR on NK cell and the adhesion receptor CD2 which is known 
to mediate interactions between NK cells and accessory cells were also tested. PBMC 
isolated from Gambian individuals (n=28) were incubated at a 1:3 ratio for 6 hours with 
erythrocytes infected with schizont-stage Plasmodium falciparum and autologous 
immune plasma and the relevant blocking antibody or isotype control.  
Blocking of soluble IL-12 significantly decreased the frequency of CD56dim NK cells 
producing IFN- in response to PRBC and autologous immune plasma compared to 
isotype-matched control antibody. The mean percentage of CD56dim NK cells 
producing IFN- when incubated with IL-12 blocking antibody was 2% (SD±1.5) in 
comparison to 3% (SD±3.51) with isotype control, representing a modest but significant 
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decrease in frequency of 1% (p<0.05, Fig. 5.7A). Blocking of soluble IL-18 also 
significantly decreased the frequency of CD56dim NK cells producing IFN- in 
comparison to incubation with isotype control. The mean percentage of CD56dim NK 
cells producing IFN- when incubated with IL-18 blocking antibody was 2.18% 
(SD±2.04) in comparison to 3% (SD±3.51) with isotype control, representing a modest 
mean decrease of 0.82% (p<0.05, Fig. 5.7A). Blocking of the CD2 receptor also 
significantly decreased the frequency of CD56dim NK cells producing IFN- in 
comparison to incubation with isotype control antibody. The mean percentage of 
CD56dim NK cells producing IFN- when incubated with CD2 blocking antibody was 
2.07% (SD±1.74) in comparison to 3% (SD±3.51) with isotype control, representing a 
mean decrease of 0.93% (p<0.05, Fig. 5.7A). Blocking of IL-2 and the IFN receptor 
had no significant effect on IFN- production in the presence of parasite erythrocytes 
and autologous plasma.  
We next determined whether IL-12, IL-18 and CD2 were required for IFN- production 
by CD56dim NK cells in the presence of accessory cells and immune autologous plasma, 
or whether plasma alone was capable of inducing this response. To do this we repeated 
the previous 6 hour incubation using enriched NK cells isolated through negative 
selection to remove accessory PBMCs that could serve as a source of co-stimulatory 
cytokines or receptor-mediated signals. CD2 blocking antibody was also added to some 
samples to prevent the possibility of NK cells providing each other with activating CD2 
ligands. 
NK cells were enriched using a MACS NK Cell Isolation Kit (Miltenyi Biotec) according 
to the manufacturer’s instructions, as described in section 2.2.4. NK cells were enriched 
to >80% purity. When the original functional assays were repeated using enriched NK 
cells a significantly higher frequency of CD56dim NK cells produced IFN- after 
incubation with PRBCs and autologous plasma than PRBCs alone despite the absence 
of accessory PBMCs to act as a source of CD2 ligands, IL-12 or IL-18. A mean of 0.14% 
CD56 NK cells expressed IFN- after incubation with PRBCs alone in comparison to a 
mean of 1.05% after incubation with PRBCs in the presence of plasma (Fig. 5.7B). This 
suggested that while IL-12, IL-18 and CD2 may upregulate production of IFN- by 
CD56dim NK cells in the presence of PRBCs and autologous plasma, NK cells are still 
able to produce IFN- in the absence of these signals. The co-stimulatory effects of IL-
12, IL-18 and CD2 were noticeable however, as only a mean of 1.05% of isolated 
CD56dim NK cells expressed IFN- in response to parasitized cells and plasma in 
comparison to 2.77% when using mixed PBMCs (p<0.0001, Fig. 5.7B).   
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While this may suggest that NK cells were able to mount plasma-dependent responses 
to PRBCs in the absence of accessory cell factors, it must be noted that the enrichment 
process was not 100% efficient, with potential implications for these results. This will be 
discussed in more detail in the relevant discussion section. 
5.3.11 Degranulation by Gambian CD56dim NK cells in response to PRBCs and 
malaria-exposed autologous plasma does not require IL-2, IL-12, IL-18, or the 
CD2 or IFN receptors 
 
A significant correlation was found between the percentage of CD56dim NK cells 
producing presenting CD107a and the percentage of cells shedding CD16 after 
stimulation with PRBCs and autologous plasma suggesting degranulation under these 
conditions is significantly associated with anti-malarial antibody-antigen complexes 
binding to CD16 (p<0.0001, Fig. 5.6A).  However, it remained possible that additional 
co-factors such as pro-inflammatory cytokines provided by PBMCs could also 
contribute to the degranulation response. Therefore we also assessed degranulation 
responses as measured by presentation of CD107a in the same blocking and enriched 
NK assays previously mentioned.  
Blocking of IL-2, IL-12, IL-18 and the IFN and CD2 receptors had no significant effect 
on degranulation, suggesting that degranulation was not dependent on these factors 
(Fig. 5.7C).  
In keeping with these results, when the original functional assays were repeated using 
enriched Gambian NK cells rather than mixed PBMCs a noticeably higher percentage 
of CD56dim NK cells still demonstrated degranulation after 6 hours incubation with 
parasitised cells and autologous plasma in comparison to incubation with parasitised 
cells alone. A mean of 17.54% CD56 NK cells expressed IFN- after incubation with 
parasitised cells alone in comparison to a mean of 23.23% after incubation with 
parasitised cells and plasma (Fig. 5.7D).  
 
5.3.12 Shedding of CD16 by CD56dim NK cells in response to PRBCs and 
malaria-exposed plasma does not require accessory factors 
 
In order to assess that shedding of CD16 by Gambian CD56dim NK cells was primarily 
dependent on anti-malarial antibodies present in autologous plasma rather than other 
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factors, the percentage of cells shedding CD16 was also assessed in blocking assays. 
Blocking of IL-2, IL-12, IL-18, CD2 and the IFN receptor had no significant effect on 
the percentage of cells shedding CD16, suggesting that this effect was perhaps driven 
primarily by binding of anti-malarial antibody-antigen complexes to CD16 (Fig. 5.7E). 
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Figure 5.6 Gambian CD56dim NK responses to PRBCs with autologous plasma in the presence of blocking antibodies 
or after enrichment 
A, C, E) PBMCs were thawed and incubated with either (bars, left to right) PRBCs, PRBCs with 1% autologous plasma, or 
PRBCs with 1% autologous plasma and additional antibodies; rat IgG2a isotype control; anti-IL-2 Ig; mouse IgG1 isotype 
control; anti-IL-12 Ig; anti-IL-18 Ig; anti-CD2 Ig; or anti-IFNα/βR Ig. Cells were fixed and stained for functional markers; A) 
IFN-γ; C) CD107a; D) CD16 (n value=28, paired Wilcoxon test, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05). 
B, D) NK cells were enriched and incubated with either (bars, left to right) Raji cells with mouse IgG1 isotype control, Raji 
cells with Rituximab, URBCs, URBCs with 1% autologous plasma, PRBCs, PRBCs with 1% autologous plasma, or PRBCs 
with 1% autologous plasma and anti-CD2 Ig. Cells were fixed and stained for functional markers; B) IFN-γ; D) CD107a (n 
value=5) 
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5.3.13 Anti-AMA-1 plasma titres do not correlate with IFN- production or 
degranulation by CD56dim NK cells in response to PRBCs and plasma 
 
Prior to the current study, the Gambian PBMC and plasma donors used in this study 
(n= 66) were tested for prior malarial exposure via an ELISA assay testing for the 
presence of antibodies against apical membrane antigen 1 (AMA-1), a common 
malarial antigen expressed on merozoites. The plasma of all donors tested positive for 
antibodies against AMA-1 but varied considerably in their relative concentration of this 
antibody. 
We hypothesised that the heterogeneity seen in Gambian donors in their CD56dim IFN-
 production, degranulation and CD16 downregulatory responses to parasitised cells 
and plasma could be due to individual differences in the quality or quantity of anti-
malarial antibodies produced by donors. We therefore elected to analyse whether anti-
AMA-1 titres correlated with these responses in our Gambian cohort. 
No significant correlation was found between IFN- production and anti-AMA-1 plasma 
titres. This indicated that while the presence of autologous plasma does significantly 
increase IFN- production by Gambian CD56dim NK cells through partially antibody-
driven mechanisms, antibodies directed against AMA-1 specifically are not a primary 
contributor to this response (Fig. 5.8A). 
Similarly, no significant correlation was found between degranulation and anti-AMA-1 
plasma titres. This suggested that while the presence of autologous plasma significantly 
upregulates degranulation by Gambian CD56dim NK cells against parasitised cells 
through a primarily antibody-driven mechanism, antibodies directed against AMA-1 
specifically are not a primary contributor to this response either (Fig. 5.8B). 
Surprisingly, a significant positive correlation was found between downregulation in 
CD16 and anti-AMA-1 titres (p<0.05, Fig. 5.8C). When this trend was inspected visually 
however, it became apparent that this was largely due to a correlation between CD16 
downregulation and anti-AMA-1 titres at only the very highest relative concentrations of 
anti-AMA-1, as indicated by a the steepness of the curve at the distal end of the x-axis 
(Fig. 5.8C). Potential explanations for this trend will be discussed in more detail in the 
relevant discussion section. 
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Figure 5.8 Correlations of Gambian NK responses to parasitized erythrocytes and autologous plasma versus 
normalised anti-AMA titres  
Gambian plasma was tested via ELISA for titres of antibody targeting apical membrane antigen 1 to assess prior malarial 
exposure. PBMCs from anti-AMA positive individuals were thawed and incubated with PRBCs at a 1:3 ratio with 1% 
autologous plasma. Cells were incubated for 6 hours at 37oC before being stained and fixed for functional markers. Correlation 
plots show anti-AMA titres versus percentage of CD56dim NK cells expressing; A) IFN-γ; B) CD107a; C) CD16 (n value=47, 
Pearson correlation coefficient, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05).  
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5.3.14 High frequencies of CD56dim FcεRIγ- CD57- and CD56dim FcεRIγ- CD57+ 
NK cells in Gambian individuals compared to both HCMV+ and HCMV- 
Europeans 
 
Published studies by several research groups have indicated that prior infection with 
human cytomegalovirus (HCMV) drives the expansion of differentiated CD57+  CD56dim 
NK cells, as well a recently identified CD56dim subset tentatively referred to as ‘adaptive’ 
NK cells characterised by reduced expression of the adaptor molecule FcεRIγ. Both 
differentiated and ‘adaptive’ CD56dim NK cells have exhibited enhanced capacity to 
respond to antibody in models of viral infection and cancer. Given our interest in 
antibody-dependent responses to malaria and the endemicity of HCMV in the Gambia, 
we chose to investigate the relative contribution of these cells to the IFN- and 
degranulation responses we previously observed. 
As the Gambia is endemic for HCMV with an estimated ~85% of individuals infected by 
12 months of age 229, we expect relatively high frequencies of both differentiated and 
adaptive NK cells amongst this population. In contrast, epidemiological studies of 
Europe indicate an average HCMV infection frequency of below 80% in Caucasian 
adults of childbearing age, with infection rates as low as 30-45% in certain 
demographics 232. To assess this we compared the total proportion of CD56dim NK cells 
that were either FcεRIγ+ CD57- (hereafter referred to as ‘Canonical Immature’), FcεRIγ- 
CD57- (hereafter ‘Adaptive Immature’), FcεRIγ+ CD57+ (‘Canonical Mature’) or FcεRIγ- 
CD57+ (‘Adaptive Mature’) in 66 Gambians, 20 HCMV+ European controls and 20 
HCMV- European controls.  
Gambian individuals had significantly fewer Canonical Immature NK cells than both 
HCMV+ and HCMV- European donors, with a mean of 40.06% (SD±19.48) in 
Gambians in comparison to a mean of 48.91% (SD±17.71) in HCMV+ Europeans 
(p<0.01%, Fig. 5.9B) and 63.14% (SD±14.93) in HCMV- European donors (p<0.0001%, 
Fig. 5.9B).  
Conversely, Gambian individuals had significantly more Adaptive Immature NK cells 
than both HCMV+ and HCMV- European individuals, with a mean of 13.47% 
(SD±10.47) in Gambians in comparison to 8.9% (SD±8.18) in HCMV+ Europeans 
(p<0.05, Fig. 5.9B) and 6.9% (SD±4.43) in HCMV- Europeans (p<0.05, Fig. 5.9B).   
Gambian donors also had significantly fewer Canonical Mature NK cells than both 
HCMV+ and HCMV- European donors, with a mean of 18.09% (SD±11.33) in 
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Gambians in comparison to a mean of 28% (SD±16.45) in HCMV+ Europeans 
(p<0.01%, Fig. 5.9B) and 27.34% (SD±11.4) in HCMV- European individuals (p<0.01%, 
Fig. 5.9B). 
Finally, Gambians also had significantly more Adaptive Mature NK cells than both 
HCMV+ Europeans and HCMV- Europeans, with a mean of 28.28% (SD±21.55) in 
Gambians versus 14.18% (SD±14.33) in HCMV+ Europeans (p<0.01%, Fig. 5.9B) and 
2.59% (SD±5.05) in HCMV- Europeans (p<0.0001, Fig. 5.9B).  
On average a mean of 41.75% of total CD56dim NK cells in Gambians were Adaptive 
(either Immature or Mature) in comparison to 23.08% in HCMV+ Europeans and 9.49% 
in HCMV- Europeans (Fig. 5.9B).  
A mean of 46.46% of total CD56dim NK cells in Gambians were Mature (either Canonical 
or Adaptive) in comparison to 42.18% in HCMV+ Europeans and 29.92% in HCMV- 
Europeans (Fig. 5.9B).  
 
5.3.15 Downregulation of FcεRIγ is significantly associated with higher 
expression of CD2 and NKG2C in Gambian individuals 
 
Previously published studies by other research groups have indicated that 
downregulated expression of FcεRIγ is associated with increased expression of the 
activating receptor NKG2C as well as increased expression of the activating receptor 
CD2 in European individuals. We chose to evaluate this in our sampled Gambian 
individuals to confirm that CD56dim NK cells from Gambian donors downregulating 
FcεRIγ exhibited the same adaptive phenotype as seen in European counterparts. 
Ex vivo staining of Gambian CD56dim NK cells revealed that a significantly greater 
proportion of Adaptive Immature NK cells expressed CD2 in comparison to Canonical 
Immature, though the absolute difference was relatively small (mean difference 5.42%, 
p<0.05, Fig. 5.9C). Adaptive Mature NK cells were also significantly more likely to 
express CD2 than their Adaptive Immature counterparts, and this difference was far 
greater (mean difference 21.3%, p<0.0001, Fig. 5.9C). Adaptive Mature cells were the 
most likely to express CD2 of all subsets, with a mean of 90.98% of these cells 
expressing the receptor.  
Expression of CD57 without loss of FcεRIγ did not significantly increase CD2 
expression. From this we conclude that loss of FcεRIγ is associated with increased 
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expression of CD2, and this effect seems to be most prominent on differentiated CD57+ 
NK cells; though expression of CD57+ alone seems to have no significant effect on 
CD2 expression.  
Staining of Gambian CD56dim NK cells also revealed that a significantly greater 
proportion of Adaptive Immature NK cells expressed NKG2C in comparison to 
Canonical Immature (mean difference 10.84%, p<0.001, Fig. 5.9D). Expression of 
CD57 without loss of FcεRIγ also significantly increased NKG2C expression (mean 
difference 13.64%, p<0.0001, Fig. 5.9D), though Adaptive Mature cells were still 
significantly more likely to express NKG2C than cells expressing CD57 without 
concurrent loss of FcεRIγ (mean difference 8%, p<0.0001, Fig. 5.9D). From this we 
conclude that both loss of FcεRIγ and expression of CD57 are associated with 
increased expression of NKG2C, and this effect seems to be synergistic, with Adaptive 
Mature NK cells the most likely to express NKG2C overall with a mean of 26% of these 
cells being NKG2C+ (Fig. 5.9D). 
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5.3.16 Gambian CD56dim Adaptive and Mature NK cells are more likely to 
produce IFN- in response to antibody-dependent control stimuli than less 
differentiated subsets 
 
Published studies by several research groups have indicated that both differentiated 
and ‘adaptive’ CD56dim NK cells from European donors have enhanced capacity to 
produce IFN- in response to antibody-antigen complexes in models of viral infection 
and cancer. We wished to confirm this in our Gambian donors using Raji cells and 
Rituximab antibody as an antibody-dependent control stimulus.  
Both Adaptive Immature and Canonical Mature NK cells were significantly more likely 
to produce IFN- in response to control stimuli than Canonical Immature cells, 
suggesting that both maturity and adaptation led to increased sensitivity to activation 
via antibody. A mean of 4.17% (SD±3.13) of Canonical Immature NK cells produced 
IFN- in response to Raji cells and Rituximab in comparison to a mean of 7.42% (SD±6) 
for Adaptive Immature (p<0.01, Fig. 5.10A) and a mean of 5.71% (SD±4.01) for 
Canonical Mature cells (p<0.01, Fig. 5.10A).  
Whilst FcεRIγ- adaptation alone led to higher production of IFN- than CD57+ alone, 
this effect appeared to be synergistic, as cells that were both Adaptive and Mature were 
the most likely to produce IFN- of all subsets. A mean of 9.63% (SD±7.46) of Adaptive 
Mature NK cells produced IFN-, significantly more than Adaptive Immature (p<0.01, 
Fig. 5.9A) or Canonical Immature (p<0.01, Fig.5.10A). 
 
5.3.17 Gambian CD56dim Adaptive Immature NK cells are significantly more 
likely to produce IFN-γ- than other subsets in response to PRBCs and 
autologous plasma 
 
We next chose to investigate whether Adaptive or Mature CD56dim NK cells also 
exhibited similar enhanced antibody-dependent IFN- production in response to 
infected erythrocytes in our Gambian donors. 
All FcεRIγ/CD57-defined subsets were more likely to produce IFN- in response to 
infected erythrocytes and autologous plasma than URBCs with plasma, indicating an 
antibody-dependent response to PRBCs but not URBCs (Fig. 5.10A).  
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There was no significant difference in the percentage of cells producing IFN- between 
FcεRIγ/CD57-defined subsets except for Adaptive Immature NK cells. These cells were 
by far the most likely to produce IFN-γ, with a mean of 12.95% (SD±12.33) producing 
IFN-γ in comparison to a mean of 7.18% (SD±5.69) in Canonical Immature cells 
(p<0.05, Fig. 5.9A). Adaptive Immature cells were more likely to produce IFN-γ even in 
comparison with Adaptive Mature cells (mean = 7.29%, SD±4.67, p<0.05, Fig. 5.10A) 
though the latter had previously demonstrated the highest responses to antibody-
dependent control stimuli (Fig. 5.10A). 
These results did not conform to expectations based on our antibody-dependent Raji 
controls (Fig. 5.10A), suggesting that antibody alone may not determine the IFN- 
response of these cells. Previous experiments in this chapter on the total CD56dim NK 
cells population suggested that, in addition to anti-malarial antibodies, PBMC-derived 
IL-12 and IL-18 as well as the adhesion receptor CD2 play a role in the NK IFN- 
response to parasitised cells and plasma. We hypothesised that these co-factors may 
affect the IFN- production of different FcεRIγ/CD57- defined subsets to varying 
degrees. This was further investigated by analysing the effects of blocking antibodies 
on the responses of these subsets in section 5.3.20. 
5.3.18 Both Adaptive and Mature Gambian CD56dim NK cells are more 
likely to degranulate in response to antibody-dependent control stimuli 
than less differentiated subsets 
 
Published studies by several research groups have indicated that both ‘mature’ and 
‘adaptive’ CD56dim NK cells from European donors have enhanced capacity to 
degranulate in response to antibody in models of viral infection and cancer. We wished 
to confirm this in our Gambian donors, again using Raji cells and Rituximab antibody 
as an antibody-dependent control stimulus.  
Both Adaptive Immature and Canonical Mature NK cells were significantly more likely 
to degranulate in response to control stimuli than Canonical Immature cells, though this 
effect was minimal with Canonical Mature cells and far more prominent with Adaptive 
Immature. A mean of 31.58% (SD±11.39) of Canonical Immature cells degranulated in 
response to Raji cells and Rituximab in comparison to a mean of 43.6% (SD±11.82) for 
Adaptive Immature cells (p<0.0001, Fig. 5.10B) and a mean of 33.93% (SD±11.31) for 
Canonical Mature cells (p<0.05, Fig. 5.10B).  
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A combination of adaptation and maturity did not appear to significantly upregulate the 
degranulation response beyond adaptation alone. A mean of 45.71% (SD±13.07) of 
Adaptive Mature cells degranulated, which while significantly more than Canonical 
Mature cells (p<0.0001, Fig. 5.10B), was not significantly higher than the mean number 
of Adaptive Immature cells seen degranulating under the same conditions. 
 
5.3.19 Higher frequency of degranulation within CD56dim Adaptive Mature 
NK cell populations in response to PRBCs and autologous plasma 
 
We next chose to investigate whether adaptive or differentiated CD56dim NK cells also 
exhibited similar enhanced antibody-dependent degranulation in response to infected 
erythrocytes in our Gambian donors. 
All FcεRIγ/CD57-defined subsets were more likely to degranulate in response to 
infected erythrocytes and autologous plasma than URBCs with plasma, indicating an 
antibody-dependent response to PRBCs but not URBCs (Fig. 5.10B).  
Both Adaptive Immature and Canonical Mature NK cells were significantly more likely 
to degranulate in response to control stimuli than Canonical Immature cells, suggesting 
that both maturity and adaptation led to increased sensitivity to activation via antibody. 
A mean of 27.57% (SD±15.16) of Canonical Immature cells degranulated in response 
to parasitized cells and plasma in comparison to a mean of 34.79% (SD±15.18) for 
Adaptive Immature cells (p<0.01, Fig. 5.10B) and a mean of 35.29% (SD±21.69) for 
Canonical Mature cells (p<0.05, Fig. 5.10B).  
There was no significant difference between the percentage of cells degranulating 
between Adaptive Immature and Canonical Mature NK cells. Adaptation and maturity 
did not appear to be synergistic, as although cells that were Adaptive Mature were more 
likely to degranulate on average this difference was not significant from cells that were 
Adaptive or Mature alone (mean 37.59%, SD±21.72, Fig. 5.10B). 
These results did not conform to expectations based on our antibody-dependent Raji 
controls where FcεRIγ- adaptation appeared to be the primary driver of antibody-
dependent granulation whilst CD57+ maturity had little to no effect (Fig. 5.10B). This 
suggested that antibody alone may not determine the degranulation response of CD57+ 
cells in response to parasitized cells. However, previous experiments on the total 
CD56dim NK cells population did not indicate any role for PBMC-derived IL-2, IL-12 or 
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IL-18 or the receptors IFNR or CD2 in the NK degranulation response to parasitized 
cells and plasma, suggesting this may be due to an untested co-factor (Fig. 5.10B).  
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5.3.20 Production of IFN-γ by Gambian CD56dim Canonical Immature NK cells is 
partially dependent by IL-12, IL-18 and CD2 
 
Blocking assays utilised antibodies against the IL-2, IL-12 and IL-18 as well as 
antibodies against the adhesion receptor CD2. PBMC isolated from Gambian 
individuals (n=28) were incubated at a 1:3 ratio for 6 hours with PRBC, autologous 
plasma and the relevant blocking antibody or isotype control.  
Blocking of soluble IL-12 significantly decreased the percentage of Canonical Immature 
FcεRIγ+ CD57- NK cells producing IFN-γ in comparison to the IgG1 isotype control 
antibody. The mean percentage of Canonical Immature cells producing IFN-γ when 
incubated with IL-12 blocking antibody was 1.12% (SD±0.8) in comparison to 1.83% 
(SD±1.31) with isotype control, representing a mean decrease of 0.71% (p<0.01, Fig. 
5.11A).  
Blocking of IL-18 also significantly decreased the frequency of Canonical Immature 
cells producing IFN-γ in comparison to IgG1 isotype control antibody. The mean 
percentage of Canonical Immature cells producing IFN-γ when incubated with IL-18 
blocking antibody was 0.91% (SD±0.85) in comparison to 1.83% (SD±1.31) with isotype 
control, representing a mean decrease of 0.92% (p<0.001, Fig. 5.11A).   
Additionally, blockade of the NK CD2 receptor significantly decreased the frequency of 
Canonical Immature cells producing IFN- The mean percentage of Canonical 
Immature cells producing IFN-γ when incubated with CD2 blocking antibody was 1.02% 
(SD±0.88) in comparison to 1.83% (SD±1.31) with isotype control, representing a mean 
decrease of 0.81%. (p<0.001, Fig. 5.11A).  
These data indicate that the antibody dependent responses of less differentiated, 
canonical NK cells are more dependent on accessory cytokines and co-stimulatory 
molecules than other subsets.  
 
5.3.21 Enhanced production of IFN-γ by Gambian CD56dim Adaptive Immature 
NK cells is mediated by IL-12 
 
Blocking of soluble IL-12 significantly decreased the percentage of Adaptive Immature 
NK cells producing IFN- in comparison to the IgG1 isotype control antibody. The mean 
percentage of Adaptive Immature cells producing IFN- when incubated with IL-12 
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blocking antibody was 8.95% (SD±8.01) in comparison to 13.76% (SD±12.66) with 
isotype control, representing a mean decrease of 4.81% (p<0.05, Fig. 5.11B). In 
contrast, blocking of IL-18 and the CD2 receptor had no significant effect on IFN- 
production in the presence of parasite erythrocytes and autologous plasma (Fig. 5.11B).  
These results indicated that the production of IFN- by Adaptive Immature NK cells in 
response to parasitized cells and plasma was mediated by both antibody and IL-12, 
potentially explaining the significantly high levels of IFN-γ production found in this 
subset. This issue will be discussed in more detail in the relevant discussion section. 
In both Canonical Mature and Adaptive Mature NK cells blocking of IL-12, Il-18 and 
CD2 appeared to have no significant effect on the percentage of cells producing IFN-γ 
(Fig. 5.11C-D).  
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Figure 5.11 Gambian CD56dim NK IFN-γ responses to PRBCs with autologous plasma in the presence of 
blocking antibodies  
A-D) PBMCs were thawed and incubated with either (bars, left to right) PRBCs with 1% autologous plasma alone, 
or PRBCs with 1% autologous plasma and either; mouse IgG1 isotype control; anti-IL-12 antibody; anti-IL-18 
antibody; or anti-CD2 antibody. Cells were stained and fixed for functional markers; A) IFN-γ; B) CD107a; C) CD16 
(n value=28, paired Wilcoxon test, **** p<0.0001, *** p<0.001, ** p<0.01, * p<0.05). 
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5.4 Discussion 
 
In this study I have attempted to characterise the NK antibody-dependent response to 
Plasmodium falciparum malaria in a representative in vitro model of infection, using 
mixed peripheral blood mononuclear cells and autologous plasma from confirmed 
malaria-exposed Gambians and malaria-naïve Europeans. 
Given the recent interest in so-called ‘adaptive’ NK cells and their seemingly enhanced 
capacity to respond to antibody, I have also specifically characterised the role of this 
particular subset in the antibody-dependent response to malaria in this Gambian cohort. 
I have also examined the role of pro-inflammatory co-factors on the NK cell antibody-
dependent response to infected erythrocytes, utilising blocking assays and other 
techniques to investigate the influence of pro-inflammatory cytokines and accessory 
leukocytes on this response. 
 
5.4.1 Plasma-independent IFN- production by CD56dim NK cells in response to 
blood-stage malaria is significantly greater in Gambians than Europeans 
 
In this study, cryopreserved PBMCs from 66 Gambian donors with prior malarial 
exposure and 40 European donors without prior exposure were incubated with 
Plasmodium-infected erythrocytes (PRBCs) or uninfected (URBCs); either alone, or in 
the presence of immune or non-immune autologous plasma. Cells were then stained, 
fixed and imaged using an LSRII flow cytometer to determine the expression of various 
functional markers. Production of pro-inflammatory IFN- and presentation of CD107a 
as a measure of cytotoxic activity were used to assess the relative responses of CD56dim 
NK cells cultured under these conditions, while downregulation of CD16 was used to 
determine the contribution of antibody-antigen complexes to these responses.  
CD56dim NK cells from Gambian donors were significantly more likely to produce IFN-γ 
and degranulate when cultured for a short period of 6 hours in the presence of PRBCs 
than when cultured with URBCs (Fig. 5.3A-B). This result concurs with previous work 
our group has published on the subject, where we have seen NK cells producing IFN-γ 
after a short period incubated with PRBCs 82,188 as well as demonstrating signs of 
cytotoxic killing 190. IFN-γ production in response to infected erythrocytes was also 
considerably heterogenous, with some donors expressing no IFN-γ at all in response 
to parasitised cells, while in others nearly a fifth of CD56dim NK cells produced the 
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cytokine. This is also in keeping with our previously published observations on the 
subject where the antibody-independent NK response to parasitised cells varied largely 
between donors 190.  
Curiously however, CD56dim NK cells from European donors did not produce significant 
levels of IFN-γ when incubated for 6 hours with PRBCs in comparison to controls. This 
conflicts with previous observations published by our group, where NK cells obtained 
from European donors produced noticeable levels of IFN-γ in response to incubation 
with falciparum-infected erythrocytes after only 6 hours of co-culture 82. The number of 
donors tested in our previous studies were considerably smaller than in the study 
described in this thesis however, and given the heterogenicity we have also observed 
in these responses it may be that a small sample size does not give reliable results. 
Additionally, while noticeable levels of IFN-γ were observed in some donors after 6 
hours in previous studies, this response did not reach optimal in all donors until much 
later at around 24 hours. This is more in keeping with the results of our longer-term 
assays where both Gambian and Europeans were able to produce IFN- after being 
cultured in the presence of PRBCs for 18 hours. 
Regardless, it appears that the acute antibody-independent response of Gambian 
CD56dim NK cells to infected erythrocytes is more potent than that of Europeans, 
particularly in regard to IFN-γ production. Given the heterogenicity of the observed in 
the antibody-independent IFN-y responses to malaria, it is clear that donors within a 
single population differ in the magnitude by which they respond to this parasite, possibly 
as a result of differential expression of receptors that mediate activation. It is possible 
that these differences manifest both at an inter-group as well as inter-individual level as 
a result of either genetic differences or immunological adaptation to the local microflora, 
causing Gambian donors to respond more potently in comparison to Europeans. It is 
worth noting that all the sampled European donors were of White British ethnicity, and 
as such it is very likely that genetic differences exist between these donors and native 
Gambians. 
Previous work conducted by Dr Asia Wolf in our lab demonstrated higher baseline 
responsiveness to pro-inflammatory cytokines in African populations in Uganda, partly 
as a result of higher baseline expression of activating cytokine receptors such as CD25 
191. It is possible that NK cells from Gambian individuals may demonstrate similarly high 
expression of cytokine receptors which may mediate activation in instances of malarial 
infection. Previous studies have identified IL-12 and IL-18 produced by myeloid 
accessory cells 188 and (speculatively) trans-presentation of IL-15 by dendritic cells 191 
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as important antibody-independent activating signals for NK cells in instances of 
malarial infection. Consequently, future work on the subject should involve investigating 
the expression of the receptors for these cytokines on Gambian NK cells versus the 
cells of Europeans.  
In addition, while the specific physical contacts that occur between NK cells and 
accessory cells in instances of malarial infection remain largely uncharacterised, 
binding of LFA-1 expressed on the NK cell surface to ICAM-1 expressed on PBMCs 
has been suggested to mediate activation 103. It may also be worth investigating whether 
expression of this receptor varies between European and Gambian populations in 
future work.  
The receptors which mediate direct interactions between NK cells and infected 
erythrocytes are similarly unknown or disputed, but should any be definitively identified 
in the coming years it would also be beneficial to investigate whether their expression 
varies between Gambian and European populations. 
 
 
5.4.2 Significant enhancement of IFN- production to PRBCs in the presence of 
autologous plasma is likely due in part to anti-malarial antibodies, but further 
work is required to confirm this 
 
CD56dim NK cells from Gambian donors were significantly more likely to produce IFN-γ 
and degranulate when cultured in the presence of erythrocytes infected with late-stage 
Plasmodium falciparum than when cultured with URBCs. These responses were 
relatively small, but were greater enhanced in the presence of autologous plasma.  
This indicated that NK cells were perhaps responding to anti-malarial antibody-antigen 
complexes through CD16, resulting in considerable greater production of pro-
inflammatory cytokines and enhanced cytotoxic responses in comparison to the 
antibody-independent response.  
In support of this explanation, plasma from malaria-naïve Europeans elicited a much 
smaller IFN- response and weaker CD16 downregulation in autologous CD56dim NK 
cells. This would be in keeping with the interpretation that NK responses to PRBCs in 
the presence of plasma were perhaps driven primarily by anti-malarial antibodies, as 
European donors were malaria-naïve and thus would have no such antibodies.  
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However, the European response to parasitised erythrocytes in the presence of plasma 
was still significantly greater compared to the response to parasitised erythrocytes 
alone, suggesting that non-immune plasma can still upregulate NK cell responses to 
parasitised erythrocytes to a certain extent through alternative (albeit weaker) antibody-
independent mechanisms. These could include residual pro-inflammatory cytokines 
possibly present in European plasma, inflammatory factors produced by accessory cells 
in response to PRBCs capable of inducing moderate downregulation of CD16, or 
soluble blood components such as haem which are known to be immunogenic 213. 
Variance in the composition and concentration of such plasma-derived proteins 
between European and Gambian donors could also perhaps explain the differences in 
their responses to uninfected erythrocytes in the presence of plasma. 
Future work in this area should take into account the possibility that plasma may contain 
immune mediators other than antibody, and perhaps test for their presence using 
techniques such as multiplex immunoassays. Alternatively, future work in this area may 
involve the use of purified anti-malarial antibodies rather than mixed immune plasma, 
allowing for the assessment of antibody-dependent responses without concern for other 
potentially confounding immunological mediators. This would also allow us to control 
for any differences between the composition of Gambian and European plasma. 
At the time of writing there are currently no full published studies on the autologous 
antibody-dependent NK response to malaria in exposed subjects. As such these results 
are relatively novel, though they appear to be in concert with a recent study published 
by Arora et al in 2018 where non-autologous pooled malaria-immune plasma was 
shown to illicit significant antibody-dependent cytotoxic responses against parasitised 
cells in malaria-naïve NK cells obtained from US donors 233. While this is encouraging, 
the use of pooled plasma and relatively low sample numbers in the aforementioned 
study prohibits too great a comparison to our own results where we have taken care to 
match self-plasma to self-cells from naturally-exposed donors in order to better replicate 
the variation in anti-malarial responses that are likely to exist in vivo. 
 
5.4.3 Plasma-dependent production of IFN-γ by CD56dim NK cells in response to 
blood-stage malaria is upregulated by IL-12 and IL-18 produced by accessory 
peripheral blood mononuclear cells 
 
Blocking experiments utilising antibodies directed against various different factors 
known to activate NK cells revealed that the cytokines IL-12 and IL-18 play a role in 
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upregulating the plasma-dependent production of IFN- in response to PRBCs. Several 
studies have suggested that antibody-dependent production of IFN- by NK cells in 
response to other targets such as cancer cells can also be upregulated by co-
stimulation with pro-inflammatory cytokines such as IL-12, IL-2 and IL-18, offering some 
support for these data 113,114, 109.  
IL-12 and IL-18 do not appear to be strictly necessary to induce plasma-dependent IFN-
 production in response to malaria however, as subsequent experiments carried out 
using enriched NK cells rather than mixed PBMCs suggested that immune plasma 
alone may be sufficient to provoke a response (Fig. 5.6D). Assuming that the primary 
source of IL-12 and IL-18 during the anti-malarial response are myeloid dendritic cells 
and CD14+ monocytes as our research group has previously confirmed 45,188, IFN- 
production by NK cells in the absence of these cells would suggest that the cytokines 
they produce are not obligatory to elicit a response. However, it must be noted that the 
enriched NK cells used in these assays were not 100% pure due to limitations of the 
enrichment process, allowing for the possibility that a small number of contaminatory 
dendritic cells and/or monocytes may have been present in the final solution. 
Consequently these results cannot be said to be entirely definitive. In future 
experiments it may be worth repeating these experiments with a pure NK cell line in 
order to control completely for the possibility of confounding cellular contamination. 
When the Gambian CD56dim response was broken down by FcεRIγ/CD57-defined 
subset it was revealed that the different subsets had very different reactions to IL-12 
and IL-18. Canonical Immature NK cells proved to be the most responsive to both 
cytokines, exhibiting a significant decrease in IFN- production when either was 
blocked. Previously published research by others in the field has indicated that both 
Immature CD57- cells and Canonical FcεRIγ+ cell have increased sensitivity to IL-12 
and IL-18 in comparison to their Mature or Adaptive counterparts. In both Canonical  
FcεRIγ+ and Immature CD57- cells higher affinity for IL-12 has been linked to higher 
levels of transcription of the IL12Rβ2 gene which encodes the beta 2 subunit of the IL-
12 receptor 126,137. In Canonical cells specifically it has also been discovered that 
transcription of the IL18RAP gene which encodes an accessory subunit of the IL-18 
receptor is as much as four-fold higher than in adaptive NK cells 137. Consequently, the 
fact that we find Canonical Immature CD56dim NK cells to be the most responsive to IL-
12 and IL-18 in our own study is well in keeping with the established view of these cells 
as highly cytokine-responsive. 
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IFN- responses to PRBCs within Adaptive Immature NK cells in contrast were 
unresponsive to IL-18, though surprisingly they retained the ability to respond to IL-12, 
which may explain why IFN- production in this subset was so significant. This will be 
discussed in more detail in section 5.4.5. 
In contrast, neither Canonical Mature nor Adaptive Mature NK cells responded to either 
IL-12 or IL-18, suggesting IFN- production by these cells was primarily induced by 
antibody-antigen complexes with little requirement for accessory cytokines. Whilst 
recent results published by Hammer et al in 2018 have suggested that Adaptive Mature 
NK cells can respond to IL-18 when also stimulated by antibody 146, we found no 
evidence for this in our own study. We note however that in Hammer et al’s study NK 
cells were artificially supplemented with IL-18, whereas in our own study the source of 
IL-18 is assumed to be monocytes present within the PBMCs as we have observed in 
our previously published work 45,188. Consequently, it may be that the concentrations of 
IL-18 present in culture media in our own assays were not high enough to observe this 
effect. Future work should perhaps include repeat antibody-stimulation assays directed 
against malaria with or without the presence of supplemental cytokine to assess this 
issue more directly. 
Blocking of these factors did not appear to have any significant effect on the general 
degranulation response of CD56dim NK cells to blood-stage malaria, and also did not 
appear to affect CD16 expression. This suggested that cytotoxic responses to blood-
stage malaria are largely driven directly by immunoglobulin-opsonised parasitised cells 
with minimal input from other soluble accessory factors (Fig. 5.6B-C). 
 
5.4.4 Plasma-dependent production of IFN- CD56dim NK cell response to blood-
stage malaria is upregulated by binding of the NK CD2 receptor to accessory 
blood mononuclear cells 
 
Blocking of the NK receptor CD2 significantly downregulated plasma-dependent 
production of IFN- in response to PRBCs (Fig. 5.6A). CD2 has several known ligands, 
including the lymphocyte differentiation marker CD48, the adhesion molecule CD58, 
and the glycoprotein CD59 234. These ligands can be expressed on a range of cells, 
including NK cells themselves, as well as both erythrocytes and accessory peripheral 
blood mononuclear cells such as monocytes 234,235. Binding of CD2 to CD58 expressed 
on target cells has been shown to synergise with antibody crosslinking of CD16, leading 
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to enhanced antibody-dependent NK cell responses through increased phosphorylation 
of intracellular signalling molecules 149. Binding of CD2 to CD58 expressed on 
accessory monocytes has also been shown to mediate presentation of cytokines to 
CD2-expressing cells, also leading to enhanced NK cell responses [228]. 
Consequently, the downregulation in IFN- production seen in CD56dim NK cells during 
the antibody-dependent response to malaria after blocking of CD2 may be due to 
multiple mechanisms. CD2 may mediate interactions between CD56dim NK cells and 
each other, parasitised erythrocyte targets, accessory PBMCs, or all of the above.  
However, when the CD2 blocking assay was repeated using enriched NK cells 
incubated alone with PRBCs and immune plasma, there was no noticeable decrease 
in IFN- production in comparison to unblocked controls (Fig. 5.6D). This indicated that 
CD2 was not involved in mediating interactions between either NK cells and erythrocyte 
targets or NK cells and each other, but rather interactions between NK cells and non-
NK accessory PBMCs.  
When the CD56dim IFN- response was broken down by FcεRIγ/CD57-defined subset, 
only Canonical Immature FcεRIγ+ CD57- NK cells demonstrated any significant 
downregulation of IFN- production as a result of blocking CD2. These cells also 
demonstrated the greatest sensitivity to cytokine, responding to both IL-12 and IL-18. 
Previous work by other researchers has suggested that binding of CD2 expressed on 
T-cells to CD58-expressing monocytes can mediate presentation of cytokines such as 
IL-12, leading to enhanced T-cell activation [228]. Here we suggest that a similar 
mechanism exists for NK cells during the antibody-dependent response, by which CD2-
expressing NK cells bind accessory PBMCs, leading to increased exposure to cytokines 
such as IL-12 and IL-18, which upregulate the antibody-dependent response.  
Consequently, future work in this area should include blocking these cytokines and CD2 
simultaneously. If blocking of CD2 does not significantly reduce activation beyond what 
is activated by blocking cytokines alone, it would confirm the role of CD2 in mediating 
cytokine presentation by accessory cells. 
Blocking of CD2 did not appear to have any significant effect on the general 
degranulation response of CD56dim NK cells to blood-stage malaria, and also did not 
appear to affect CD16 expression. This again suggested that cytotoxic responses to 
blood-stage malaria during the antibody-dependent response are largely driven by 
immunoglobulin. 
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Figure 5.12. Proposed model for activation of natural killer cells during the antibody-dependent 
response to malarial infection 
Previous research has established that NK cells are activated to produce IFN- during the adaptive 
immune response to malaria by IL-2 produced by activated T-cells. Based on the results of the current 
study, we also propose that NK cells can also be activated by binding of anti-malarial antibody-antigen 
complexes to the CD16 receptor, resulting in both production of IFN- and degranulation. We also propose 
that IFN- production in response to anti-malarial antibody is upregulated by IL-12 and IL-18 produced by 
peripheral blood mononuclear cells, as well as binding of the CD2 receptor to the same. 
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5.4.5 Adaptive Immature CD56dim FcεRIγ- CD57- NK cells exhibit the strongest 
plasma-dependent IFN- response to malaria, but this is lost upon maturation to 
CD57+ cells 
 
Adaptive NK cells are known to be more responsive to antibody-dependent stimulation, 
leading to enhanced production of IFN- in response to virally-infected cells and 
tumours 141 144. This altered functionality is thought to be driven by reduced expression 
of the transcription factor PLZF, leading to hypermethylation of certain promotor DNA 
regions 145 and subsequent downregulated expression of certain adaptor molecules 137. 
Our own data confirmed this, as both Adaptive Immature and Adaptive Mature NK cells 
demonstrated significantly enhanced IFN- production in response to Raji tumour cells 
and Rituximab antibody. 
This would explain why Adaptive Immature cells exhibit greater IFN- production during 
the plasma-dependent response to malaria than their Canonical Immature 
counterparts, as the latter lack the epigenetic modifications that make adaptive cells 
more responsive to activation through the CD16 Fc receptor. This would also lend 
weight to our interpretation that the upregulation of immune responses seen in NK cells 
in response to infected cells and malaria-exposed plasma was due to the presence of 
anti-malarial antibodies in the latter. 
It is curious however that IFN- production within the Adaptive Immature  subset was 
greater than in the Adaptive Mature subset. The latter are considered to be even more 
responsive to antibody-dependent stimulation as a result of increased expression of the 
CD16 receptor associated with CD57+ maturity 126. Our own assays also confirmed that 
Adaptive Mature cells were the most likely to produce IFN- in response to Raji tumour 
targets and Rituximab antibody. 
These results indicated that the antibody-dependent response of Adaptive Immature 
cells may be dependent on additional activating co-factors not applicable to their Mature 
counterparts. Subsequent blocking assays revealed that IFN- production by Adaptive 
Immature cells is partially mediated by IL-12, whereas Adaptive Mature CD57+ cells 
appear to be largely unresponsive to this cytokine. This offers an explanation for the 
higher responsiveness of Adaptive Immature cells relative to Adaptive Mature as the 
former likely possess the increased sensitivity to antibody indicative of Adaptive NK 
cells 141 144 but also retain some ability to integrate cytokine into these responses. 
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Adaptive Mature cells in contrast are also sensitive to antibody but do not appear to be 
able to respond as well to cytokine. 
These results are somewhat contradicted by the established literature on the subject. 
Early studies conducted on Adaptive NK cells by Schlums et al in 2015 indicated that 
they express lower levels of transcription of the genes encoding subunits of the IL-12 
and IL-18 receptors, and consequently demonstrate reduced capacity to respond to 
these cytokines when provided without other forms of stimulation 137. A more recent 
study by Hammer et al published in 2018 has suggested that Adaptive NK cells are able 
to respond to IL-18 when supplemented with it during both germline receptor mediated 
and antibody-dependent responses to target cells, whilst remaining largely 
unresponsive to IL-12 146. It is worth noting however that in the latter study ‘adaptive’ 
NK cells were defined as being purely FcεRIγ- CD57+ (what we would term ‘Adaptive 
Mature’), whilst in our own study it is the FcεRIγ- CD57- ‘Adaptive Immature’ NK cells 
that demonstrated responsiveness to IL-12 during the antibody-dependent response. 
Adaptive Immature cells have been previously observed in the work of Schums et al 137 
but were not investigated phenotypically in terms of differences in transcription factor, 
adaptor protein or cytokine receptor expression. It could therefore be that this subset 
represents an intermediate population with important functional characteristics against 
certain infectious agents. 
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Figure 5.13. Proposed model for differential induction of IFN- production by NK cell FcεRIγ/CD57-
defined subsets during the antibody-dependent response to erythrocytes infected with 
Plasmodium falciparum 
Based on the results of the current study, we propose that the activating co-factors that influence the 
production of IFN- by NK cells during the antibody-dependent response to malaria vary depending on 
the FcεRIγ/CD57-defined status of the cell. FcεRIγ+ CD57- cells are able to integrate IL-12, IL-18 and 
CD2 as co-factors, and FcεRIγ- CD57- are able to integrate IL-12, whilst FcεRIγ+ CD57+ and FcεRIγ- 
CD57+ cells seem to produce IFN- primarily in response to antibody alone. 
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5.4.6 The nature of the malarial antigen driving antibody-dependent anti-malarial 
responses 
 
To select Gambian donors with prior malarial exposure for use in these assays, plasma 
samples from 641 Gambian donors were tested with ELISA for the presence of 
antibodies directed against apical membrane antigen 1 (AMA1). AMA1 is a protein is 
expressed on the surface of blood-stage merozoites, and is involved in the invasion of 
healthy erythrocytes 236. Naturally-acquired antibodies directed against AMA1 are often 
found in the plasma of patients infected with Plasmodium falciparum, and due to its 
limited antigenic diversity it is considered to be both a potential vaccine candidate and 
a useful marker for use in ELISA assays testing for prior malarial exposure 237. 
AMA1 is only expressed on the free merozoite stage of Plasmodium falciparum, and is 
generally not expressed on the surface of infected erythrocytes containing late-stage 
schizonts as utilised in the incubation assays in this study. Consequently, we did not 
expect to find any significant relationship between plasma titres of anti-AMA1 antibodies 
and CD56dim NK cell activation against this stage. 
To our surprise we found that high titres of anti-AMA1 antibodies in plasma appear to 
associate significantly with subsequent downregulation of CD16 during the antibody-
dependent NK cell response to schizont-stage malaria (p<0.05, Fig. 5.7C). This effect 
was only apparent at the very highest titres of anti-AMA1 however, and we found no 
such correlation between anti-AMA1 titres and direct functional markers of NK cell 
activation such as IFN- production (Fig. 5.7A) or degranulation (Fig. 5.7B). 
Consequently, it seems unlikely that anti-AMA1 antibodies themselves are capable of 
inducing downregulation of CD16 during the NK cell response to schizont-stage 
malaria. Rather we suggest that high titres of anti-AMA1 may be indicative of high anti-
malarial antibodies in general, and as such the association between high titres of anti-
AMA1 antibodies and downregulation of CD16 is largely coincidental rather than 
functional. 
Though AMA1 is not expressed on the surface of schizont-infected erythrocytes, there 
are several other malarial antigens that are, such as Plasmodium falciparum 
erythrocyte membrane protein 1 (PfEMP1), which mediates parasite sequestration 
through binding to vascular endothelial cells. Antibodies against PfEMP1 constitute 
most of the antibodies generated during the antibody-dependent response to malaria, 
and consequently it is considered to be an immunodominant peptide 238. Recent 
research conducted by Arora et al in 2018 has confirmed that antibodies against 
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PfEMP1 present in pooled malaria-immune plasma can elicit cytotoxic responses 
against parasitised erythrocytes by non-autologous NK cells, as do custom antibodies 
directed against parasite-derived RIFIN molecules which are also expressed on the 
erythrocyte surface 239. The use of pooled non-autologous plasma and custom 
antibodies in the aforementioned study prohibits us from generalising these results too 
extensively however, as the quality and quantity of antibodies directed against PfEMP1 
and RIVIN proteins may vary between donors in vivo.  Nonetheless, future work in this 
area will likely involve conducting assays designed to neutralise these antigens through 
antibody blocking or knockout mutation to observe the resulting effect on NK cell 
antibody-dependent responses in a more representative model of infection. 
 
 
5.3.7 HCMV exposure is associated with increased frequencies of Adaptive and 
Mature NK cells  
 
The differentiation of CD56dim NK cells into a functionally distinct ‘Adaptive’ phenotype 
appears to be mediated primarily by exposure to cells infected with certain viruses, the 
most widely reported of which is human cytomegalovirus (HCMV) 131,132. In areas of the 
globe where malaria is still present HCMV infection is also generally widespread, 
particularly in Africa, South-East Asia and South America 151. In Gambia HCMV is 
endemic, with 85% of infants infected by one year of age in countries such as Gambia 
229. In contrast infection rates in Europe are far lower on average, particularly amongst 
Caucasians whom make up 100% of our European donors 232. Consequently we 
hypothesised that our Gambian donors would possess higher frequencies of both 
Adaptive Immature and Adaptive Mature NK cells than HCMV- European controls. 
Happily, our results appear to confirm this hypothesis. After gating CD56dim NK cells by 
FcεRIγ/CD57-defined subset, Gambian donors demonstrating significantly higher 
frequencies of both Adaptive subsets than European HCMV- donors, and consequently 
also demonstrate lower frequencies of both Canonical subsets. In addition, Gambian 
donors demonstrated significantly higher frequencies of Mature CD57+ cells in 
comparison to HCMV- Europeans with 46.46% Gambian cells expressing CD57 in 
comparison to only 29.92% in HCMV- Europeans. Prior work by both our own research 
group and others has suggested that exposure to HCMV-infection also drives 
expansion of CD57+ cells 240,241, a theory that is further substantiated by these results. 
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Unexpectedly, Gambian donors also demonstrated significantly higher frequencies of 
Adaptive CD56dim NK cells and significantly lower frequencies of Canonical  cells than 
European donors who were HCMV+ (Fig. 5.8D). This can perhaps be explained by 
differences in the average period of time the average HCMV+ Gambian is infected with 
the virus versus the average HCMV+ European of the same age. In Gambia 85% of 
infants are infected by one year of age and maintain chronic infections throughout life, 
whereas in most European countries less than 80% of individuals are infected by 
reproductive age 229, 242. Consequently it is possible for a Gambian adult and a 
European adult of the same age to both test seropositive for HCMV whilst having been 
infected for very different periods of time. As a result HCMV+ Gambians would logically 
possess more adaptive NK cells than HCMV+ Europeans of the same age due to longer 
periods of HCMV exposure. 
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CHAPTER 6 
Overview of Results and Plans for Future Work 
 
In this thesis, I have made six main findings with the potential for future investigation. 
 
6.1 NK cells preferentially form conjugates with malaria-infected erythrocytes 
 I have confirmed that human natural killer cells are able to distinguish between 
uninfected erythrocytes and erythrocytes infected with schizont-stage Plasmodium 
falciparum, and preferentially form conjugates with the latter, as well as demonstrating 
for the first time that both undifferentiated and differentiated NK cells can form these 
conjugates. Conjugate formation is transient, the majority of these being lost within 3 
hours of co-culture.  
I was unable to determine the relative frequencies of conjugation between infected 
erythrocytes and either undifferentiated or differentiated NK cells, as was one of my 
original aims. This was due to the low frequency of conjugation events and innate 
limitations of the imaging methodology used. In future work this issue could be 
addressed by making alterations to the experimental protocol designed to increase the 
frequency of conjugation events.  
Though an original aim of the study was to assess the impact of the presence of 
accessory cells on conjugate formation, the presence of additional cell types appears 
to have limited the extent to which NK cells could interact with infected erythrocytes 
directly. In contrast, other researchers have previously been able to achieve much 
higher conjugate frequencies using purified peripheral NK cells or NK92 tumour lines 
190, 103. Whilst NK92 cells are inappropriate for my own aims given their lack of 
phenotypic diversity 195, using purified peripheral NK cells would allow for more frequent 
contacts to occur between NK cells and infected targets whilst still maintaining the 
diversity in NK cell differentiation I wish to study.  
It may also be possible to simulate the presence of accessory PBMCs to a certain extent 
using supplementary cytokines and soluble ligands, though this may be a somewhat 
limited approach given that several studies have suggested that full physical contact is 
required between NK cells and activating accessory cells to optimise presentation of 
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cytokines such as IL-12 and IL-15, as well as activating ligands such as MICA and MICB 
[22], [26], 60. 
In addition, although the original aim of this study was to evaluate the frequency of 
conjugation in an antibody-independent context, I observed potent degranulation 
responses in NK cells as a result of stimulation with anti-malarial antigen-antibody 
complexes in the assays described in Chapter 5. Therefore, it may also be informative 
to perform the conjugation assays described in Chapter 3 with the addition of malaria-
immune plasma to ascertain whether antibody ligation increases the frequency of 
conjugation between NK cells and infected erythrocytes, and whether this varies based 
on the differentiation and adaptive status of NK cell subsets. Furthermore, it would be 
informative to analyse the stability of antibody induced conjugates to test whether these 
can be detected beyond the 2-3 hour time frame observed in the absence of antibody 
or whether antibody mediated conjugated formation would also be rapidly lost, for 
example through the cleavage of CD16. 
 
6.2 CD16 shedding after antibody stimulation is not due to internalisation 
 I have demonstrated through a reliable imaging-based methodology that the 
downregulation of the NK cell Fc receptor CD16 seen after stimulation with antibody-
antigen complexes is due to shedding of CD16 alone, and does not involve 
internalisation of CD16 as has been previously reported. 
The results of this study are relatively definitive, and in keeping with observations made 
both by our own lab group and other researchers using alternative techniques 213, 212, 
198. The clinical consequences of CD16 shedding on the NK anti-malarial response 
however remains a relevant avenue of research. As the antibody-dependent response 
of NK cells to malaria is dependent on this receptor, it would be interesting to evaluate 
how quickly levels of CD16 are able to regenerate to homeostatic levels after 
downregulation in response to anti-malarial antibodies. Given that CD16 is shed rather 
than internalised and recycled, we can safely assume that the reconstitution of 
homeostatic levels of CD16 expression require de novo synthesis and export of CD16. 
Any delays in this process would limit the capacity of NK cells to respond to future 
antibody-dependent stimuli, perhaps with functional consequences on the ability of NK 
cells to shape the immune response through IFN- production and clearance of 
parasitised cells through cytotoxicity. Research by our own lab in an influenza model of 
antibody-dependent stimulation has suggested that expression levels of CD16 can take 
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several weeks to normalise in-vitro after stimulation with antibody-antigen complexes 
198, and recently published research by other groups has found similar results in a 
lymphoma model where serial downregulation of CD16 via antibody stimulation was 
also associated with reduced capacity to produce perforin 221. Future work in this area 
may therefore involve assessing the impact of CD16 shedding on long-term antibody-
dependent NK responses to malaria. Work by our lab has also indicated that the use of 
metalloprotease inhibitors designed to prevent cleavage of CD16 by the 
metalloprotease ADAM-17 results in sustained degranulation responses by NK in 
response to influenza 198. It would be interesting to run a similar assay in a malaria 
model to assess the impact of inhibiting CD16 shedding on the anti-malarial immune 
response and parasite clearance. 
Conversely, recent research published by Srpan et al in 2018 has suggested that 
shedding of CD16 on NK cells in response to antibody-stimulation can actually result in 
a significant upregulation of antibody-independent serial killing of target cells, mostly 
notably by increasing expression of the activating NKG2D receptor and easing cellular 
motility 221. Uninfected erythrocytes are not known to express ligands for NKG2D, and 
a prior study by Chen et al in 2014 confirmed that antibody-independent cytotoxic killing 
of falciparum-infected erythrocytes is not dependent on this receptor 40. 
 However, Srpan et al did not test receptors other than NKG2D, therefore it is possible 
that the upregulation seen in antibody-independent killing capacity after antibody-
induced shedding of CD16 may also involve increased expression of other molecules. 
Several studies have indicated that the antibody-independent response to malaria in 
NK cells is mediated by the activating co-receptors LFA-1 and DNAM-1 103, 40. Additional 
future work may involve testing the expression levels of these receptors after antibody-
dependent stimulation. 
 
6.3 CD56dim NK cells can respond robustly to malaria through antibody-
dependent mechanisms 
 I have shown for the first time in a full study that human natural killer cells have robust 
antibody-dependent responses to erythrocytes infected with Plasmodium falciparum in 
the presence of autologous anti-malarial antibodies, and that this response involves 
both production of pro-inflammatory interferon gamma and cytotoxic degranulation. 
Whilst stimulation of NK cells with anti-malarial antigen-antibody complexes provoked 
significant levels of degranulation, in the current study I was not able to ascertain the 
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effects of degranulation on parasite growth or viability due to time constraints. In future 
work it may be valuable to assess the effects of NK cell cytotoxicity on parasites directly 
through growth inhibition assays designed to measure the effects of cytotoxic activity 
on parasite population growth 40, or Chromium-51 release assays designed to detect 
the lysis of infected erythrocytes 243. 
Additionally, whilst the study described in this thesis strongly suggested a role for anti-
malarial antibodies in stimulating the NK cell response to malaria, I was not able to 
determine which malarial antigens expressed on infected erythrocytes were the most 
immunogenic. Research published in this area during the preparation of this thesis has 
confirmed that antibodies directed against Plasmodium-derived PfEMP1 and RIFIN 
proteins can elicit cytotoxic responses against parasitised erythrocytes by NK cells in 
models using knockout strains of malaria lacking expression of these proteins and 
pooled immune-plasma 239. While we generally avoid the use of pooled plasma in our 
own work as it does not allow us to assess the role of  diversity in donor responses, 
using similar knockout parasite strains in our own assays would allow us to determine 
the contribution of various malarial antigens to the antibody-dependent NK cell 
response whilst taking into account potential variation in antibody repertoire between 
individuals. 
 
6.4 The antibody-dependent response of CD56dim NK cells to malaria involves 
additional co-factors 
 I have shown for the first time that the antibody-dependent response of human natural 
killer cells to erythrocytes infected with Plasmodium falciparum is partially dependent 
on interleukins 12 and 18 produced by accessory cells, as well as binding of the NK cell 
expressed CD2 to ligands within PBMCs. 
Whilst ligation of the CD2 receptor led to upregulation of the antibody-dependent 
response to malaria in NK cells, in the described study I was not able to determine 
which specific ligand(s) on which specific accessory peripheral blood mononuclear cells 
bound NK-expressed CD2 due to time constraints.  
Previous work by other researchers has confirmed that binding of CD2 expressed on 
lymphocytes to CD58-expressing monocytes can mediate presentation of cytokines 
such as IL-12, which my own work has also identified as an important source of NK cell 
activation during the anti-malarial response [228]. Alternatively, it is possible that 
ligation of CD2 itself leads to an upregulated response, as in addition to serving as an 
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adhesion receptor CD2 is also capable of transducing co-activating signals through the 
CD3 zeta subunit of the CD16 complex 244. 
CD2 has several described ligands, including CD48, CD58, and CD59 [130]. These 
ligands can be expressed on a range of cells, including various accessory peripheral 
blood mononuclear cells. Consequently, in order to fully investigate the role of this 
receptor in the antibody-dependent NK cell response to malaria, future assays will likely 
involve a combination of blocking antibodies directed against these ligands as well as 
targeted depletion of specific accessory cell subsets in order to determine which cells 
provide which signals. Additional assays could include the simultaneous use of blocking 
antibodies against CD2 and blocking antibodies against accessory cell-derived 
cytokines to determine whether CD2 ligation has any effect independent of cytokine 
presentation. 
 
6.5 The antibody-dependent response of CD56dim NK cells to malaria is 
enhanced in ‘Adaptive’ FcεRIγ- and ‘Mature’ CD57+ NK cells 
 I have shown for the first time in full study that the antibody-dependent response of 
human natural killer cells to erythrocytes infected with Plasmodium falciparum varies 
significantly depending on whether NK cells are FcεRIγ positive or negative (here 
referred to as ‘Canonical’ or ‘Adaptive’ respectively), and/or CD57 positive or negative 
(here referred to as ‘Mature’ or ‘Immature’). Adaptive Immature NK cells appear to be 
the most likely to produce interferon gamma during the antibody-dependent response 
to malaria due to their enhanced responsiveness to antibody and ability to integrate    
IL-12, whilst both Adaptive and Mature NK cells have enhanced antibody-dependent 
cytotoxic responses that appear to be primarily driven by anti-malarial antibodies. I have 
also demonstrated that HCMV exposure is associated with the differentiation of these 
subsets, and that Gambians possess significantly higher frequencies of these cells than 
Europeans individuals, likely due to endemic exposure to HCMV from childhood. 
In future work it would be interesting to examine the extent to which a larger Adaptive 
and/or Mature NK cell compartment contributes to the clearance of parasites. Future 
work is planned where this will be investigated via NK cell activation assays and 
parasite growth inhibition assays incubating NK cells from either HCMV negative or 
positive donors with parasitised erythrocytes in the presence of pooled malaria-immune 
plasma. This approach would allow us to evaluate to what extent a larger adaptive or 
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differentiated NK cell compartment effects the anti-malarial response whilst controlling 
for anti-malarial antibody titres. 
 
6.6  CD56dim Adaptive Immature NK cells form an intermediary subset with the 
capacity to response to both anti-malarial antibody and IL-12 
 Lastly, I have shown for the first time that the different FcεRIγ/CD57-defined human 
natural killer cell subsets respond differently to the co-factors IL-12, Il-18 and CD2 
during the antibody-dependent response to malaria. Canonical Immature NK cells 
(FcR1+CD57-) are able to integrate all of these signals during the antibody dependent 
response to malaria, while Adaptive Immature NK cells (FceR1-CD57-) can integrate 
only IL-12 and make superior antibody dependent IFN- responses. 
In future it would be of value to investigate the underlying phenotypic changes that 
distinguish canonical undifferentiated NK cells from other subsets, particularly in terms 
of transcription factor, adaptor protein or cytokine receptor expression. Early studies 
conducted on Adaptive mature FcεRIγ- CD57+ NK cells by Schlums et al indicated that 
they express lower levels of transcription of the genes encoding subunits of the IL-12 
and IL-18 receptors, and as a result demonstrate reduced capacity to respond to these 
cytokines 137. Adaptive Immature cells were also found to be present, but were not 
investigated by gene expression profiling. It could therefore be that this subset 
represents an intermediate population which retains some ability to respond to IL-12, 
either innately, or after induction through exposure to antibody-antigen complexes. 
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6.7 Summary 
 
In summation, I believe that I have demonstrated that anti-malarial immunity in humans 
may depend not only on the breadth and depth of the antibody repertoire but also on 
the differentiation and adaptation state of antibody dependent effector cells, including 
NK cells. Further in-vitro experiments and field studies tracking the association these 
factors with malarial infection and clinical symptoms could address this hypothesis 
further, and provide useful insights into the interplay between the innate and adaptive 
anti-malarial responses. 
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